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1.1 The genetic basis of cancer
Over the past 30 years, considerable information has been gathered on regulation of cell
growth and proliferation which led to the discovery of many cancer-associated genes. This
complex body of knowledge revealed that cancer is the result of many dynamic changes in
the genome influencing a variety of cellular mechanisms such as cell cycle control,
apoptosis, angiogenesis, cell adhesion and motility (Figure 1-1) (Hanahan and Weinberg,
2000).
Figure 1-1: Acquired capabilities of
cancer. It is suggested that the defects
leading to cancer are a manifestation of
six alterations in cell physiology that
collectively dictate malignant cell growth:
(1) self-sufficiency in growth signals, (2)
insensitivity to anti-growth signals, (3)
evading apoptosis, (4) limitless
replication potential, (5) sustained
angiogenesis and (6) acquiring invasive
and metastatic properties.
(Reproduced from Hanahan and
Weinberg, Cell, 100, 57-70, 2000.)
A short overview of the key discoveries which have led to our current view and
understanding of cancer development is given below.
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In 1890, the German biologist David von Hansemann was the first to observe several
spindle bodies and other mitotic aberrations in tumor cells (von Hansemann, 1890). More
then twenty years later, Theodor Boveri proposed that chromosome defects in a given cell
were the underlying cause of cancer (Boveri, 1914). Boveri’s idea lacked experimental
support, which was not provided until the discovery by Peter Nowell and David
Hungerfold in 1960 (Nowell and Hungerfold, 1960). They described the Philadelphia
chromosome in chronic myelogenous leukemia (CML) cells. Following the introduction of
chromosome banding, this Philadelphia chromosome was shown to result from a reciprocal
translocation between chromosomes 9 and 22 (Rowley, 1973). With further improvement
of cytogenetic methods many other non-random chromosomal rearrangements were
identified in leukemic disorders as well as in solid tumors (Mitelman, 2000). The frequent
association between certain chromosome rearrangements and specific tumor types was
strongly suggestive for a causal role of these genetic alterations in the development of
cancer. Moreover, certain chromosome rearrangements were strong prognostic indicators
and were of diagnostic relevance in these cases.
The discovery of cellular proto-oncogenes (Stehelin et al., 1976) paved the way to a
mechanistic understanding of how these translocations lead to cancer. In a first type of
rearrangements, translocations can lead to an aberrant expression of certain proto-
oncogenes. This was illustrated by the t(8;14) (q24;q32) translocation in Burkitt’s
lymphoma which resulted in a translocation of the MYC oncogene into the 5’ region of the
immunoglobulin heavy chain (IGH) gene. The translocation juxtaposed the IGH promoter
region with the MYC coding sequences, resulting in abnormal timing and levels of MYC
expression and leading to a proliferative advantage of the transformed cell (Taub et al.,
1982; Adams et al., 1985; Rowley, 2001). A second type of genetic aberration was the
formation of tumor-specific fusion genes. This was examplified by the above mentioned
t(9;22) translocation in CML which resulted in fusion of the ABL and BCR genes
(Shtivelman et al., 1985; Rowley, 2001). The resulting chimeric BCR/ABL protein showed
an increased tyrosine kinase activity leading to a deregulation of cell cycle control and
apoptosis, through activation of the AKT oncoprotein (Skorski et al., 1997). Other
mechanisms which lead to inappropriate activation of proto-oncogenes are point mutations,
as examplified by these occurring in members of the RAS-family (Tabin et al., 1982), and
gene amplifications which manifest as homogeneously staining regions or double-minute
chromosomes in tumors. One of the first oncogenes identified in this way were MYCN, in
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neuroblastomas (Schwab et al., 1983) and MYCL, in small cell lung carcinomas. Although
they are a less frequent cause, viral infections can also play a role in tumor formation. This
is the case in several cervical cancers and some hepatomas (Weinberg, 1994). From the
above data it is clear that proto-oncogenes can be activated by different mechanisms
leading to a disruption of their control of normal cell growth. However, increased activity
of a single proto-oncogene is generally not sufficient to induce malignant transformation of
a normal cell leading to the concept that multiple proto-oncogenes work together to
transform cells (Weinberg, 1985). Moreover, proto-oncogenes work in concert with a wide
variety of other genetic changes to eventually produce the malignant phenotype. One group
of genes interacting with the proto-oncogenes are tumor suppressor genes.
In contrast to the dominantly acting proto-oncogenes, tumor suppressor genes are genes
whose loss or inactivation contributes to malignant transformation. The existence of tumor
suppressor genes was evidenced from studies of hereditary cancers which showed a clear
pattern of inheritance and a tendency for earlier age of onset as compared to sporadic
tumors. Based on population incidence curves, Alfred Knudson proposed that two genetic
events or ‘hits’ were sufficient to develop retinoblastoma (Knudson, 1971, 2001). In
inherited cases, one of these hits was transmitted through the germ-line while in the
sporadic form of the disease both hits were acquired at the somatic level. Studies of
retinoblastoma patients with cytogenetically constitutional deletions and loss of
heterozygosity (LOH) showed consistent involvement of the chromosomal region 13q14
(Cavenee, 1983) finally leading to cloning of the first tumor suppressor gene, the
retinoblastoma gene (RB1) (Friend et al., 1986; Fung et al., 1987; Lee et al., 1987). Further
studies showed that the RB1 gene played a central role in the cell cycle control and cell
differentiation pathways which were disrupted in most of the cancer types investigated
(Weinberg, 1995). The discovery of the RB1 gene provided a molecular basis for
Knudson’s ‘two-hit’ hypothesis as the proposed two hits affected both alleles of a single
gene, hence the concept of tumor suppressor gene inactivation as a basis of tumor
predisposition was born. Today, Knudson’s model still holds true for most tumor
suppressor genes (Macleod, 2000). However, the notion that loss of a single allele or
haploinsufficiency can be sufficient to promote tumor formation or progression was
recently reported for tumor suppressor genes involved in familial cancer syndromes (i.e
APC and PTEN) (Di Cristofano et al., 1998; Kwabi-Addo et al., 2001; Yan et al., 2002)
pointing at another mechanism of tumor suppressor gene inactivation. Tumor suppressor
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genes which directly intervene in prevention of tumor formation have also been called
‘gatekeepers’ and include the RB1 (retinoblastoma) (Figure 1-2), NF1 (Neurofibromatosis
type I), VHL (von Hippel-Lindau) and APC (Adenomatous polyposis coli) genes (Kinzler
and Vogelstein, 1997; Macleod, 2000). Their loss of function is rate-limiting for tumor
initiation and restoring ‘gatekeeper’ function in tumor cells suppresses neoplasia. By
contrast, ‘caretaker’ tumor suppressor genes are indirectly associated with tumor initiation.
Inactivation of a caretaker leads to genetic instability and accumulation of additional
mutations. Many caretakers are DNA repair genes such as the MSH2 and MLH1 genes
involved in Hereditary Nonpolyposis Colorectal Cancer (HNPCC) or the ATM protein
kinase. Loss of the caretaker function predisposes to cancer by increase of the DNA
mutation rate and increased chances for loss of function mutations in gatekeeper genes. As
a consequence, restoring the function of a caretaker gene would not stop tumor growth if
mutation of one or more gatekeepers had already taken place. The definitions of
gatekeepers and caretakers are flawed when applied to TP53. As an inducer of apoptosis,
TP53 appears to act as a gatekeeper but in its role as “the guardian of the genome”, TP53
can clearly be defined as a caretaker whose major function is to prevent genomic
instability. Finally, some tumor suppressor genes function as ‘landscapers’. The
‘landscaper’ phenomenon was first described in patients with juvenile polyposis syndrome
(JPS) wherein the initiating lesions occurred in the stromal cells surrounding the tumor and
not in the tumor cells themselves (Kinzler and Vogelstein, 1998). The landscaper tumor
suppressor genes act by modulating the microenvironment in which tumor cells
preferentially will grow by direct/indirect regulation of extracellular matrix proteins, cell
surface markers, adhesion proteins or secreted growth/survival factors. In other words, loss
of function of a ‘landscaper’ causes the microenvironment to either function or grow
aberrantly, promoting the neoplastic conversion of adjacent epithelia. Since we know that
germline mutations in PTEN and DPC4 have both been associated with JPS it would be
interesting to determine whether the stromal or epithelial compartment of hamartomatous
lesions show PTEN or DPC4 mutations.
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          Figure 1-2:  Central role of the Retinoblastoma (Rb) tumor suppressor gene in the G1
          to S checkpoint control of the cell cycle.
          (Detailed information is available at http://www.cellsignal.com/retail/reference/pathway/G1S.asp)
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From the above presented data it is clear that cancer does not arise by a single mutation in
a proto-oncogene or by loss of both alleles of a tumor suppressor gene. It is now widely
accepted that cancer occurs as a consequence of several mutations in multiple genes. This
‘multi-step’ model is well illustrated by studies of colorectal cancer. In this tumor at least
seven independent genetic defects appear to be required to transform a normal colon
epithelial cell to a metastasizing carcinoma (Kinzler and Vogelstein, 1996). It has been
argued that an underlying genetic instability is absolutely required for the generation of
multiple mutations that underlie cancer. There is now evidence that most cancers may be
genetically unstable and that instability can occur in two different forms. The so-called
‘mutator’ phenotype, first observed in colorectal cancer, is caused by mutations in one or
several mismatch repair genes. In patients with HNPCC and some sporadic colorectal
cancers, nucleotide changes occur at high frequency in microsatellite repeats and other
repetitive tracts (Kinzler and Vogelstein, 1996). This genetic instability is termed
microsatellite instability or MIN (Thibodeau et al., 1993). MIN tumors are, in general,
diploid and do not show increased rates of chromosome losses and gains. By contrast,
almost 85% of colorectal cancers are highly aneuploid. This nearly always results in
karyotypic variability from cell to cell. This form of genetic instability, termed
chromosomal instability or CIN (Lengauer et al., 1997, 1998), has also been observed in
other solid tumors, including breast, prostate, oropharynx and lung tumors. Unlike MIN
tumors, CIN colon cancers generally do not have instability at the nucleotide level. The
molecular mechanism of CIN remains a mysterious and somewhat controversial issue in
cancer research. Yeast studies have identified more than 100 genes, which gave raise to
CIN when mutated in yeast cells (Spencer et al., 1990). Many of these genes have several
homologues in humans and are involved in chromosome metabolism, spindle assembly and
dynamics, cell cycle regulation and checkpoint control (Lengauer et al., 1998). One gene
proposed as a potential ‘master’ initiator of CIN is the APC tumor suppressor gene (Fodde
et al., 2001; Kaplan et al., 2001). Another class of CIN candidates are those genes involved
in the mitotic-spindle checkpoint and sister-chromatid separation pathways (Amon, 1999;
Jallepalli and Lengauer, 2001). Studies showed that defects in such pathways can lead to
the types of chromosome loss observed in CIN cancers (Cahill et al., 1998; Michel et al.,
2001). Overall, the above mentioned data show that, at least in colon, MIN and CIN are
essentially equivalent mechanisms for acquiring the genetic alterations that are needed for
tumorigenesis. Whereas CIN seems to be the predominant pathway in most sporadically
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occurring solid tumors, hereditary mutations that result in MIN seem to bypass the
requirement for CIN during colorectal tumorigenesis.
An essential step in tumor progression is the acquisition of limitless replicative potential.
In contrast to normal human cells, which proliferate for a limited period of time before
entering senescence (irreversible growth arrest), tumor cells escape replicative senescence,
proliferate indefinitely and become immortal. Interestingly, tumor cells have acquired the
ability to maintain their chromosomal ends, called telomeres, at a stable length. The
enzyme responsible for adding telomeric repeats to the chromosome ends, telomerase, was
shown to be activated in 90% of tumors. Re-activation of telomerase activity is thereby an
essential mechanism for ongoing proliferation and malignancy of tumor cells. Telomerase
is consequently not only a target for cancer diagnosis but also for the development of novel
anti-cancer therapeutic agents (Shay et al., 2001; Stewart and Weinberg, 2002).
At a certain time during the development of most human cancer types, cancer cells will
escape from the primary tumor mass, invade adjacent tissue and travel through blood
vessels or lymphatic system to distant sites of the body where they can extravasate and
form new tumor colonies or metastases. The process of invasion and metastasis is the
result of interactions in a microsystem involving cancer cells, host cells and extracellular
matrix as the basic elements and in which genes coding for extracellular proteases,
integrins and cell-cell adhesion molecules play a key role (Mareel et al., 1995). Analogous
to the regulation of oncogenes and tumor suppressor genes during tumor development, the
regulation of invasion-promoter and invasion-suppressor complexes plays a crucial role in
the progression to the invasive phenotype. For example, experimental studies have
convincingly shown that the E-cadherin/catenin complex exerts an invasion-suppressor
function  (Vleminckx et al., 1991) and mediates an important role in cell-cell adhesion and
signal transduction (Vermeulen et al., 1996). Downregulation of any of the elements in this
complex has been observed in nearly all forms of cancer to be accompanied with invasion
and metastasis indicating that its functional elimination is a key step in the acquisition of
metastatic properties. Invasion and metastasis are associated with the highest degree of
malignancy rendering the disease most of the time incurable.
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1.2 Merkel cell carcinoma
Merkel cell carcinoma  (MCC) is a rare aggressive neuroendocrine skin tumor first
described by Toker in 1972. The disease affects mostly elderly people and occurs
predominantly on the sun-exposed areas of the skin. MCC is thought to be derived from
Merkel cells, although formal proof for this assumption is lacking. Merkel cells are mainly
located in the basal epidermis and have properties of both epithelial and neuroendocrine
cells. Their structure, function and origin will be discussed in more detail below.
1.2.1 Merkel cells: distribution, structure and function
The German anatomist and histopathologist Friedrich Sigmund Merkel showed a great
interest in the possible existence of receptor cells for touch sense in the skin. After
perfecting staining and fixation techniques, Merkel discovered peculiar cells associated
with nerve fibers in mammalian and avian skin, and called these cells “Tastzellen” or
“touch-cells” (Merkel, 1875, 1878). These cells are now called Merkel cells. He postulated
that these cells functioned as receptors for mechanical stimuli in all animals, from
amphibians to man.
It is now known that Merkel cells are widely distributed in the skin and oral mucosa of
every vertebrate class. In addition, they can be found in the outer root sheet of all sinus hair
follicles and most vellus hair follicles.  Merkel cells occur also as serotonergic basal cells
in the basal portion of taste buds in some lower vertebrates such as the frog. There they are
responsible for the initiation of taste bud morphogenesis (Toyoshima et al., 1999) and for
the maintenance of the morphological integrity of taste buds (Hamasaki et al., 1998).
Mammalian Merkel cells typically appear as large, oval, clear cells in or near the basal
layer of the epidermis. By contrast, in birds they are localized in the dermal connective
tissue. Merkel cells are often difficult to visualize by light microscopy and may be
confused with other clear cells such as melanocytes and Langerhans cells. With the
introduction of electron microscopy, Merkel cells were easier identified and their structure
could be studied in more detail (Cauna, 1962). Ultrastructurally, Merkel cells are
characterized by the following features: 1) numerous dense cored granules of 80-100 nm in
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diameter, which show a tendency to accumulate at the attaching site of the nerve terminal;
2) Golgi-complexes in the cytoplasm opposite the major aggregation of dense cored
granules; 3) many microvilli extending randomly from the cell surface; 4) desmosomal
attachments to neighbouring keratinocytes; 5) highly pleomorphic nucleus with several
deep invaginations; 6) frequent contact with nerve terminals; and 7) occasional appearance
of nuclear inclusions. Microvilli and dense cored granules are the most typical and constant
structures of Merkel cells (Figure 1-2).
Figure 1-2: Electron micrograph showing a
Merkel cell and associated nerve terminal (N)
in the hard rabbit-palate. The Merkel cell
contains numerous dense cored granules in the
cytoplasm at the attaching site of the nerve
terminal and has microvilli (arrowheads)
extending from the cell surface and
desmosomal attachments to neighbouring
keratinocytes. Double arrows point to a
synapse-like junction between the Merkel cell
and nerve terminal (x 10,300). Inset: nuclear
inclusion occasionally appears in the Merkel
cell nucleus (x 25,000).
(Reproduced from Toyoshima K., et al.
In:Suzuki H., Ono T., (eds.) Merkel cells,
Merkel cell carcinoma and Neurobiology of
the skin. Elsevier Science B.V., Amsterdam,
2000:p6.)
Immunohistochemical studies show that Merkel cells contain properties of both epithelial
and neuroendocrine-derived cells. They express namely antigens to the low-molecular
weight epithelial cytokeratins (CK) 8, 18, 19 and 20, of which the latter is a well-
established marker of mammalian Merkel cells and Merkel cell carcinoma (Moll et al.,
1995). Expressed neuroendocrine markers include neuron-specific enolase, chromogranin,
synaptophysin and neuropeptide vasoactive intestinal polypeptide but not neurofilament
(Haag et al., 1995). Most of these substances are located in the dense cored granules of
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Merkel cells. For this reason, it was also suggested that the dense cored granules were the
equivalent of synaptic vesicles with the above listed substances serving as
neurotransmitters between Merkel cell and nerve terminal. However, none of the
substances seem to be implicated in the postulated synaptic transduction process. This
leaves the question about the functional role of these substances wide open. So far, there
has been no convincing report on exocytosis of these substances from Merkel cells to
support the assumption of a paracrine or neuroendocrine role.
Studies of developing human foetuses showed that Merkel cells play a role in the
formation of the subepidermal nerve plexus (Narisawa and Hashimoto, 1991; Narisawa et
al., 1992; Narisawa et al., 1993), the development of hair follicles, sweat glands and the
nerves within the nail bed (Moll and Moll, 1993; Kim and Holbrook, 1995). In adults
however, Merkel cells are involved in the deep touch response acting as cutaneous
mechanoreceptors. They are closely associated with terminal axons, which directly contact
the basal surface of the Merkel cells via fusion with the basal lamina of the epidermis. The
cells are found in both hairy and glabrous skin as well as mucous membranes and are
concentrated in the skin of acral areas in humans. Although Merkel cells may rarely occur
alone, without terminal nerve association in the epidermis or dermis, they are usually
found in clusters forming specialized, slowly adapting type I mechanoreceptors such as the
tactile hair disc of Pinkus (Haarscheibe) in hairy skin (Pinkus, 1902; Suzuki et al., 2000).
The hair discs are considerably elevated above the ordinary skin surface, and each contains
one thick hair at its center (Figure 1-3). Under the thick epidermis of the hair discs are
numerous Merkel cells. Other specialized structures associated with Merkel cells in
humans are the hederiform ending of Merkel-Ranvier found in glabrous skin, nose, lip,
palate, and genitalia, and the Merkel touch spots (Tastscheiben) found on the palpebral
margin of the eyelid (Winkelmann and Breathnach, 1973; Munger and Halata, 1984).
In all mammalian Merkel cell receptors, the Merkel cells and nerve terminals are always
oriented in a way that the Merkel cell faces the direction from which physiological stimuli
would normally occur and the nerve terminal on the opposite site (Figure 1-4). Apart from
the contact area with the nerve terminal, the surface of Merkel cells forms numerous
cytoplasmic processes between surrounding cells. This arrangement suggests that the
Merkel cell functions as mechanoelectric transducer with synaptic link to the nerve
terminal. This hypothesis is supported by the finding of increases in cytosolic calcium
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concentrations within Merkel cells during mechanical stimulation and appears to be
essential for the characteristic slowly adapting response of Merkel cell receptors (Baumann
et al., 2000; Tazaki et al., 2000).  Intensive investigation to identify the neurotransmitter
substance, which may be released at this putative synapse, remained negative. As
mentioned previously, various candidates had been found immunohistochemically in the
dense cored granules of Merkel cells without clear evidence for a neurotransmitter function
of any of these substances (Gottschaldt and Vahle-Hinz, 1982).
Figure 1-3: Scanning electron microscopy of hair
disc in rat abdominal skin. Hair disc is domed structure
elevated above the surrounding skin and bears one thick
hair near its center.
(Reproduced from Suzuki H., et al. In:Suzuki H., Ono T.,
(eds.) Merkel cells,  Merkel cell carcinoma and
Neurobiology  of the skin.  Elsevier Science  B.V.,
Amsterdam, 2000:p98.)
Figure 1-4: Electronmicrograph of a Merkel nerve
ending from an epithelial peg of the incisive papilla of a
domestic goat. The longitudinal axis of the Merkel cell
(arrow) is arranged parallel to the surface of the mucosa
(horizontally far outside the picture). The nerve terminal
(arrowhead) is positioned below the Merkel cell. The
direction of pressure is indicated by the arrow.
(Reproduced from Halata Z. and Baumann K.I.,
In:Suzuki H., Ono T., (eds.) Merkel cells,  Merkel cell
carcinoma and Neurobiology  of the skin.  Elsevier
Science  B.V.,  Amsterdam, 2000:p41.)
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1.2.1 Merkel cells: developmental origin
Until now, the developmental origin of Merkel cells is still a matter of debate. The
presence of both epithelial and neuroendocrine ultrastructural and immunocytochemical
features in normal Merkel cells has led to considerable controversy about their origin.
According to one view, Merkel cells arise from the neural crest. After separating from
Schwann cells they migrate from the mesenchyme through the dermis and into the
epidermis, thereby arriving as immigrant cells into the epidermis with extensions of dermal
sensory nerves (Hashimoto, 1972). Due to the presence of bioactive amines and peptides in
the dense cored granules of Merkel cells, they have been classified as members of the
amine precursor uptake and decarboxylation (APUD) system (Winkelmann, 1977).
Originally, it was suggested that all APUD cells were derived from the neural crest and
therefore Merkel cells were also held as derivatives of the neural crest. Many
neuroendocrine cells however can develop from other sources than the neural crest and
may be endodermal  (Andrew, 1982) or mesodermal in origin (Forssmann et al., 1983).
This indicated that a similarity in production of peptide hormones in neuroendocrine cells
does not necessarily mean a common developmental origin. These findings together with
the observed expression of low-molecular weight simple cytokeratins in Merkel cells
contributed to a change in the opinion about their developmental origin. The hypothesis
that they are from epidermal origin derived from precursors of keratinocytes (Moll et al.,
1986) prevails, at least by some authors, over the neural crest immigration theory. Studies
of embryonic and fetal human skin using cytokeratin 20 antibodies demonstrated the
occurrence of Merkel cells as early as fetal week 8 (Moll and Moll, 1992). At that time the
epidermis starts also to develop epidermal intermediate cells (suprabasal keratinocytes) and
Merkel cells were found basally and suprabasally. So the late embryonic/early fetal basal
keratinocytes which express both stratified and simple epithelial CKs may be the
precursors of suprabasal keratinocytes exclusively expressing stratified epithelial CKs and
of Merkel cells expressing only simple epithelial CKs. However, a definitive statement
about the origin of mammalian Merkel cells remains difficult. In addition, low-molecular
weight cytokeratins were also detected in nonepithelial cells, such as glial cells (Viehweg
and Naumann, 1996). The expression of cytokeratins is therefore not necessarily an
indication of the epidermal origin of mammalian Merkel cells.
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1.2.3 Merkel cell carcinoma: epidemiology and clinical features
Originally, the tumor was believed to be derived from poorly differentiated eccrine sweat
glands (Toker, 1972). Subsequent evaluations by immunohistochemistry and electron
microscopy showed neurosecretory granules and suggested the Merkel cell to be the cell of
origin. A variety of alternative names were then proposed such as primary small cell
carcinoma of the skin, murky cell carcinoma and neuroendocrine carcinoma of the skin but
the name Merkel cell carcinoma was prevailing based on ultrastructural features similar to
Merkel cells (O'Connor and Brodland, 1996).
Since Toker’s initial description of this rare skin tumor, less than 2000 cases of MCC have
been reported in the world literature to date (Gollard et al., 2000). However, although the
true incidence of MCC is unknown, there appears to be an increased prevalence of MCC in
regions with a high incidence rate of skin cancer such as Queensland, Australia. MCC
predominantly occurs in persons older then 65 years of age, but patients ranging in age
from 7 to 95 years have been reported (Hitchcock et al., 1988; Messina et al., 1997). In
addition, the tumor has also been described in young adults with congenital ectodermal
dysplasia syndromes (Wick et al., 1983; Gherardi et al., 1990). Caucasians are most
commonly affected with equal distribution between men and women, but there have been
occasional reports in the black population and in Polynesians (Haag et al., 1995). The most
frequently involved sites for primary lesions include the skin of the head and neck region
(50% or more) of which 20% of these affect the periorbital region and eyelid, followed by
extremities (40%) and trunk or mucous membranes (10% or less) (Ratner et al., 1993). The
tumor typically presents as a rapidly growing, firm, nontender nodule with a slightly red to
violaceous color measuring up to several centimeters in greatest dimension. The overlaying
skin is usually intact, smooth, and shiny, although ulceration may be present (Figure 1-5).
Occasionally, telangiectases may be found overlying the tumor, mimicking basal cell
carcinoma. In its early stages, MCC has a nonspecific appearance resulting in a broad
differential diagnosis including undifferentiated squamous cell carcinoma, solid basal cell
carcinoma, malignant melanoma, adnexal tumors, adult neuroblastoma, metastatic small
cell lung carcinoma and cutaneous malignant lymphoma.
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Figure 1-5: Clinical photos of patients with Merkel cell carcinoma on the scalp (A) and the forearm (B).
(Source: Dept. of Dermatology, Ghent University Hospital, Ghent, Belgium)
The predilection for sun-exposed skin in elderly whites and the fact that MCC can be
associated with other UV-induced skin cancers including basal cell carcinoma, squamous
cell carcinoma, Bowen’s disease and actinic keratoses has implicated prolonged sun-
exposure as a possible etiological factor (Pitale et al., 1992). The presence of primary
lesions on non sun-exposed sites such as the oral mucosa and genitalia, however, indicates
that other etiological factors are also important (Tennvall et al., 1989).
1.2.4 Merkel cell carcinoma: histological features and diagnosis
The vast majority of MCC tumors arises within the dermis and can extend into the
subcutaneous fat and muscle tissue. The tumor may rarely involve the overlying epidermis
or may appear to be separated from the overlying epidermis by a grenz zone. The tumor
cells are round with scanty cytoplasm. In the majority of tumors the nuclei show finely
granular dispersed chromatin. Nucleoli are few or absent, very small and usually located
adjacent to the nuclear membrane. Mitotic figures are numerous, necrotic and apototic cells
are often seen within and around the tumor. Vascular and lymphatic invasion of tumor
cells is frequently seen, as well as a surrounding dense infiltrate of lymphocytes and
plasma cells (Ratner et al., 1993; Haag et al., 1995).
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Based on light microscopy studies the tumor was subdivided into three main histologic
subtypes (Gould et al., 1985; Goessling et al., 2002). Most Merkel cell carcinomas
represent the “intermediate” cell variant. This variant consists of nodules and diffuse sheets
of basophilic cells with minimal cytoplasm and round or oval nuclei (Figure 1-6A). The
“small cell” variant is histologically identical to other small cell carcinomas and consists of
irregular, hyperchromatic cells, often showing areas of “crushing” artifacts resulting in
nuclear molding (Figure 1-6B). The “trabecular” or “classic” variant is the most well-
differentiated but is seen in less then one fourth of the cases. This variant is composed of
delicate ribbons of small basophilic cells (Figure 1-6C).
A     B        C
Figure 1-6: (A) Intermediate variant of MCC showing vesicular, basophilic nuclei with prominent nucleoli
and multiple mitoses. (B) Small cell variant, histologically indistinguishable from bronchial small cell
carcinoma. (C) Trabecular variant is rarely observed and normally only seen as a small component of a
mixed variant.  (Reproduced from Goessling et al., Journal of Clinical Oncology 20: 588-598, 2002)
The differential diagnosis includes metastatic small cell carcinoma of the lung, a tumor
which is often indistinguishable using light microscopy alone. Therefore, electron
microscopy and immunohistochemistry play a key role in the correct diagnosis of MCC.
The tumor cells of MCC are ultrastructurally similar to normal Merkel cells containing
cytoplasmic dense cored granules and bundles of intermediate filaments or paranuclear
fibrous bodies. These properties can be sufficient to distinguish MCC from other tumors
such as squamous cell carcinoma but most of the time additional immunohistochemical
studies are needed for definitive confirmation of MCC (Table 1-1). The markers
cytokeratin 20 (CK20) and thyroid transcription factor 1 (TTF-1) are especially useful in
distinguishing Merkel cell carcinoma from metastatic small cell lung carcinoma. Positive
staining of CK20 is observed in MCC and not in SCLC, while TTF-1 is expressed in
SCLC but not in MCC (Leonard et al., 1996a; Cheuk et al., 2001).
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Table 1-1: Immunocytochemical differentiation of MCC from other tumors
(Adapted with minor modifications from O’Connor and Brodland, Dermatol Surg., 22: 262-267, 1996)
                                                                   Immunocytochemical reactant
NSE CK8,18,19 CK20 NFP LCA S100* CH A VIP TTF-1 CK7
MCC + +
(Paranuclear)
+ + - -      +
(50%)
 +
(33%)
- -
SCLC + +
(Diffuse)
-
Rare
- - + - + +
SCC - - - - - - - - - -
Melanoma + - - - - + - - - -
Lymphoma - -      -      -      + - - - - +
(weak)
NSE, neuron-specific enolase; CK, cytokeratin antigen; NFP, neurofilament protein; LCA, leukocyte
common antigen; CH A, chromogranin A; VIP, vasoactive intestinal peptide; TTF-1, thyroid transcription
factor-1; MCC, Merkel cell carcinoma; SCLC, small cell lung carcinoma; SCC, squamous cell carcinoma
*A polyclonal antibody is used directed against the αβ dimer form of the S100 protein (S100-A)
1.2.5 Merkel cell carcinoma: prognosis and treatment
Clinically, MCC is a high-grade, aggressive cutaneous malignancy with a high propensity
for local recurrence and regional lymph node metastasis. Specifically, local recurrence
develops in 26% to 44% of patients after excision of the primary tumor and is usually
apparent within 4 months. Regional lymph node involvement occurs in 55% to 66% of
patients and is found at initial presentation in 12% to 31%. The median time between
treatment of the primary tumor and clinically detectable nodal metastasis is 7 to 8 months.
In patients with nodal involvement, 11% to 66% die of their disease within 5 years.
Systemic disease is associated with a particularly poor response. Although rare at initial
presentation, one third of patients will develop distant metastases, with the most commonly
involved sites being liver, bone, brain, lung and skin. Nearly 50% of the patients followed
for 24 months will develop systemic metastases with a mortality rate of 67% to 74%
(Smith et al., 2000).
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Because of the high degree of local recurrence and early lymph node and distant
metastases in patients with MCC, aggressive treatment is given at the time of initial
diagnosis. Although no widely adopted classification system exists, treatment guidelines
have been based on three clinical stages of disease: local disease without lymph node or
systemic involvement (stage I), regional lymph node development without systemic
disease (stage II), and systemic metastases (stage III). Most treatment guidelines include
wide excision of the primary tumor, alone, or in combination with adjuvant radiation
therapy, therapeutic regional lymph node dissection or selective regional lymph node
dissection (Ratner et al., 1993). A recently performed study by Smith et al. (2000) showed
that combining selective lymphadenectomy and irradiation led to improved survival rates
compared with radiotherapy alone. In addition, selective lymphadenectomy allowed more
accurate treatment with less morbidity to the patient.  Chemotherapy is most widely used
in patients with systemic disease. Due to the rarity of the condition, no firmly established
chemotherapy exists for MCC. The treatment regimens are generally based on those for
small cell lung carcinoma. MCC appears initially to respond to various chemotherapy
agents including cisplatin and etoposide, but the response is typically short-lived
(Redmond et al., 1991; Sharma et al., 1991; Goessling et al., 2002). Table 1-2 presents a
treatment guideline for MCC developed at the H. Lee Moffitt Cancer Center in Florida,
USA.
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Table 1-2: Treatment guideline for Merkel cell carcinoma
                  (Reproduced from Smith et al., Cancer Control 7:72-83, 2000)
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Surprisingly, a few cases of MCC showing complete spontaneous regression have been
reported in the literature (Connelly et al., 2000; Maruo et al., 2000). Since its first
description by O’Rourke and Bell, (1986) the mechanism of spontaneous regression in
MCC is unknown and partially hampered by the lack of long-term follow-up studies of
previously published cases. A recent report by Maruo et al. (2000) described the complete
clinical course of an 80-year-old Japanese woman with regressing MCC, including
histopathological analysis of the tumor just before complete disappearance. The results
revealed that the tumor cells were completely replaced by numerous foamy cells, similar to
a previously described case with spontaneously regressing malignant melanoma (Kanzaki
and Nishiyama, 1985). The authors speculated that in malignant melanoma, tumor cells
might be killed by humoral immunity-mediated membrane lysis in the early stage and by
cell-mediated vacuolization in the late stage of spontaneous regression, while macrophages
finally replace the tumor cells. The same phenomenon could occur in regressing MCCs
although further detailed investigations will be necessary to support this hypothesis.
Nevertheless, Merkel cell carcinoma remains an extremely aggressive tumor not
underestimating the importance of an early diagnosis and aggressive treatment.
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1.3 Genetics of Merkel cell carcinoma
1.3.1 Cytogenetic studies
In contrast to other more common tumor types, the available cytogenetic data for MCC are
sparse. A total of 37 cases have been examined of which eight cases were analyzed in this
study (Table 1-3). One of the major advantages of karyotyping is that the entire genome is
analyzed within one analysis. By this method not only gains and losses of chromosomal
segments can be detected but also the chromosomal rearrangements (e. g. unbalanced
translocations) which lead to these unbalances. Karyotyping is also essential in the
detection of balanced chromosomal rearrangements which may lead to oncogene-
activation or fusion genes. One of the most striking findings of cytogenetic studies of MCC
was the occurrence of structural rearrangements involving the short arm of chromosome 1
in almost 40% of the investigated cases, often leading to loss of chromosomal region 1p36.
This chromosomal region is often deleted in a wide variety of neoplasms including
neuroendocrine tumors such as neuroblastoma and melanoma but also other tumors such as
breast carcinoma, colon carcinoma and hepatocellular carcinoma. Several candidate tumor
suppressor genes have been mapped to 1p36 but thusfar none of the investigated
candidates seemed to be directly involved in tumors with 1p loss (Schwab et al., 1996;
Judson et al., 2000; Steele-Perkins et al., 2001).
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Table 1-3: Overview of the reported chromosomal abnormalities in MCC
Reference Case Tumor
 typea
Modal
number
Structural and numerical abnormalities
Kusyk et al.,
1986 1 LNM 54-64
+X,del(1)(q?23q?24)x2,i(13q),der(15)t(15;21)(q13;q25), +6,
+7,+9,+10,+11,+18,+19,+20,+mar
Hopfner et al.,
1987 2 P 47 i(8q),+6,-10,+12
Rosen et al.,
1987 3 CL 47-48 der(1)t(1;17)(p36;q21),i(5p)x2,der(7)t(7;8)(q26;q22)
Sozzi et al., 1988 4
5
6
7
8
P
LNM
LNM
LNM
P, LNM
45
48
49
44
54
inv(1)(p33q11),+del(1)(p22p33),+1
der(1)t(1;?)(p36;?),+1,+3,+6
i(7p),del(11)(p13p14),der(15)t(15;?)(p12;?),+6,+11,+12
del(1)(p22p32)(q41q44),del(3)(q13q29),+1
del(1)(q31q44),t(1;3)(q31;q26),+1,+9,+10,+11,+12,+14,+18,
+19,+20,+21,+4mar
Sandbrick et al.,
1988 9 LNM 48 del(7)(q31.2),+6,+11
Shabtai et al.,
1989 10 LNM 46 del(2)(p11),del(22q)(q12),-5,-14,-17,+20,-22
Koduru et al.,
1989
11
12
13
LNM
LNM
P, LNM
46
46
47
der(1)t(1;13)(q21;p13),del(5)(q31)
i(1q),der(2)t(2;?)(q37;?),i(6p),der(10)t(10;?)(p15;?),der(17)t
(17;?)(p13;?),-4,+mar
der(1)t(1;6)(q22;p25),der(21)t(21;?)(p13;?),+12,-20
English et al.,
1990
14 LNM 47 +7 or add(7)(q?)
Smadja et al.,
1991
15 BMM 46 dup(1)(q11q44),t(2;3)(p13;q?26q?27),der(15)t(15;?)(p12;?)
Ronan et al.,
1993
16 CL 46 t(1;17)(p36;q21),t(1;6)(p22;q26),r(8),+2,-8,-17
Leonard et al.,
1993
17
18
19
20
21
22
LNM
REC
P
LNM
REC
REC
43
49
44
55
47-49
43-44
der(1)t(1;5)(p36;p13),i(11p)(p10),-1,-11,-13,-22,+mar
+X,-Y,add(7)(p22),i(9q),i(11p),-7,-9,-11,+14
del(1)(p22),del(1)(q21),der(1)(1;?)(q21;?),-1,-3,-11,-13,
-13,+18
+1,-8,+7mar
+1,-5,-8,-13,-13,+5mar
-9,-13,-22
Schlegelberger et
al., 1994
23 LNM 46-48 der(X)t(X;10)(p22;q23),t(1;15)(q12;p13),t(1;16)(q21;p13),
t(1;14)(p12;q32),add(10)(p11),+18,+19
Gibas et al., 1994 24 P 46 del(1)(p36.1)
Tope et al., 1994 25 P 46-48 -Y,+5,+7,+18
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Table 1-3 (continued)
Moll et al., 1994 26
27
CL
CL
45-50
49
i(5p)x2,add(1)(p?),t(1;12)(p13;q13),del(1)(p?),del(2)(q33),
add(6q),add(12q)
del(11)(q21),t(5;17)(p15;p13),t(1;7)(q32;p15p),+6,+20,+Y
Perlman et al.,
1995
28 PM 46 der(1)t(1;3;22)(p34;q28→q11;q12),der(3)t(1;3)(p35;q11),
der(22)t(3;22)(q29;q11)
 Vazquez-
 Mazariego et
 al., 1996
29 LNM 46 der(6)t(1;6)(q23;q27),der(9)t(1;9)(q11;p24)
Larsimont et al.,
1996
30 P 47 +6
Van Gele et al.,
1998
31
16
P
CL
46
47
der(1)t(1;1)(p36.31;q12)
ins(1;?)(p36.2;?),ins(6;?)(q15;?),dic(8;8)(8qter→8p21.2::8p
21.2-->8qter),+r?
Van Gele et al.,
accepted
32
33
34b
35b
36
16
37
CL
CL
CL
CL
CL
CL
M, LNM
46
60
48
46
41
45-46
45
t(7;8;14)(7pter→7q11.23::14q31.1→qter;8pter→8q23::7q11.
23→7q31.1::8q23→8qter;14pter→14q31.1::7q31.1→7qter),
der(9)(9pter→9q34::13q22.2→qter),der(13)(13pter→13q12.
3::16q23q24→16qter),del(12)(q12q14)
+der(X)(Xpter→Xq?::16p?q?→16p?q?),+der(1)(1pter→1q23
::3q23→3qter),del(2)(pter→p13::p16→qter),+der(2)(:2p24;9
qter→9q12),der(3)(3pter→3q23::7q21→7qter),der(4)(1qter
→1q12::4p16→4qter),der(5)(5p15;11qter→11q14.2),+der
(5)(5pter→5q12;18qter→18q?),+der(5)(5pter→5q12;22p?q?
),+6,+8,del(11)(q14.2),+del(12)(q12),+12,der(14)(8p?q?→8p
?8q?::Xq?→Xq?::14p11.1→14qter),+15,+18,der(19)t(19;20)
(p13.3;p?q?),+20,+20,+der(21)(21qter→21p11.2::14q12→
14qter),+22
i(5)(p10)x2,der(7)t(7;11)(q36,q14)
der(1)t(1;17)(p36.3;q21.3),8,der(10)t(10;12)(q23;p11.21)
der(1)(3qter→3q13.3~21::1p35.1→qter),der(3)(3pter→3q
13.3~21::1p36.1→1pter),3,i(4)(p10),der(6)(6pter→6q16;8q2
2→8qter),-10,der(11)(11pter→11q24::3q23→3q25-26.1::
13q?→13q?::3q?29→3qter),-13,der(14)(21qter→21q21::
3p?3q?→3p?q?::13q?→13q?::14p11.2→14qter),der(16)(16
pter→16q24::13q?→→13qter),der(17)(Yqter→Yp11.2::17q1
1.1→17qter::1p35.1→1p34.3::3q13.3~21→3qter),der(20)(20
pter→20q13::4q13→4qter),-21,der(22)(22pter→22p11.2::
3q11.2::22p11.2→22qter)
ins(1;?)(1pter→1p36.2::1q12::?::1p36.2→1qter),ins(6;1;?)(6
pter→6q15::1q12::?::6q15→6qter),dic(8;8)(8qter→8p21.2::8
p21.2→8qter),der(1)r(1;?)(q12::?)
t(3;9;15;17;22)(3pter→3q13.1::22q12→22qter;9pter→9q13::
3q13.1→3q25-26.1::9q13→9q34::15q21.1→15qter;15pter
→15q21.1::3q25-26.1→3qter;17pter→17q24::9q34→9qter;
22pter→22q12::17q24→17qter),-10
aLNM; Lymph Node Metastasis, P; Primary tumor, CL; Cell Line, REC, Recurrence at site, PM; Pulmonary
Metastasis, M; Metastatic tumor
bCases 34 and 35 are subclones of the originally described cell line MKL-1 by Rosen et al., 1987
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1.3.2 Molecular cytogenetic studies
Molecular cytogenetic analyses have been widely applied in the study of cancer genetics.
However, at the start of this study this methodology has not been exploited to investigate
MCC. Therefore, two whole genome scanning methods with proven complementary
resolving power (Van Roy et al., 2001; Van Limbergen et al., 2002) were used in this
study. Firstly, we applied a technique called ‘comparative genomic hybridization’ (CGH)
which enables the whole genome to be screened for chromosomal losses, gains and gene
amplifications in one single experiment. We analyzed 26 tumor samples and eight cell
lines by CGH. This study revealed a characteristic pattern of chromosomal gains and losses
occurring in MCC (see Part 2). A second approach was the use of multiplex FISH
(Speicher et al., 1996) in combination with CGH and karyotyping. This technique allows
hybridization of 24 differentially labeled chromosome-specific painting probes onto tumor
metaphase spreads. In contrary to conventional FISH, prior knowledge of the nature of
chromosomal rearrangements is not required. In addition, M-FISH allows detection of
balanced translocations which is not possible with CGH. By combined analysis of six
MCC cell lines and one MCC tumor a detailed characterization of previously unnoticed
(complex) rearrangements was obtained. The results of this study are described in Part 2.
1.3.3 Loss of heterozygosity (LOH) studies and candidate gene analysis
In LOH studies highly polymorphic markers such as microsatellites (Weissenbach et al.,
1992) or single nucleotide polymorphisms (SNPs) (Sherry et al., 2001) are used to detect
small deleted regions by comparing the genotype of a tumor to that of its matching normal
DNA. Shortest regions of overlap (SROs) of deleted regions are defined which can point to
the possible presence of one or more putative tumor suppressor genes in this particular
region (Devilee et al., 2001). So far there have been only a few LOH studies performed in
the search for possible candidate tumor suppressor genes involved in MCC. Three LOH
studies on the short arm of chromosome 1 showed frequent occurrence of 1p deletions and
resulted in the delineation of multiple SROs, indicating that more than one tumor
suppressor gene is likely to play a role in the development of MCC (Harnett et al., 1991;
Vortmeyer et al., 1998; Leonard et al., 2000) (Table 1-4). A targeted analysis of two 1p36
breakpoints was performed by FISH with region specific probes and polymorphic markers
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in this study. This led to the identification of two distinct regions, 1p36.2 and 1p36.3
respectively being involved in MCC (see Part 2). A possible candidate tumor suppressor
gene for MCC tumors with distal 1p36 deletions was the TP73 gene. Mutation analysis of
this gene together with TP53 was performed for MCC in this study resulting in one TP73
missense mutation and several TP53 mutations (see Part 3 and Table 1-4). Other LOH
studies to search for deletions at 3p, 13q, 10q and 9p have been performed together with
mutation analysis or expression studies of candidate tumor suppressor genes such as FHIT,
RB1, PTEN (see Part 3),  p16INK4a and p14ARF located in these deleted regions (Table 1-4).
Table 1-4: Overview of reported LOH and molecular analysis studies in MCC
References Number  of
cases
Chromosomal
region
SRO at Candidate gene analysis:
Gene:                                  Results:
Harnett et al., 1991  3 tumors 1p 1p35-36  Not done
Leonard et al., 1996b 26 tumors 3p 3p13-21.1  Not done
Sozzi et al., 1996 14 tumors 3p14.2 Not
applicable
FHIT gene: - abnormal FHIT products in
57% MCCs lacking three or more exons
Leonard and
Hayward,  1997
24 tumors 13q 13q14.3 RB1 gene:  - no detectable RB1 expression
by Western blot analysis
Schmid et al., 1997 25 tumors 17p Not
applicable
TP53 gene: - TP53-immunoreactive nuclei
in 20% MCCs but no mutations in exons
4-8 by SSCP
Vortmeyer et al., 1998 10 tumors 1p 1p35-36  Not done
Van Gele et al., 2000 10 tumors
      and
5 cell lines
1p
      17p
Not
applicable
Not
applicable
TP73 gene:  - one missense mutation
TP53 gene: - four missense and one non-
sense mutation by direct sequencing of
cDNA
Leonard et al., 2000 22 tumors
      and
6 cell lines
1p 1p36
1p35
1p32-33
Not done
Van Gele et al., 2001 26 tumors
      and
8 cell lines
10q23 10q23.3 PTEN gene: - one  nonsense mutation
- one homozygous deletion
                       of exon 9
Cook et al., 2001 29 tumors
      and
5 cell lines
9p 9p24
9p21
p16INK4a and p14ARF genes: - no mutations
                                            - expression of
both proteins detected by Western blots
and immunohistochemical studies
Popp et al., 2002 6 cell lines 17p Not
applicable
TP53 gene: - two missense mutations by
sequencing of exons 5-8
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1.3.4 Genetic similarities and differences between MCC, SCLC, melanoma, SCC
            and BCC
Unlike SCLC, only few CGH studies have been performed for MCC, cutaneous malignant
melanoma, squamous cell carcinoma (SCC) of the skin and basal cell carcinoma (BCC).
Table 1-5 gives an overview of the most frequently chromosomal gains and losses detected
by CGH in at least one of the above mentioned tumor types. These data illustrate that the
most common genetic changes are found between MCC and SCLC.
Table 1-5: Presence (+) or absence (-) of gains and losses detected by CGH in MCC,
                 SCLC, SCC, melanoma and BCCa
aGrey boxes are used to facilitate visual inspection of similarities between MCC and other tumor
 types; WCG, whole chromosome gain; WCL, whole chromosome loss
bRepresentation of frequently occurring chromosomal abnormalities in MCC, SCLC, SCC, melanoma
 and/or BCC based on CGH reports
Results based  on CGH  studies of  cVan Gele et al., 1998 and Popp et al., 2002; dRied et al., 1994, Levin et
al., 1995 and  Petersen et al., 1997;  ePopp et al., 2002; fBastian et al., 1998 and Balázs et al., 2001; gAshton
et al., 2001
In addition to gains and losses, distinct high-level amplifications are often observed in
SCLC, SCC and melanoma whereas gene amplifications are rarely seen in MCC and BCC.
MCCc SCLCd SCCe Melanomaf BCCg
1q+b          + WCG - - + -
+2 - - - + -
3p- + + + - -
3q+ + + - - -
4p- + + + - -
4q- - + - - -
5p+ + + - - -
5q- + + - - -
6p+ + WCG - - + +
6q- - - - + -
7p+ + WCG - + + WCG + WCG
8p- + + + + -
8q+ + + + + WCG -
9p- - - + + -
 9p+ - - - - +
9q- - - - - +
10q-          + WCL + -          + WCL -
11q- + - - - -
 11q+ - - + - -
13q- + + - - -
17p- + + - - -
17q+ - + - + WCG -
+19 + - - - -
+20 + - - + -
Xq+ + WCG + - - + WCG
Aims of the study 38
1.4 Aims of the study
The aim of this thesis was to make a contribution to the understanding of the genetic basis
of Merkel cell carcinoma. To this purpose three strategies were applied:
1. Molecular cytogenetic identification of critical genomic regions in Merkel cell
carcinoma.
In view of the frequent occurrence of 1p abnormalities in MCC, we applied FISH with
region specific probes and microsatellite markers to study two MCC cases carrying
1p36 rearrangements in order to delineate the position of putative tumor suppressor
gene(s). To search for other critical chromosomal regions implicated in MCC various
whole genome screening methods were used. Standard karyotyping was performed on
two MCC tumors and six MCC cell lines. Twenty-six tumor samples and eight MCC
cell lines were investigated by CGH to search for characteristic patterns of
chromosomal losses, gains and gene amplifications. M-FISH in combination with
karyotyping, conventional FISH and CGH was applied in order to describe complex
chromosomal rearrangements in further detail. The results of these studies are reported
in Part 2.
2. Mutation analysis of candidate tumor suppressor genes in Merkel cell carcinoma.
Mutation analysis was performed for (candidate) tumor suppressor genes TP73
(1p36.3) and PTEN (10q23.3) both located in chromosomal regions which were shown
to be recurrently lost by one or more of the above mentioned techniques. The results of
these studies are described in Part 3.
3. Differential gene expression analysis in Merkel cell and small cell lung carcinoma.
In view of the current limited understanding of the molecular pathogenesis of MCC
and the clinical, morphological and genetic similarities with SCLC, we performed
gene expression profiling analysis of 10 MCC and 4 SCLC cell lines using Atlas
cDNA expression arrays containing 1891 unique genes involved in many cellular
functions. We searched for biological markers to improve differential diagnosis of
MCC and SCLC. In addition, we aimed to identify specific gene expression signatures
associated with the phenotypically different subgroups of MCC. The results of this
study are described in Part 4.
PART 2
Identification Of Critical
Genomic Regions
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2.1 Molecular cytogenetic identification of critical genomic regions
2.1.1.  Molecular analysis of 1p36 breakpoints in two Merkel cell carcinomas
Van Gele M., Van Roy N., Ronan S.G., Messiaen L., Vandesompele J., Geerts M.L.,
Naeyaert J.M., Blennow E., Bar-Am I., Das Gupta T.K., van der Drift P., Versteeg R.,.
Leonard J.H, and Speleman F.  Genes Chrom Cancer, 23: 67-71 (1998).
2.1.2. Characteristic pattern of chromosomal gains and losses in Merkel cell
carcinoma detected by comparative genomic hybridization
Van Gele M., Speleman F., Vandesompele J., Van Roy N., and Leonard J.H.
Cancer Res, 58: 1503-1508 (1998).
2.1.3. Combined karyotyping, CGH and M-FISH analysis allows detailed
characterization of unidentified chromosomal rearrangements in Merkel cell
carcinoma
Van Gele M., Leonard J.H., Van Roy N., Van Limbergen H., Van Belle S., Cocquyt V.,
Salwen H., De Paepe A., and Speleman F.  Int J cancer (accepted).
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2.1.1.  Molecular analysis of 1p36 rearrangements in Merkel cell carcinomas
Our initial interest in MCC was triggered by reports describing 1p abnormalities, often
leading to loss of distal 1p material and a paper by Ronan et al. (1993) describing an
unbalanced 1;17 translocation. As both 1p deletions and 1;17 translocations were
frequently recognized in neuroblastoma, a pediatric neuroectodermal tumor, a pilot study
was set up in order to study 1p abnormalities in MCC.
In this report, FISH with region specific probes and high-polymorphic microsatellite
markers were used to study two particular chromosome 1p36 rearrangements in an MCC
tumor and MCC cell line, respectively. Our analysis showed that two distinct regions,
1p36.3 and 1p36.2, can be implicated in MCC. Each of these regions could harbour a
putative tumor suppressor locus. Our findings provided thus further evidence for a role of
at least two tumor suppressor genes on 1p involved in MCC.
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Molecular Analysis of 1p36 Breakpoints in Two Merkel
Cell Carcinomas
M. Van Gele,1 N. Van Roy,1 S.G. Ronan,3 L. Messiaen,1 J. Vandesompele,1 M.L. Geerts,2 J.M. Naeyaert,2
E. Blennow,4 I. Bar-Am,5 T.K. Das Gupta,3 P. van der Drift,7 R. Versteeg,7 J.H. Leonard,6 and F. Speleman1*
1Department of Medical Genetics, University Hospital, Ghent, Belgium
2Department of Dermatology, University Hospital, Ghent, Belgium
3Department of Surgical Oncology, University of Illinois, Chicago, Illinois
4Department of Molecular Medicine, Karolinska Hospital, Stockholm, Sweden
5Applied Spectral Imaging Ltd., Tel Aviv, Israel
6Queensland Radium Institute Laboratory, Queensland Institute of Medical Research, Brisbane, Queensland, Australia
7The Institute of Human Genetics, Academic Medical Centre, University of Amsterdam, The Netherlands
Merkel cell carcinoma (MCC) is a rare aggressive neuroendocrine tumor of the skin. Only little information is available on the
genetic alterations occurring in this tumor. Cytogenetic studies thus far have not shown recurrent chromosomal changes,
although various structural chromosome 1 rearrangements, including deletions, often leading to loss of distal 1p material appear
to be frequent. We report on fluorescence in situ hybridization and loss of heterozygosity analyses of an MCC tumor and MCC
cell line UISO. The present study has shown that two distinct regions in the most distal band 1p36 on the short arm of
chromosome 1 can be implicated in MCC. One region at 1p36.3 was delineated by a distal deletion in the MCC tumor as a
result of an unbalanced translocation, resulting in loss of all markers distal to ENO1. This region was previously shown to be
deleted in different tumor types including neuroblastoma. In cell line UISO an insertion in 1p36.2 was identified. The insertion
breakpoint indicates a second, more proximal, region on 1p involved in MCC. The insertion breakpoint was mapped within a
cluster of repetitive tRNA and snRNA genes and thus could coincide with the constitutional 1p36 breakpoint previously
reported in a patient with neuroblastoma. Genes Chromosomes Cancer 23:67–71, 1998.  1998 Wiley-Liss, Inc.
Merkel cell carcinoma (MCC), or neuroendo-
crine carcinoma, is a rare tumor of the skin that was
first described by Toker in 1972. The tumor is
thought to be derived from Merkel cells, which are
located in the basal epidermis in areas of tactually
sensitive skin. They are thought to be mechanore-
ceptors of neuroendocrine origin, although their
exact function is still controversial. The disease
occurs predominantly in older fair-skinned people.
To date, karyotypic analysis on MCC has been
performed on 24 tumors and five cell lines. Only
three loss of heterozygosity (LOH) studies have
been reported thus far (Harnett et al., 1991; Leo-
nard et al., 1996; Leonard and Hayward, 1997). All
of these studies showed a variety of chromosomal
abnormalities. No particular recurrent chromosome
translocation has been described, but structural
rearrangements involving chromosome 1 have been
frequent. Often, 1p rearrangements, including dele-
tions, were observed. Loss of chromosome arm 1p
material has also been described in many other
tumors includingmelanoma, colon carcinoma, breast
carcinoma, hepatocellular carcinoma, pheochromo-
cytoma, and neuroblastoma (for review, see Schwab
et al., 1996). These observations strongly suggest
the presence of tumor suppressor genes on 1p that
are implicated in the development of these tumors.
Combined cytogenetic and molecular analyses in
neuroblastoma allowed us to propose at least three
distinct putative tumor suppressor loci on 1p (Ver-
steeg et al., 1995). In the present study, we used a
similar approach for MCC and found two chromo-
some 1 rearrangements, each of which could point
at distinct chromosomal regions harboring putative
tumor suppressor loci.
Patient UHG-VM was a woman born in 1915.
She was first seen in the Department of Dermatol-
ogy in June 1995 with a preliminary diagnosis of
B-cell lymphoma. Clinically, she had a rapidly
growing tumor on the right lower calf, with two
palpable lymph node metastases in the right ingui-
nal region. Biopsies from the primary tumor and of
the pathologically enlarged inguinal lymph nodes
were diagnosed as MCC by histological examina-
tion. Immunohistochemistry showed positivity for
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NSE and CAM 5.2 (paranuclear dots). Staging
procedures included computed tomographic exam-
inations of the chest, abdomen, and brain and bone
marrow examination. No internal tumors or metas-
tases were detected. The general clinical condition
of the patient was poor, and treatment was started
with photon therapy of the primary tumor and the
right inguinal region. During this therapy, multiple
in-transit metastases developed and treatment was
changed to electron beam therapy (cumulative dose
of 60 Gy). The volume of the primary tumor regressed
about 40%. The patient died in October 1995.
Karyotyping was performed on G-banded meta-
phase cells obtained from short-term cultures of
tumor UHG-VM according to standard procedures.
The karyotype of cell line UISO has been de-
scribed by Ronan et al. (1993). Fluorescence in situ
hybridization (FISH) was performed according to
the method of Van Roy et al. (1994) by using the
following DNA probes: chromosome-specific plas-
mid (pBS) libraries for all individual chromosomes,
pUC1.77 (D1Z1 for the heterochromatic region of
chromosome 1), p1–79 (D1Z2 on 1p36.33), c102
(D1S172 on 1p36.33), p58 (CDC2L1 on 1p36.33,
Oncor P5124-dig), 27 (ENO1 on 1p36.32-p36.31),
12A-2 (NPPA on 1p36.31-p36.23), and cHE2.6
(A12M2 on 1p36.1). PACs LLNLP704N14224Q and
LLNLP704I09167Q were shown to flank the 2-Mb
cluster of tRNA and snRNA genes at 1p36.2 (van der
Drift, personal communication). The following CEPH
YAC clones for the 1p regionwere used: 807h7 (RIZ on
1p36), 209e9 (MYCL1 on 1p34.3), and 728f1. The YAC
clone 728f1 shows three distinct hybridization patterns
on chromosome 1 (1p36.2-p36.13, 1p12, and 1q21) due
to the presence of multiple tRNA and snRNA genes
and pseudogenes at these sites (unpublished data).
FISH images were recorded on a Leitz DM micro-
scope with a black-and-white CCD camera (Sony
IMAC-CCD 830) and the ISIS software program from
Metasystems (Germany) for image capture anddigitiza-
tion. Color prints weremade on a digital colorMitsubi-
shi printer CP-D1E. LOH analysis was performed by
using the following microsatellite CA-repeat markers
for the short arm of chromosome 1: D1S243, D1S214,
D1S228, D1S199, D1S234, D1S211, D1S220, and
D1S216. The CA-strand primers were fluorescein la-
beled at the 5 end. CA-repeat fragments were ampli-
fied essentially as described by Schleiermacher et al.
(1994). All polymerase chain reaction fragments were
electrophoresed on an ALF; Automated DNA se-
quencer (Pharmacia) on a 6% LongRanger; (AT
Biochem) 8 M urea denaturing gel. In every lane, size
markers (63, 135, 250, and/or 334 bp) were loaded to
correct for minor bandshifts during gel electrophoresis.
Genotyping for allmarkerswas carried out by using the
FragmentManager; 1.1 software.
Karyotype analysis performed on short-term cul-
tures of MCC tumor UHG-VM showed a 1p rear-
rangement as the only structural chromosomal
change. Additional material was translocated onto
the short arm of one chromosome 1. The banding
pattern of this additional material suggested a 1q
origin (Fig. 1a), which was confirmed by FISH with
a chromosome 1 library (not shown). Cohybridiza-
tion of pUC1.77 (D1Z1) and p1–79 (D1Z2) demon-
strated the presence of D1Z1 sequences in the
translocated 1q segment, indicating that an entire
chromosome 1 long arm was translocated. This
hybridization also showed loss of the D1Z2 locus on
the der(1) (Fig. 2a). Subsequent hybridizations
with 1p-specific probes showed that the deleted
segment was small because only the most distal
markers D1S172, CDC2L1, and D1Z2 were lost.
Because ENO1 was retained, the deleted segment
did not extend further than subband 1p36.31 (Fig.
3). LOH analysis was in agreement with the data
obtained by FISH (Fig. 3). Thus, the karyotype is
described as 46,XX,der(1)t(1;1)(p36;q12–21).ish der(1)
t(1;1)(p36.31;q12) (wcp1,D1Z1, D1S172,
CDC2L1, D1Z2,ENO1, NPPA, A12M2,
MYCL1).
In the MCC cell line UISO, the abnormal chro-
mosome 1 was originally described as an unbal-
anced translocation t(1;17)(p36;q21) together with
other cytogenetic abnormalities (Ronan et al., 1993).
The derivative chromosome 1 is shown in Figure
1b. Cohybridization of libraries specific to chromo-
somes 1 and 17 could not demonstrate the presence
of chromosome 17 material on the der(1) (not
Figure 1. Partial G-banded karyotypes showing the chromosomes 1
of tumor UHG-VM (a) and cell line UISO (b).
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shown). The staining pattern of the chromosome 1
library indicated that the der(1) was the result of an
insertion rather than an unbalanced translocation
(Fig. 2b). To confirm the presence of the insertion
and to determine the insertion breakpoint, a panel
of 1p probes was tested with D1Z2 by two-color
hybridization. Overlap or close colocalization of
both probes on the der(1) indicated that the tested
DNA probe mapped distal to the insertion break-
point. Separation of both signals indicated that the
tested DNA probe mapped proximal to the inser-
tion breakpoint. Using this approach, we initially
mapped the 1p breakpoint betweenRIZ and A12M2
(Fig. 2c). A12M2 has been shown to map within a
2-Mb tRNA–snRNA gene cluster on 1p36.2 (van
der Drift et al., 1994). Hybridization with YAC
728f1 showed that this gene cluster was split
because of the insertion (not shown). This observa-
tion was confirmed by cohybridization with two
PAC clones flanking the tRNA–snRNA gene clus-
ter (Fig. 2d). All tested 1p markers were present in
one copy on the der(1), and LOH markers (Fig. 3)
were found to be retained, indicating that no
detectable loss of 1p material resulted from the
insertion at 1p36.2. In a first attempt to identify the
chromosomal origin of the inserted material, we
hybridized metaphases from this cell line with
libraries from each individual human chromosome,
but no specific staining at 1p36 could be observed.
Further attempts with microdissection and SKY
analysis also remained inconclusive.
In the MCC tumor, cytogenetic and FISH analy-
ses demonstrated translocation of an entire chromo-
some 1 long arm onto the distal end of the short arm
(1p36) of a chromosome 1 as the sole karyotypic
change. Gibas et al. (1994) also reported a 1p36
abnormality as the only chromosomal change in an
MCC tumor. Furthermore, loss or structural rear-
rangements of band 1p36 with other karyotypic
abnormalities occurs frequently in MCC. Together
with the literature data, the present observation
provides further evidence for a role of one or more
genes on 1p in the development of MCC. Recently,
LOH for one or more 1p loci was observed in 75%
of MCC tumors (Leonard et al., unpublished data).
In MCC tumor UHG-VM, FISH using region-
specific probes and LOH analysis showed loss of
the most distal part of 1p (1p36.31= pter) includ-
ing markers D1Z2, CDC2L1, and D1S172. The
analysis of cell line UISO showed an insertion at
1p36.2. This insertion breakpoint was located proxi-
mal to the deleted region in tumor UHG-VM and
between the RIZ gene, which encodes for a retino-
blastoma binding protein (Buyse et al., 1995) and
the adenovirus integration site (A12M2), which is
located within a cluster of tRNA–snRNA genes
(van der Drift et al., 1994). Molecular analysis of the
MCC tumor UHG-VM and MCC cell line UISO
thus provides evidence for involvement of two
distinct loci within 1p36.
Loss of chromosome arm 1p material has also
been reported in many other tumors including
neuroblastoma. In neuroblastoma, a tumor of neuro-
endocrine origin as is MCC, several putative tumor
suppressor loci on 1p have been proposed. An
imprinted tumor suppressor gene is thought to
reside in a frequently deleted region in 1p36.3
delineated by loci D1S47 (telomeric) and D1S244
(centromeric) (Caron et al., 1995; Schwab et al.,
1996). The monoallelically expressed TP73 gene,
which is a TP53 homologue, maps within this
region (Kaghad et al., 1997). One of the more
proximal putative neuroblastoma tumor suppressor
loci is delineated by the 1p breakpoint of the
constitutional 1;17 translocation found in a patient
with neuroblastoma and coincides with the inser-
tion breakpoint of the MCC cell line UISO (Lau-
reys et al., 1995; van der Drift et al., 1995). Cloning
of the constitutional 1;17 breakpoint and the UISO
1p36 insertion breakpoint will resolve whether the
same gene in both rearrangements is affected and
Figure 2. FISH on tumor UHG-VM using probes for region 1q12
(D1Z1, red) and 1p36.33 (D1Z2, green; a) and cell line UISO using
probes for chromosome 1 (pBS-1; b), probes for loci D1Z2 (red) and
A12M2 (green; c), and probes for PAC clones LLNLP704N14224Q
(red) and LLNLP704I09167Q (green) flanking the repetitive tRNA–
snRNA gene cluster on 1p36.2. (d). Arrowheads point at the abnormal
chromosome 1.
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could play a similar role in the development of both
tumors and possibly also in other neuroectodermal
tumors that show 1p loss.
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Figure 3. Top: Summary of the FISH and LOH data for chromosome
arm 1p markers. Open square, presence of tested FISH markers on the
der(1); solid square, absence of tested FISH markers on the der(1); open
circle, heterozygous; solid circle, LOH; shaded circle, not informative
for indicated microsatellite CA-repeat markers. Bottom: CA-repeat
) peripheral blood of UHG-VM, and (c) MCC cell line UISO. Size range
size marker was loaded (135 and 250 bp), flanking the microsatellite.
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of this microsatellite is 142–170 bp. In every lane of the gel, an interval
fragment analysis of microsatellite D1S243 in (b) MCC tumor UHG-VM,
(a
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2.1.2.  Characteristic pattern of chromosomal gains and losses in Merkel cell
carcinoma detected by comparative genomic hybridization
In view of the limited available genetic data for MCC, we decided to search for previously
unrecognised genomic regions involved in MCC. To this purpose, we applied a technique
called ‘comparative genomic hybridization’ (CGH) which allows screening of the entire
tumor genome for gains, losses and gene amplification. In contrast with karyotyping, CGH
does not require short-term cultivated tumor cells but can be performed with DNA isolated
from fresh, frozen or paraffin-embedded material (Kallioniemi et al., 1992; du Manoir et
al., 1993; du Manoir et al., 1995). Characteristic patterns of gains and losses and/or
amplification have been found previously in certain tumors or tumor subtypes (overviewed
at http://www.progenetix.net). Recurrent losses may point at the chromosomal position of
tumor suppressor genes involved in these tumors. Likewise, high level amplification often
indicates the implication of particular proto-oncogenes. The identification of recurrent
imbalances in MCC, could point at tumor suppressor genes or proto-oncogenes mapping in
these regions and offer targets for further investigations.
In this study, 26 MCC tumors and eight MCC cell lines were analyzed by CGH. Overall
frequent loss was observed for chromosomes 3p (46%), 5q (21%), 8p (21%), 10 (33%),
11q (17%), 13q (33%) and 17p (25%) and significant gains were observed for
chromosomes 1 (63%), 3q (33%), 5p (38%), 8q (38%), 19 (63%) and X (41%). We found
that this characteristic pattern of gains and losses in MCC resembled the CGH patterns
previously observed for SCLC. This observation suggests that a number of common genes
or pathways can be involved in the tumorigenesis of both MCC and SCLC. In contrast with
SCLC, no high-level gene amplifications were observed in MCC.
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2.1.3. Combined karyotyping, CGH and M-FISH analysis allows detailed
characterization of unidentified chromosomal rearrangements in Merkel cell
carcinoma
In addition to CGH, we applied M-FISH to identify and characterize chromosomal
rearrangements occurring in MCC in further detail (Speicher et al., 1996). M-FISH allows
detection of balanced translocations which is not possible with CGH. In complex
karyotypes or in poorly spread and banded metaphases a significant number of
rearrangements can be overlooked by banding analysis only, but may be detected by M-
FISH. In contrast with conventional FISH, prior knowledge of the nature of chromosomal
rearrangements is not required. Previous studies illustrated that an optimal resolving power
was obtained for M-FISH when combined with karyotyping, CGH and standard FISH
(Van Roy et al., 2001; Van Limbergen et al., 2002).
In this report, six MCC cell lines and one metastatic MCC tumor were analyzed by
karyotyping, CGH, M-FISH and FISH with region specific probes. Almost all studied
cases showed near-diploid karyotypes with simple karyotypic changes, multi-way
translocations or various numerical and structural changes. The major chromosomal
changes observed were chromosomal rearrangements involving the short arm of
chromosome 1 and the long arm of chromosome 3, gain of 5p material and loss of
chromosome 10. In addition, M-FISH allowed identification of many previously unnoticed
rearrangements distributed throughout the whole genome. Our accurate cytogenetic
profiling of the chromosomal abnormalities occurring in MCC opens new perspectives in
the search for candidate genes located in these chromosomal regions.
Part 2. Identification of critical genomic regions 56
Combined karyotyping, CGH and M-FISH analysis allows
detailed characterization of unidentified chromosomal
rearrangements in Merkel cell carcinoma
Mireille Van Gele1, J. Helen Leonard3, Nadine Van Roy1, Heidi Van Limbergen1,
Simon Van Belle2, Veronique Cocquyt2, Helen Salwen4, Anne De Paepe1, and Frank
Speleman1
1Center for Medical Genetics and 2Medical Oncology, Ghent University Hospital, Ghent,
  Belgium
3Queensland Radium Institute Laboratory, Queensland Institute of Medical Research,
  Brisbane, Queensland, Australia
4Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL,
 USA
Running title: M-FISH on Merkel cell carcinomas
Keywords: M-FISH, Merkel cell carcinoma,1p rearrangements, 3q rearrangements
Abbreviations: MCC: Merkel cell carcinoma, CGH: comparative genomic hybridization,
                        M-FISH: multiplex-fluorescence in situ hybridization
Int J Cancer (accepted)
Correspondence to:   Prof. Frank Speleman
                Center for Medical Genetics
                Ghent University Hospital
                De Pintelaan 185
                 9000 Ghent
               Belgium
                 Tel: 32-9-240 24 51
                 Fax: 32-9-240 49 70
                 e-mail: franki.speleman@rug.ac.be
Part 2. Identification of critical genomic regions 57
Abstract
Merkel cell carcinoma (MCC) is a rare aggressive neuroendocrine tumor of the skin.
Cytogenetic studies indicated that deletions and unbalanced translocations involving
chromosome 1 short arm material occur in 40% of the investigated cases. Recurrent
chromosomal imbalances detected by CGH analysis were loss of 3p, 10q, 13q and 17p and
gains of 1q, 3q, 5p and 8q. In order to study genomic aberrations occurring in MCC in
further detail we combined karyotyping, CGH and M-FISH, a strategy which proved to be
successful in the analysis of other malignancies. Analysis of 6 MCC cell lines and one
MCC tumor revealed mostly near-diploid karyotypes with an average of 5 chromosomal
rearrangements. The observed karyotypic changes were heterogeneous with 3 to 27
breakpoints per case leading to imbalance of the involved chromosomal regions confirmed
by CGH. Chromosomal rearrangements involving the short arm of chromosome 1, the long
arm of chromosome 3 and gain of 5p material were the most frequently observed
abnormalities in this study. In keeping with previous observations, this series of MCCs
showed no evidence for high level amplification. We provided a detailed description of
chromosomal translocations occurring in MCC which could be useful to direct future
intensive investigation of these chromosomal regions.
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Introduction
Merkel cell carcinoma (MCC) is a rare aggressive tumor which occurs mainly on
sun-exposed areas of the skin in elderly people. The tumor is thought to originate from
Merkel cells. These cells are located in the basal layers of the epidermis and are the
mechanoreceptors of the skin.1
Up to now, cytogenetic analysis of 27 tumors and 4 MCC cell lines have been
reported.2-20 Recurrent reciprocal translocations leading to fusion genes or activation of
dominantly acting oncogenes have thus far not been identified in this tumor. Structural
abnormalities involving the short arm of chromosome 1 were observed in 40% of the
studied cases often leading to loss of distal 1p-material, which suggests the involvement of
one or more tumor suppressor genes located in this region. Detailed molecular cytogenetic
analysis of two chromosomal 1p-rearrangements revealed that at least two distinct critical
regions within 1p36 were involved in MCC.20 Loss of heterozygosity (LOH) studies for
1p-markers confirmed the high incidence of allelic imbalance for the 1p region and showed
complex patterns of losses for the distal part of chromosome 1.21-23 High incidence of 1p
losses has also been described in many other tumors including colon and breast
carcinomas. Several candidate tumor suppressor genes have been mapped to the various
shortest regions of overlap on 1p but none of them seem to be directly involved in tumors
with 1p loss.24 Comparative genomic hybridization (CGH) on 26 MCC tumors and eight
cell lines showed recurrent gains of chromosome 1q, 3q, 5p, 8q, 19 and X and losses of 3p,
5q, 8p, 10q, 11q, 13q and 17p.25 In addition, losses of 3p, 9p, 10q and 13q were evidenced
by LOH analyses.26-29
In view of our limited understanding of the underlying genetic defects leading to
MCC and given the extremely poor response of MCC to current treatment protocols,
further refined analysis of chromosomal changes occurring in MCC is warranted. In the
present study we combined karyotyping, CGH, FISH with region specific probes and
multiplex-fluorescence in situ hybridization (M-FISH)30 to obtain a detailed description of
the chromosomal aberrations in 6 MCC cell lines, 3 of which were not previously
subjected to cytogenetic investigation, and one new MCC tumor. The findings in these cell
lines and tumor are discussed and compared to the available cytogenetic data for MCC.
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Material and Methods
MCC cell lines and MCC tumor sample
Details of morphology, DNA content and immunohistochemistry of cell line MCC13 was
previously described by Leonard et al.31. Characterization and cytogenetic data of cell line
UISO were published by Ronan et al.12. Cytogenetic and morphologic analysis of cell line
MKL-1 and its two subclones was described by Rosen et al.4. Only the two subclones of
MKL-1 were analyzed in this study. Cell line MCC26 was established at the Queensland
Radium Institute Laboratory, Queensland Institute of Medical Research, Brisbane,
Queensland, Australia and cell line MKL-2 at the Robert H. Lurie Comprehensive Cancer
Center, Northwestern University, Chicago, IL, USA. The latter was established from a 72-
year-old white male of which the pathological records were unfortunately not available.
Fresh tumor material from a patient with Merkel cell carcinoma (case UHG-RM) was
collected at the Department of Medical Oncology, Ghent, Belgium and primary cell
cultures were established at the Center for Medical Genetics according to standard
procedures.
Cytogenetic analysis
Cell culture, harvesting, slide preparation and G-banding were performed according to
standard procedures. Karyotypes were described according to the ISCN32 guidelines.
Comparative genomic hybridization
CGH data were published for cell lines UISO, MCC13, MCC26 and MCC tumor UHG-
RM.25 In this study, additional CGH analysis was performed for MKL-1 subclone 2.
Labeling of DNA, in situ hybridization, fluorescence microscopy, digital image acquisition
and processing were done according to du Manoir et al.33,34, with minor modifications.35
4’,6-Diamidino-2-phenylindole dihydrochloride (DAPI) (Roche Molecular Biochemicals,
Brussels, Belgium) images of metaphases were recorded prior to hybridization using a
fluorescence microscope, a high-sensitivity integrated monochrome CCD camera (Sony
IMAC-CCD S30), and dedicated software (ISIS, MetaSystems, Altlussheim, Germany).
Further processing of these images for CGH analysis was performed with the ISIS CGH
software (MetaSystems). For each case, ten to twenty metaphase cells were analyzed.  For
evaluation of CGH data, average ratio profiles with fixed limits at 1.25 and 0.75 and
standard deviation limits (the width of the confidence interval being three times the
standard deviation) as well as individual ratio profiles were analyzed.  A chromosomal
region was considered to be overrepresented (gain) or under-represented (loss) if the
average ratio profile crossed the standard deviation limit. As a control, normal to normal
hybridizations were performed.
M-FISH analysis
M-FISH for differential staining of all human chromosomes was performed according to
Van Roy et al.36. Briefly, the ‘24XCyte’ probe kit was purchased from MetaSystems
(Altlussheim, Germany), and contains combinatorially labeled chromosome paints
obtained from degenerated oligonucleotide primer polymerase chain reaction (DOP-PCR)
amplified microdissected chromosomes. Fluorescein isothiocyanate (FITC),
SpectrumOrange (SO), TexasRed (TR) and diethylcoumarine (DEAC) were used for direct
detection whereas biotin was indirectly visualized with streptavidinCy5. Metaphase slides
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were pre-treated with RNase and pepsin. Slides were denatured with 70%
formamide/2xSSCP at 80°C for 5 min. Probe mix was denatured at 75°C for 5 min,
incubated at 37°C for 30 min and subsequently applied to the slides under a 18x18 mm
coverslip. After 2-4 days of hybridization, slides were washed with 50%
formamide/2xSSC (pH 7.3-7.5) at 42°C (3x5 min), followed by three washes in 2xSSC
(42°C). Biotin-labeled probes were detected with streptavidinCy5. Slides were mounted in
Vectashield (Vector Laboratories, Burlingame, CA, USA) containing DAPI (Roche
Molecular Biochemicals, Brussels, Belgium) counterstain. Fluorescent images were
captured with a Zeiss axioplan epifluorescence microscope (Carl Zeiss) (8 position filter
wheel) equipped with a CCD camera. All six fluorochromes including the DAPI
counterstain were captured sequentially, using single-bandpass filters. Color composite
images were constructed from the separate monochrome images and processed using the
isis/mFISH imaging system (MetaSystems, Altlussheim, Germany). Distinct pseudo colors
were assigned to each pair of homologous chromosomes and to the X and Y chromosome
based upon the fluorescent color signature for each pixel. At least five metaphases from
each case were analyzed by M-FISH.
FISH with whole chromosome paints and region specific probes
Subsequent to M-FISH analysis, additional dual color FISH with whole chromosome
plasmid libraries37 and region specific probes was performed for confirmation or further
characterization of chromosomal rearrangements. Hybridization and detection were done
according to Van Roy et al.38. Refined localization for chromosome 1p breakpoints was
performed using the following probes: pUC1.77 (D1Z1, for the heterochromatic region of
chromosome 1)39, p1-79 (D1Z2, 1p36.33)40, p73 cosmid  (1p36.33)41, c176g8 (DFFB,
1p36.3)42, 12A-2 (NPPA, 1p36.31-p36.23)43, cHE2.6 (A12M2, 1p36.1)44, C1-heir1D (ID-
3, 1p36.2-p36.1)45, cosmid probe ICRFc112B2137Q (EXTL1, 1p36.1)46, P1294
(Connexin27, 1p35.1)47, YAC clone 209E9 (MYCL1, 1p34.3)48 and YAC clone 958H24
(1q32-q41).
Additional locus specific probes used in this study were: LSI D7S522/Cep7 (7q31/cen7),
LSI13 (13q14), LSI CCND1 (11q13), LSI 5qEGR1/D5S23 (5q31/5p15.2), Telvys 14q,
Telvys 17q, Telvys 18q, dual color probes LSI ABL/BCR (9q34/22q11), LSI inv(16)
(16q22tel/16q22cen), LSI MLL (spanning the MLL gene, 11q23tel/11q23cen), LSI
DiGeorge/LSI ARSA (22q11.2/22q13), LSI SRY/CEP X (Yp11.3/Xp11.1-q11.1) (Vysis,
Downers Grove, IL). BAC clones RPCI-11 178P16 (16q23-24), RPCI-11 1094H24
(17q21), EVI1 BAC clones RP11-33A1, RP11-627P8, RP11-3J21, RP11-48N2 and RP11-
816J6 (3q26) (Children's Hospital Oakland Research Institute (C.H.O.R.I.) in Oakland,
California, USA), PAC clones RPCI-1 32H9 (17q11), RPCI-1 1094H24 (17q21), RPCI-1
300F16 (RBP1, 3q23)49 and RPCI-1 83I4 (SHOX2, 3q25-q26.1)50 (Ressourcenzentrum
Primärdatenbank in the Max Planck-Institut für Molekulare Genetik in Germany
(RZPD))51, centromeric probes pα3.5 (cen3)52, p17H8 (cen17)53, pI90.22 (cen22)54 and
Y97 (cenY)55, p82H (all centromeres)56, pHUR98 (for the heterochromatic region of
chromosome 9)57, pHUR195 (for the heterochromatic region of chromosome 16)57 and
D1S80 (this probe was originally mapped to 1p58 but hybridized to the short arms of
acrocentric chromosomes (personal findings)).
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Case reports
Case 1 (cell line MCC26)
MCC26 was established from the recurrence of a tumor from a 82-year-old woman
prior to radiotherapy. The patient was initially referred to the Queensland Radium Institute
(Brisbane, Australia) with a lesion to the left lateral calf. This lesion was confirmed by
biopsy to be an MCC. Immunohistochemical analysis showed positivity for neuron
specific enolase (NSE) and low-molecular-weight keratin and negativity for S100 and
high-molecular-weight keratin. After wider excision the tumor recurred near the primary
site and radiotherapy was started. Three months later the patient presented with
lymphadenopathy in the left groin, where examination showed several nodes up to 4 cm in
diameter. The patient received palliative radiotherapy at 20 Gy in 5 fractions over 1 week.
The patient died three months later.
Immunohistochemistry of the MCC26 cell line at early passage showed a positive
reactivity for NSE and negative staining for synaptophysin, GFAP, NFP, S100, CAM 5.2,
LCA, chromogranin and somatostatin.
Case 2 (tumor UHG-RM)
A 62-year-old woman was referred to the hospital because of an induration on the
left thigh, steadily growing over a 5 week period. Physical examination revealed a tumoral
mass on the left thigh, painful by palpation, with a reddish overlying skin. There was an
enlarged lymph node with a diameter of 3 cm in the left inguinal region. Blood counts and
biochemistry were completely normal, as was the serum level of calcitonin. A complete
resection of the tumor and an inguinal lymph node dissection was done, followed by
radiotherapy at the tumorbed and the left groin.
Histopathologically, the tumor consisted of nodular aggregates of small monoform
atypical cells with a fine chromatin network. Multiple mitoses were seen. The tumor was
infiltrated by lymphocytes. The inguinal lymph nodes were infiltrated by the above
described malignant cells. Immunochemistry for NSE, CAM 5.2, EMA and chromogranin
A was positive whereas S100 and LCA were negative. These findings correlated with a
neuroendocrine tumor of the skin or Merkel cell carcinoma.
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Results
Karyotypes described by banding analysis only and revised karyotypes following
FISH analysis are listed in Table 1. Composite karyotypes were described for cell lines
exhibiting karyotypic heterogeneity. M-FISH analysis in combination with the available
cytogenetic and CGH data led to an improved karyotype description for all analyzed MCC
cell lines and the metastatic MCC tumor. All structural aberrations found with M-FISH
could be confirmed using conventional FISH.
Six of the seven studied cases (MCC13, MKL-1 (subclone 1 and 2), MKL-2, UISO
and tumor UHG-RM) were near-diploid whereas MCC26 showed a hypotriploid
karyotype. Except for the MKL-1 subclones, all cases had a complex karyotype (more than
3 structural chromosomal changes) often showing unbalanced rearrangements leading to
deletions and gains, usually in combination with numerical abnormalities. Cytogenetic
analysis of 6 cell lines and one MCC tumor revealed a total of 23 partially defined
chromosome aberrations and 7 markers which could all be further characterized by M-
FISH analysis. Gene amplifications were not detected. M-FISH images of complete
karyotypes or selected chromosomal rearrangements are shown in Fig. 1. The
chromosomes most frequently involved in rearrangements were in order of frequency 3, 1,
5, 7, 13, 14, 8, 9, 17 and 22. Chromosomal arms most commonly affected were the long
arm of chromosome 3 and the short arm of chromosome 1. Chromosomal breakpoints
determined by M-FISH, banding analysis and dual-color FISH and imbalances detected by
CGH are shown in Fig. 2. Rearrangements at 3q23, 3q25-q26.1 and 9q34 were each seen
in 2 different cases.
In MCC13, M-FISH revealed a three-way translocation involving the chromosomes
7, 8 and 14 (Table 1, Fig. 1a). This rearrangement was apparently balanced, as CGH
revealed no gains or losses for these chromosomes. In addition, an add(9)(q34) and a small
marker chromosome were characterized as a der(9)(9pter→q34::13q22.2→13qter) and a
der(13)(13pter→13q12.3::16q23q24→16qter) respectively (Table 1, Fig. 1a). Loss of
13q12.3→q22.2 material was confirmed by CGH (data not shown). Karyotypic analysis of
MCC13 also showed a del(12)(q12q14) in half of the analyzed mitoses which was not
detected by M-FISH nor CGH.
In MCC26, M-FISH revealed complex translocations involving the chromosomes
1, 3, 4 and 7. Other complex rearrangements involved chromosomes X, 8, 14, 16 and 21
which could be partially described in further detail through CGH analysis (Table 1). In
addition, an add(19)(p13) was shown to result from a nonreciprocal translocation
der(19)t(19;20)(p13.3;p?q?). The karyotype of MCC26 also showed a del(2)(p21) in all
metaphases and an add(2)(p24) present in half of the analyzed mitoses. M-FISH showed
that the add(2)(p24) resulted from a der(2)t(2;9)(p24;q12) and confirmed the presence of a
normal chromosome 2  and a chromosome 2 with a deletion in the short arm. The CGH
profile is in agreement with the presence of an interstitial 2p deletion partially masked by
the der(2)t(2;9)(p24;q12) in half of the cells (Fig. 1b). Combination of CGH and M-FISH
showed that two almost identical marker chromosomes were derived from the short arm of
chromosome 5 (Fig. 1c). In addition, M-FISH also revealed cryptic translocation with
partner chromosomes 18 and 22, respectively for these two derivative chromosomes 5. An
add(5)(pter) was identified as a der(5)t(5;11)(p15;q14.2) (Fig. 1c). A third marker
chromosome was characterized by M-FISH and CGH as a del(12)(q12) as CGH showed
overrepresentation for the 12p region (data not shown).
The karyotype of MKL-1 subclone 1 was initially published by Rosen et al.4. Two
i(5)(p10) chromosomes and one der(7)t(7;8)(q36;q22) were described. The presence of two
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isochromosomes 5p was confirmed by M-FISH whereas the derivative 7 was revised as a
der(7)t(7;11)(q36;q14) (data not shown).
In MKL-1 subclone 2, M-FISH confirmed the presence of the
der(1)t(1;17)(p36;q21).4 Deletion of the most distal part of 1p was suggestive by CGH in
addition to 17q gain (Fig. 1d). FISH with region specific probes showed indeed that the
1;17 translocation resulted in a small distal deletion including markers D1Z2 (1p36.33),
TP73 (1p36.33) and DFFB (1p36.3) whereas the NPPA gene (1p36.31-p36.23) was
retained. In addition, M-FISH identified a cryptic translocation
der(10)t(10;12)(q23;p11.21) which was confirmed by CGH (data not shown).
In cell line MKL-2, complex translocations involving chromosomes Y, 1, 3, 11, 13,
14, 16, 17, 21 and 22 were identified by M-FISH with chromosome 3 and 13 material
being translocated onto at least 3 different partner chromosomes (Table 1 and Fig. 1e). In
addition, some of the unbalanced translocations seemed to involve a “jumping” or
“segmental jumping” translocation.59,60 The donor segment 3q13.3~21→qter was
translocated to more then one recipient chromosome: der(1) and der(17) and a part of this
segment (3q23-q26) seemed additionally translocated to the der(11) resulting in gain of
3q23-q26 material in MKL-2. FISH with 1p-specific probes showed translocation of
markers D1Z2, TP73, NPPA, A12M2, ID3 and EXTL1 to the derivative chromosome 3. In
addition, an extra copy of the Connexin27 (1p35.1) and MYCL1 (1p34.3) were present on
the derivative chromosome 17 (data not shown). FISH with the LSI SRY/CEPX probe
showed that the most distal part of the short arm of chromosome Y was lost in this
derivative chromosome 17 (data not shown). In addition two marker chromosomes were
identified as an i(4)(p10) and a der(20)(20pter→20q13::4q13→4qter), respectively. An
unbalanced rearrangement der(6)t(6;8)(q16;q22) was identified by M-FISH.
The karyotype of cell line UISO, described by Ronan et al.12, was previously
revised by us and revealed insertion of material of unidentified origin to 1p36.220 and 6q,
respectively. Interestingly, the 1p36.2 breakpoint mapped within a cluster of repetitive
tRNA and snRNA genes20 and coincided with the constitutional 1p36 breakpoint
previously reported in a patient with neuroblastoma.61,62 In addition, a ring chromosome
and a der(8) were also present in UISO. M-FISH combined with CGH identified the der(8)
as a dic(8;8)(8qter→8p21.2::8p21.2→8qter) but could not reveal the nature of the
insertions and the ring chromosome. Apparently the inserted sequences and the ring
chromosome contained hybridization signals which were positive for each fluorochrome.
Since a combination of all five fluorochromes is not present in any of the used
chromosome paints, we assumed that this pattern could be explained by the presence of
repetitive DNA sequences. To test this hypothesis FISH was performed under low
stringent conditions with probes for the heterochromatic regions of chromosome 1, 9 and
16 and the alpha satellite DNA probe p82H. Using this probe mixture, hybridization
signals were detected on the derivative chromosomes 1 and 6 and the ring chromosome
(Fig. 1f) whereas hybridization with D1S80 for the short arms of the acrocentric
chromosomes was negative (data not shown). The FISH hybridization patterns point to the
presence of at least two different kinds of repetitive DNA material i.e. satellite III repeat
units and alpha satellite repetitive sequences. The significance of these findings is
presently unclear and warrants further investigation.
Karyotyping of tumor UHG-RM revealed structural abnormalities of chromosomes
3, 9, 15 and 22 (Fig. 1g). M-FISH  analysis showed that these chromosomes were involved
in one single apparently balanced but complex translocation with at least eight breaks and
cryptic involvement of chromosome 17 (Table 1, Fig. 1h). FISH with gene specific probes
for SHOX2, ABL and BCR was applied to define the 3q25-q26.1, 9q34 and 22q11
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breakpoints in these translocations. Deletion of chromosome 10 was the only numerical
change observed in the tumor. Previous mutation analysis of the PTEN (10q23) gene in
this case was negative.28
Discussion
The number of cytogenetic reports (for overview see Table 2) and molecular
investigations on Merkel cell carcinomas (MCC) are limited. Recurrent losses have been
reported for chromosomal regions 1p, 3p, 9p, 10q and 13q and gains were noticed for 1q,
3q, 5p, 6, 8q, 19 and X18,26,63,27,25,64,23,28,29 but further genetic studies are necessary to obtain
a more detailed picture of the genetic changes that lead to MCC development. To this
purpose, we combined karyotyping, CGH, M-FISH and FISH with region specific probes
to analyze 6 MCC cell lines and one metastatic MCC tumor. This approach yielded a
comprehensive and improved description of chromosomal changes which were either not
detected or only partially identified or classified as markers by G-banding alone. The
chromosomes most frequently involved in translocation events were in order of frequency
3, 1, 5, 7, 13, 14, 8, 9, 17 and 22. Eight breakpoints in the chromosome three long arm
were detected in three of the seven cases. Four breakpoints were observed in two MCCs,
each at 3q23 and 3q25-q26.1. Three additional breakpoints were located more proximal at
3q11.2, 3q13.1 and 3q13.3 whereas one was located more distal at 3q29.
Gain of 3q material has been recognized as a recurrent imbalance in MCC25 and
was here observed in one MCC. In this case, the region of gain was restricted to 3q23-q26
material, thus defining a relatively small critical region for 3q gain. We propose that this
region harbors a gene that due to dosage effect of a wild-type or mutated allele may
contribute to MCC oncogenesis. A possible candidate gene located in this region is the
ATR (ataxia-telangiectasia and Rad3-related) gene. Gain of this gene due to
isochromosome 3 formation led to loss of differentiation and cell cycle abnormalities in
rhabdomyosarcomas.65 Expression and/or mutation studies of the ATR gene should reveal
if this gene is also implicated in MCC and other tumor types with 3q gain.
Previous cytogenetic studies of MCC showed that structural rearrangements of
chromosome 1, often leading to loss of 1p material, occurred in more than half of the
reported cases. The observation of two MCC tumors with chromosome 1p rearrangements
as the sole structural chromosomal abnormality14,20 provided further evidence for a role of
tumor suppressor genes on 1p36 in MCC pathogenesis. Here, molecular cytogenetic
analysis of an unbalanced 1;17 rearrangement in MKL-1 (subclone 2) maps the 1p
breakpoint between DFFB and NPPA within band 1p36.3. This deletion breakpoint
coincides with a previously described deletion breakpoint by Van Gele et al.20. The TP73
gene was considered in many neoplasms as a strong candidate gene for this deleted region,
but mutation studies provided no evidence to support this view, indicating that the TP73
gene is probably not the primary target of deletions in this region or is inactivated by
alternative mechanisms.66,67
A second interestingly observation was made in cell line MKL-2 which showed a
complex 1p rearrangement. Distal 1p material with a breakpoint between the EXTL1
(1p36.1) and the Connexin27 gene (1p35.1) was translocated to 3q13.3~21. In addition, a
small interstitial chromosome 1 segment containing Connexin27 and MYCL1
(1p35.1→1p34.3) was translocated to a der(17) together with chromosome 3 and
chromosome Y material. This type of complex rearrangements may explain some of the
unusual LOH patterns observed by Leonard et al.23.
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M-FISH analysis revealed two isochromosomes of the short arm of chromosome 5
and two derivative 5 chromosomes containing mainly 5p material in MKL-1 (subclone 1)
and MCC26, respectively. The occurrence of i(5p) and other isochromosomes have been
reported previously in MCC3,5,8,11,15,25and could correlate to a low-level copy number gain
of genes, which interfere with growth advantage. A possible candidate gene located at
5p15 is hTERT (human telomerase reverse transcriptase).68 Regulation and/or activation of
the hTERT gene leads to telomerase activity following cellular immortalization, which is
an important step in the development of cancer.69 One of the possible mechanisms
contributing to the dysregulation of telomerase activity observed in human tumors could be
an increased expression of hTERT through gain of 5p material. This was demonstrated in a
study by Zhang et al.70 in which a number of human tumor cell lines and primary tumors
acquired extra hTERT gene copies resulting in an enhanced gene expression and
telomerase activity, possibly due to gain of 5p material. Recently, telomerase activity was
also observed in Merkel cell carcinoma suggesting a correlation between telomerase
activity and its malignant development.71 In this respect it is of interest that telomerase
suppressor genes may be located at two different regions on chromosome 3p (3p21.3-p22
and 3p12-p21.1).72 Deletion of such genes located in these regions could cause
derepression of hTERT and lead to telomerase activity in proliferating tumor cells. A
previously performed LOH and CGH study showed frequently loss of 3p in MCC and
identified a critical region of loss at 3p13-p14.26,25Loss of a possible telomerase suppressor
gene located in this region could also contribute to telomerase activity in a subset of
MCCs.
A previous study demonstrated that PTEN was involved at low frequency in MCC,
indicating that probably other tumor suppressor genes located at or distal to 10q23 could
be involved.28 In this study, two additional cases with whole chromosome 10 loss were
observed and loss of 10q23→qter was seen in one MCC. A 10q23 deletion breakpoint was
also observed in a metastatic MCC tumor described by Schlegelberger et al.13. Further
studies of PTEN and other candidate genes in these cases should reveal their involvement
in MCC development.
In conclusion, this is the first report describing M-FISH analysis of MCC in
combination with CGH, conventional FISH and banding analysis. Using this approach, the
genetic changes in 6 MCC cell lines and one metastatic MCC tumor were characterized.
We identified novel translocations widely distributed throughout the genome, including
complex chromosome 3q and 1p rearrangements. Our accurate cytogenetic profiling of the
chromosomal changes contributes greatly to the limited cytogenetic data of MCC and
opens new perspectives in the search for candidate tumor suppressor genes or oncogenes in
these chromosomal regions. Understanding the molecular basis of these chromosomal
events would finally lead to a better insight in the mechanisms affecting and regulating this
malignant disease.
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LEGENDS TO THE FIGURES
Fig. 1 Selection of M-FISH findings in relation to karyotypic, FISH and/or CGH
results.
a.   Partial karyotypes and M-FISH images of selected chromosomal rearrangements for
     MCC13 illustrating the three-way translocation t(7;8;14)(7pter→7q11.23::14q31.1→
     qter;8pter→8q23::7q11.23→7q31.1::8q23→8qter;14pter→14q31.1::7q31.1→7qter)
     (top) and the der(9)(9pter→9q34::13q22.2→13qter) and der(13)(13pter→13q12.3::
     16q23q24→16qter) (bottom).
b.  Partial karyotypes and M-FISH images of unbalanced chromosome 2 rearrangements
(top) and two normal chromosomes 9 (bottom) in MCC26 showing a
del(2)(pter→p13::p16→qter) and a der(2)(:2p24;9qter→9q12). The CGH profile of
chromosome 2 shows a consistent but statistically not significant deviation of the ratio
profile at 2p13→2p16 and a statistical loss of the very distal (2p24) part of
chromosome 2.
c. CGH (right) combined with banding (left bottom) and M-FISH (middle top) led to the
identification of two der(5) chromosomes derived from the short arm of chromosome 5
and involved in cryptic translocations namely a der(5)(5pter→5q12;18qter→18q?) and
a der(5)(5pter→5q12;22p?q?) (bottom) together with a der(5)(5p15;11qter→11q14.2)
and del(11)(q14.2) (top) in MCC26. Chromosomes 5, 18 and 22 are displayed in red,
green and blue colors respectively, chromosome 11 in grey (bottom).
d. Unbalanced 1;17 translocation (left), M-FISH (middle) and CGH profiles (right)
showing loss of distal 1p and overrepresentation of 17q material in MKL-1
(subclone2).
e. M-FISH image of a complete karyotype of cell line MKL-2.
f. Partial karyotypes and inverted black and white FISH images of the normal
chromosome 1, the derivative 1, the normal chromosome 6, the derivative 6 and the
ring chromosome in cell line UISO. Probes used for the 1q12 region (D1Z1) are shown
in red and for p82H, pHUR195 and pHUR98 in green.
g. Complete G-banded karyotype for MCC tumor UHG-RM.
h. M-FISH image of a complete karyotype of MCC tumor UHG-RM.
Fig. 2 Overview of chromosomal breakpoints and imbalances detected by
karyotyping, FISH, CGH, and M-FISH.
CGH findings were available for MCC13 (1), MCC26 (2), UISO (6), and UHG-RM (7).
CGH was performed in this study for MKL-1 (subclone 2) (4). CGH data were not
available for MKL-1 (subclone 1) (3) and MKL-2 (5).
The vertical lines on the left side of the chromosome ideogram indicate
underrepresentation, those on the right side overrepresentation of the corresponding
chromosomal regions. Dashed lines were used to indicate borderline CGH profile
deviations. The position of chromosomal breakpoints as determined by a combination of
M-FISH with banding analysis or CGH is indicated by an open circle. A filled circle means
that the position of the breakpoint could not be defined exactly. An empty arrowhead
indicates the location of an insertion breakpoint. Open squares are used to indicate the
position of the chromosomal breakpoints as determined by a combination of M-FISH with
banding analysis for the cell lines for which no CGH data were available. Filled squares
are used if the position of the breakpoint could not be defined exactly.
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3.1 Mutation analysis of candidate tumor suppressor genes
3.1.1   Mutation analysis of P73 and TP53 in Merkel cell carcinoma
Van Gele M., Kaghad M., Leonard J. H., Van Roy N., Naeyaert J. M., Geerts M. L., Van
Belle S., Cocquyt V., Bridge J., Sciot R., De Wolf-Peeters C., De Paepe A., Caput D.,
Speleman F. Br J Cancer, 82: 823-826, (2000).
3.1.2 Frequent allelic loss at 10q23 but low incidence of PTEN mutations in Merkel
cell carcinoma Van Gele M., Leonard J. H., Van Roy N., Cook A. L., De Paepe A.,
Speleman F. Int J Cancer, 92: 409-413, (2001).
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3.1.1 Mutation analysis of P73 and TP53 in Merkel cell carcinoma
TP73 (alias P73) was originally described as a monoallelic expressed gene and assigned to
1p36.33 (Kaghad et al., 1997). This region is frequently deleted in many tumor types,
including neuroblastoma, and is believed to harbour an imprinted tumor suppressor gene
(Caron et al., 1995). Interestingly, TP73 showed significant sequence similarity to the
transactivation (29%), DNA-binding (63%) and oligomerization domain (38%) of the
TP53 gene (Kaghad et al., 1997). A study by Jost et al. (1997) showed that overexpression
of TP73 in SAOS-2 cells (TP53-/-) could activate the transcription of TP53-responsive
genes like p21waf1/cip1 and inhibited cell growth in the same way as TP53 by inducing
apoptosis. However, TP73 was not directly induced in response to certain DNA-damaging
stimuli. Instead, the tyrosine kinase c-abl interacted and phosphorylated TP73 on tyrosine
residue 99 and induced TP73-mediated transactivation and apoptosis (Figure 3-1) (Agami
et al., 1999; Yuan et al., 1999).
   Figure 3-1: Diagram showing pathways of TP53 and TP73 to induce cell cycle arrest
                            and apoptosis in response to various stimuli.
                           (Reproduced from Ichimiya et al., Path Int., 50:589-583, 2000)
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In view of the frequent occurrence of distal 1p deletions in MCC, we screened the TP73
gene for inactivating mutations in five MCC cell lines and ten MCC tumors. Given the
possible complementary functions of TP73 and TP53, the mutation status of TP53 was also
examined. A TP73 missense mutation, which could possibly reduce the transcriptional
transactivation function of the amino-terminal region of TP73, was detected in one MCC
tumor. These results show that TP73, analogous to other cancers, is infrequently mutated in
MCC. In addition, four TP53 mutations located at mutational hotspot regions were
identified in two MCC cell lines and one TP53 non-sense mutation was found in a MCC
tumor. This report showed for the fist time inactivating TP53 mutations in MCC. The
finding of typical UVB induced mutations in one MCC cell line provided further evidence
for sun-exposure in the etiology of this skin tumor.
Presently, their is evidence however that several TP73 isoforms exist of which some may
exert a dominant negative effect on TP53 or TP73 activity (Yang et al., 2002). This
provides circumstantial evidence that TP73 is involved in tumorigenesis. Future
investigations should reveal if some of these isoforms play a role in MCC oncogenesis (see
General Discussion).
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Merkel cell carcinoma (MCC) is a rare aggressive neuroendocrine
skin tumour, mostly affecting elderly individuals. The majority of
primary MCCs occur on sun-exposed areas of the skin, implicating
UV exposure in its aetiology. The tumour is thought to originate
from Merkel cells, which have properties of both epithelial and
neuroendocrine cells. They are located in the basal epidermis and
are likely to play a role in signal transduction as receptors for
mechanical stimuli in all animals (Ratner et al, 1993).
Until now, little was known about the genetic basis of MCC.
Only 13 cytogenetic studies have been reported in the literature
(Mitelman et al, 1998). No consistent translocations have been
observed but structural abnormalities involving the short arm of
chromosome 1 have been noted in 40% of all examined cases.
Chromosome region 1p36, which is frequently deleted in a variety
of neoplasms including neuroendocrine tumours such as neuro-
blastoma, is often affected in MCC tumours with 1p rearrange-
ments (Van Gele et al, 1998). Several candidate tumour suppressor
genes have been mapped to 1p36 but as yet no direct involvement
of these genes in tumours with 1p36 loss could be found (Schwab
et al, 1996).
The S gene, located on 1p36.33, has also been considered 
as a candidate tumour suppressor gene. S shows significant
sequence similarity to the transactivation, DNA-binding and
oligomerization domain of 73 (Kaghad et al, 1997). Jost et al
(1997) showed that overexpression of S can activate the tran-
scription of 73-responsive genes like SZDIOFLSO and inhibit cell
growth in the same way as 73 by inducing apoptosis. Mutation
analyses for the S gene have been performed in lung carcinoma,
oligodendrogliomas, prostatic carcinoma, neuroblastomas,
colorectal carcinoma, oesophageal carcinoma and hepatocellular
carcinoma (Kovalev et al, 1998; Mai et al, 1998D, 1998E; Nimura
et al, 1998; Nomoto et al, 1998; Sunahara et al, 1998; Takahashi et
al, 1998; Ichimiya et al, 1999; Mihara et al, 1999). Except for two
mutations in primary neuroblastomas resulting in amino acid
substitutions in the C-terminal region of p73 (Ichimiya et al,
1999), no other mutations have been reported.
We decided to perform mutation analysis of the S gene in
order to investigate the possible involvement of S in MCC onco-
genesis. Five MCC cell lines and ten MCC tumours with known
1p status were examined for mutations in the S gene by direct
sequence analysis. In view of the possible complementary func-
tions of S and 73, the status of 73 was also investigated.
0$7(5,$/6$1'0(7+2'6
Samples
Tumour samples were collected at the University Hospitals of
Ghent and Leuven, Belgium and the University of Nebraska
0XWDWLRQDQDO\VLVRI3 DQG73 LQ0HUNHOFHOO
FDUFLQRPD
M Van Gele1, M Kaghad6, JH Leonard5, N Van Roy1, JM Naeyaert2, ML Geerts2, S Van Belle3, V Cocquyt3, J Bridge7, 
R Sciot4, C De Wolf-Peeters4, A De Paepe1, D Caput6 and F Speleman1
Departments of 1Medical Genetics, 2Dermatology and 3Medical Oncology, University Hospital, Ghent, De Pintelaan 185, B-9000 Ghent, Belgium; 4Department of
Pathology, University Hospital, Minderbroederstraat 12, B-3000 Leuven, Belgium; 5Queensland Radium Institute Laboratory, Queensland Institute of Medical
Research, Herston Road, Brisbane, 4029, Queensland, Australia; 6Sanofi Recherche, Innopole BP 137, 31676 Labege cedex, France; 7Department of Human
Genetics, University of Nebraska Medical Center, Omaha, NE 68198–5440, USA
Summary The p73 gene has been mapped to 1p36.33, a region which is frequently deleted in a wide variety of neoplasms including tumours
of neuroectodermal origin. The p73 protein shows structural and functional homology to p53. For these reasons, p73 was considered as a
positional and functional candidate tumour suppressor gene. Thus far, mutation analysis has provided no evidence for involvement of p73 in
oligodendrogliomas, lung carcinoma, oesophageal carcinoma, prostatic carcinoma and hepatocellular carcinoma. In neuroblastoma, two
mutations have been observed in a series of 140 tumours. In view of the occurrence of 1p deletions in Merkel cell carcinoma (MCC) and the
location of p73 we decided to search for mutations in the p73 gene in five MCC cell lines and ten MCC tumours to test potential tumour
suppressor function for this gene in MCC. In view of the possible complementary functions of p73 and TP53 we also examined the status of
the TP53 gene. Sequence analysis of the entire coding region of the p73 gene revealed previously reported polymorphisms in four MCCs. In
one MCC tumour, a mis-sense mutation located in the NH2-terminal transactivation region of the p73 gene was found. These results show that
p73, analogous to neuroblastoma, is infrequently mutated in MCC. This is also the first report in which the role of TP53 in MCC has been
investigated by sequencing the entire coding region of TP53. TP53 mis-sense mutations and one non-sense mutation were detected in three
of 15 examined MCCs, suggesting that TP53 mutations may play a role in the pathogenesis or progression of a subset of MCCs. Moreover,
typical UVB induced C to T mutations were found in one MCC cell line thus providing further evidence for sun-exposure in the aetiology of this
rare skin cancer. © 2000 Cancer Research Campaign
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Medical Center, Ohama, NE, USA. One part of the sample was
snap-frozen in liquid nitrogen and another part was stored at
–80°C until analysis. MCC tumour cell line UISO was kindly
provided by Dr SG Ronan and Prof Dr TK Das Gupta (Illinois,
USA). Cell line MKL-1 was given by Prof Dr ST Rosen (Illinois,
USA). Cell lines MCC13, MCC14/2 and MCC26 were a gift from
Dr JH Leonard (Queensland, Australia). All cell lines were grown
in RPMI-1640 medium (Gibco-BRL, 52400-025). DNA of the
tumour samples and cell lines was prepared by standard proteinase
K digestion, phenol–chloroform extraction, and ethanol precipita-
tion protocols. Constitutional DNA of the patients was isolated by
using the Qiagen blood and cell culture Midi Kit (Westburg,
13343). RNA extraction from the tumour samples and cell lines
was done with RNeasy Midi Kits (Westburg, 75144).
Fluorescence in situ hybridization
In order to determine the copy number of chromosome 1 and pres-
ence or absence of 1p deletions, fluorescence in situ hybridization
(FISH) was performed on metaphases or interphase nuclei
according to Van Roy et al (1994). DNA probes used were
pUC1.77 ('=) for the heterochromatic region of chromosome 
1 (1q12) and p1–79 ('=) for the subtelomeric region of
chromosome 1 (1p36.33).
Reverse transcriptase polymerase chain reaction and
sequencing analysis
cDNA synthesis was performed using 5 µg of total RNA incubated
in a 20 µl volume reaction containing 50 mM Tris–HCl (pH 8.3),
10 mM dithiothreitol (DTT), 10 mM potassium chloride (KCl), 0.5
mM dNTP, 20 U RNAsin (Promega), 150 U Super-script II
Reverse Transcriptase (Gibco-BRL) and 50 ng µl–1
oligo-d(T) primer for 1 h at 37°C. The primer pairs sense: 
5′-AGGGGACGCAGCGAAACC; antisense: 5′-GGCAGCTTG-
GGTCTCTGG; and sense: 5′-GGTGACACGCTTCCCTG; anti-
sense: 5′-GGTGGGAGGCTGTCAGTG were used to amplify the
entire coding region of S and 73 respectively by reverse tran-
scription polymerase chain reaction (RT-PCR). Long range PCR
was performed using the Expand™ Long Template PCR system
(Boehringer Mannheim). PCR reactions were performed in a 50 µl
reaction volume containing 2 µl of reverse transcriptase products,
500 µM dNTP, 300 nM primers, 10% dimethylsulphoxide, 5 µl of
buffer 1 and 3.5 units of 7DT and Pwo enzyme mix. The PCR
amplification consisted of 35 cycles of 95°C for 0.5 min, 58°C for
1 min, 68°C for 2.5 min after starting with a denaturing step at
95°C for 1 min and ending at 68°C for 10 min. The PCR products
were purified by spin dialysis sequentially on S400 and P10 resins.
Subsequently, the PCR products were directly completely
sequenced on an ABI PRISM™ 377 sequencer (Perkin-Elmer)
using specific nested sequencing primers and the Big Dye
Terminator Sequencing Kit. Cases 6, 7, 8, 9 and 10 (see Table 1)
were sequenced on an ALF™ Express automated DNA sequencer
(Pharmacia) using a Thermo Sequenase fluorescent labelled
primer cycle sequencing kit with 7-deaza-dGTP (Amersham, RPN
2438). To confirm the S nucleotide change found in case 4 
the following primer pair sense: 5′-CCAGTTCAATCTGCTGA-
GCAG-3′ and antisense: 5′-CCACTTTGAGGTCACTTTCC-3′,
located in exon 4, were used to amplify genomic tumour DNA and
constitutional DNA of the patient. PCR conditions were the same
as those described above. The PCR products were sequenced using
the same primers as those to amplify genomic DNA.
Table 1 Summary of mutation analysis of p73 and TP53 in Merkel cell carcinoma
Cell lines 1p∆a Expressed p73 Transcript AA change TP53 Transcript AA change
allele(s)b sequence sequence
UISO Noc G/C wt – wt –
MKL-1 No G/C wt – wt –
MCC13 No G/C;A/T wt – mut 857C>T;858C>T S241F
mut 967C>T P278S
MCC14/2 No G/C wt – mut950T>A V272E
MCC26 No G/C wt – N/Ad
MCC samples
Case 1 No G/C;A/T 1118C>T;1157T>Ce No wt –
1781G>A;1940G>A No
Case 2 Yes A/T 1118C>T;1157T>C No wt –
1781G>A;1940G>A No
Case 3 No G/C;A/T 1118C>T;1157T>C No wt –
1781G>A;1940G>A
Case 4 No G/C;A/T mut 439C>T S110L mut550A>T K139X
Case 5 Yes G/C;A/T 1118C>T;1157T>C No wt –
1781G>A;1940G>A
Case 6 NT G/C wt – wt –
Case 7 No G/C;A/T wt – wt –
Case 8 No G/C;A/T wt – wt –
Case 9 No G/C;A/T wt – wt –
Case 10 No G/C;A/T wt – wt –
a 1p∆, deletion in the short arm of chromosome 1 determined by fluorescence in situ hybridization with the telomeric D1Z2 probe
performed on chromosome metaphases or interphase nuclei. NT: not tested. b Refers to the polymorphism of G/C and A/T alleles in exon
2, as determined by RT-PCR on mRNA and subsequent sequencing of products. c UISO carries an insertion on 1p36.2 of unknown origin
(Van Gele et al, 1998). d NA, not available due to lack of TP53 mRNA expression, as determined by RT-PCR. eRefers to the tightly linked
polymorphisms located in exon 9 and exon 14, as determined by RT-PCR on mRNA and subsequent sequencing of products.
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Mutation analysis of p73 and TP53 in MCCs
cDNA of five MCC cell lines and ten MCC tumours was amplified
by RT-PCR and, consequently, cycle-sequenced using specific
nested PCR primers for the detection of mutations in S. In addi-
tion, allelic expression for S was determined based upon the
known linked polymorphisms in exon 2. The sequencing results
and allelic expression data are summarized in Table 1. A C to T
mutation at codon 110 was found in one out of ten MCC tumours
for S, resulting in a serine to leucine substitution. This
nucleotide exchange was also present in the genomic DNA of the
tumour but not in the constitutional DNA (Figure 1). No mutations
were found in the cell lines. Silent nucleotide substitutions at
codon 336 (GCC to GCT) and codon 349 (CAT to CAC) located in
exon 9 and at codon 557 (GCG to GCA) and at codon 610 (GCG to
GCA) located in exon 14 were found in four (40%) of the ten
examined tumours. These polymorphisms were also found in the
constitutional patient DNA.
The same panel of MCC cell lines and MCC tumours was also
examined for mutations in the 73 gene. Four 73 mutations
were found in two out of five MCC cell lines and one non-sense
mutation was observed in one MCC tumour (see Table 1).
',6&866,21
Thus far, mutation analyses for S have been performed in
several types of carcinomas, oligodendrogliomas and neuroblas-
tomas (Kovalev et al, 1998; Mai et al, 1998D, Nimura et al, 1998;
Nomoto et al, 1998; Sunahara et al, 1998; Takahashi et al, 1998;
Ichimiya et al 1999; Mihara et al, 1999). No mutations were found
except for one somatic and one germline mutation in a series of
140 neuroblastomas (Ichimiya et al, 1999). Like MCC, neuro-
blastoma is a tumour of neuroendocrine origin frequently carrying
distal 1p deletions. The two mutations found in neuroblastoma
(P405R and P425L) were located within the COOH-terminal
region of S (Ichimiya et al, 1999). Recently, Takada et al (1999)
showed that the COOH terminus of S had a transactivation func-
tion whose activity was significantly reduced by the mis-sense
mutations detected in the neuroblastoma tumours.
In the present study, one mis-sense mutation of S in one out of
ten MCC tumours was found: a heterozygous C to T transition at
nucleotide 439, resulting in a serine to leucine substitution at
codon 110 within exon 4. In comparison to the mutations observed
in neuroblastoma, this mutation was located in the NH2-terminal
region (residues 1–112) of S. The transcriptional transactivation
function of the NH2-terminal region of S was shown to have an
activity as strong as that of 73 (Takada et al, 1999). Further
analysis may show that the observed mis-sense mutation in MCC
leads to a reduction or complete loss of the transactivation function
of the NH2-terminal region of S. The MCC tumour carrying the
mutated S allele still expresses the remaining wild-type allele.
Similar to 73, this mis-sense mutation might exert a dominant
negative effect by an increased stability of the mutant protein
compared to that of wild-type protein. Further studies are needed
to verify this hypothesis.
The finding of S mutations in neuroblastoma and MCC may
also stimulate mutation analyses in other tumour types. Although
the low frequency of mutations in both tumours seems to exclude a
direct role for S in tumorigenesis, other mechanisms than muta-
tions in S may lead to tissue-specific up- or down-regulation of
the gene. In this respect, the available data on allelic expression of
S are conflicting. Nomoto et al (1998) found biallelic expression
of S in normal lung tissue and distinct patterns of allelic expres-
sion in different normal tissues. In contrast, Mai et al (1998E)
reported monoallelic expression in normal lung tissue and
increased and biallelic expression in lung tumour samples.
Ichimiya et al (1999) found low S expression in neuroblastoma,
while S transcripts were easily detectable in breast carcinoma
and colorectal carcinoma under the same conditions. Although we
performed no quantification of the S mRNA, we observed 
biallelic expression in one MCC cell line and eight MCC primary
tumours. Clearly, further studies on S expression in normal and
cancerous tissues is warranted.
As yet, only one study investigated the possible role of 73 in
MCC (Schmid et al, 1997). Using immunohistochemical staining,
TP53 expression was studied in 25 Merkel cell carcinomas. Only
five tumours showed 5–10% TP53-immunoreactive tumour
nuclei. Single-strand conformation polymorphism (SSCP) analysis
Mutation analysis of p73 and TP53 in Merkel cell carcinoma 825
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Figure 1 p73 sequencing profiles of genomic tumour DNA (case 4) showing the heterozygous mutation at codon 110 (TCG→TTG) (A) and of the
constitutional DNA (B)
A T G T N G C C G A T G T C G C C GA B
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for exons 4–8 did not reveal mutations in these five tumours which
lead the authors to conclude that 73 alterations play only a
minor part in the genesis of MCC. However, using this approach it
could not be ruled out that the presence of mutations in the other
exons of 73 were missed. Also, mis-sense and non-sense muta-
tions not leading to accumulation of the gene product would be
overlooked in those cases not investigated by SSCP analysis. We
also investigated 73 for the presence of mutations by
sequencing of the entire coding region of the 73 gene. 73
mutations were found in two out of five MCC cell lines and in one
out of ten tumours. In cell line MCC13, three mutations were
found at dipyrimidine sites, namely a double base pair C to T tran-
sition at nucleotides 857, 858 and a single base pair C to T transi-
tion at nucleotide 967 both leading to amino acid substitutions at
codon 241 and codon 278 respectively (Table 1). These type of
mutations are characteristically induced by absorption of UV irra-
diation by the DNA (Brash et al, 1991). The mutation found in
MCC14/2 is a hemizygous T to A transversion at nucleotide 950
since no wild-type sequence was present. This point mutation is
translated into an amino acid substitution from valine to glutamic
acid at codon 272. The amino acid changes at codon 241, 272 and
278 reside in mutational hotspots of the sequence-specific DNA-
binding domain of the TP53 protein. Alterations in these residues
of the TP53 protein will typically result in defective contacts with
the DNA and finally lead to the loss of the ability of TP53 to act as
a transcription factor. For the particular amino acid substitution at
residue 241, Cho et al (1994) could show that DNA contact was
not possible as the defective TP53 protein was unable to make
contact with the phosphate backbone in the major groove of the
DNA. The non-sense mutation at nucleotide 550 in the MCC
tumour (case 4) predicted the generation of a truncated TP53
protein. Accumulation of truncated TP53 variants can result in a
dominant negative effect and loss of normal TP53 function.
In conclusion, we describe the finding of a sporadic S NH2-
terminal located mis-sense mutation in MCC together with the
observation of two previously reported loss of function mutations
within the COOH-terminal transactivation region of S in
neuroblastoma. These mutations provide circumstantial evidence
for a role of S in these malignancies of neuroectodermal origin.
At present, the exact physiological function of S in tumour
development is unclear. In view of these findings, we propose
further investigations of S in normal development and tumori-
genesis. Further insights in its role in apoptosis (Jost et al, 1997)
and possibly other mechanisms such as cell cycle control and cell
differentation may provide additional clues for possible contribu-
tion of S in tumorigenesis. This report also shows for the first
time the occurrence of inactivating 73 mutations in 19% of the
investigated MCCs. The C to T mutations in cell line MCC13 are
known to be caused by UVB irradiation and thus provide further
evidence for sun-exposure in some Merkel cell carcinomas.
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3.1.2 Frequent allelic loss at 10q23 but low incidence of PTEN mutations in Merkel
cell carcinoma
The finding of loss of chromosome 10 or the chromosome 10 long arm in more than one
third of the studied MCC cases by CGH led us to assume that loss of gene function of a
putative tumor suppressor gene located on 10q could contribute to MCC development or
progression. In 1997, a new tumor suppressor gene called PTEN (alias MMAC1 or TEP1)
was identified and mapped onto 10q23.3. PTEN encodes for a dual-specificity phosphatase
and shows extensive homology with the cytoskeletal proteins tensin and auxilin which are
involved in focal cell adhesion (Li and Sun, 1997; Li et al., 1997; Steck et al., 1997).
Studies with Pten knockout mice showed that Pten is essential for embryonic development
and tumor suppression through its ability to control cellular differentiation and anchorage-
dependent growth (Di Cristofano et al., 1998). In addition, PTEN is involved in cell
proliferation and regulation of apoptosis through negative regulation of the PI3K/PKB/Akt
cell survival signaling pathway (see Figure 3-2) (Stambolic et al., 1998; Yamada and
Araki, 2001). PTEN is frequently mutated in a wide variety of human cancers including
brain, breast, endometrium, kidney and prostate, indicating its critical role in the
pathogenesis of many neoplasms. A very high proportion of PTEN mutations are located in
the phosphatase core motif located in exon 5, pointing at the importance of the phosphatase
activity in the tumor suppressor function of PTEN (Ali et al., 1999).
Figure 3-2: Reported sites of action of PTEN. Extracellular interactions trigger signaling from integrins
and growth factor receptors. The major function of PTEN is downregulation of the PI3-kinase product
PtdIns(3,4,5)P3, which regulates Akt and complex downstream pathways affecting cell growth, survival and
migration. In addition, PTEN has weak protein tyrosine phosphatase activity, which may target focal
adhesion kinase (FAK) and Shc, and thereby modulate other complex pathways. The phosphatase domain of
PTEN (red) dephosphorylates and downregulates (red lines) substrate molecules.
(Reproduced from Yamada and Araki, J Cell Science, 114: 2375-2382, 2001)
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In view of the above findings, we decided to investigate the role of the PTEN gene in
MCC. In keeping with our CGH data, LOH analysis revealed a high frequency of loss at
the PTEN locus (43% of informative cases). Despite this high incidence of LOH only one
homozygous deletion for exon 9 and one non-sense mutation at exon 5, respectively were
detected. The latter was located in the phosphatase domain of PTEN and could result in a
reduced or complete loss of the tumor suppressor function of PTEN. Our results suggest
that loss of one PTEN allele and disruption of the second allele by mutation and
homozygous deletion is a relatively rare event in MCC. We propose that other alternative
mechanisms can lead to inactivation of PTEN or that other tumor suppressor genes at
chromosome 10 are implicated in the development of MCC.
Recently, studies showed that the loss of one PTEN allele (haploinsufficiency) is sufficient
to induce tumor formation and progression in certain cancer types (Kwabi-Addo et al.,
2001). We assume that this mechanism can also be implicated in MCC (see General
Discussion).
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FREQUENT ALLELIC LOSS AT 10Q23 BUT LOW INCIDENCE OF PTEN
MUTATIONS IN MERKEL CELL CARCINOMA
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Merkel cell carcinoma (MCC) is a rare, highly metastatic
skin tumor of neuroectodermal origin. The disease shares
clinical and histopathological features with small cell lung
carcinoma (SCLC). The genetic mechanisms underlying the
development and tumor progression of MCC are poorly un-
derstood. We recently showed by comparative genomic hy-
bridization (CGH) that the pattern of chromosomal abnor-
malities in MCC resembles that of SCLC. One of the most
frequently observed losses involved the entire chromosome
10 or partial loss of the chromosome 10 long arm (33% of
examined MCC cases). The PTEN tumor-suppressor gene has
been mapped to 10q23.3 and was shown to be mutated in a
variety of human cancers including SCLC. Germline PTEN
mutations have been observed in familial predisposing cancer
syndromes including Cowden disease. Interestingly, an asso-
ciation between Cowden syndrome and Merkel cell carci-
noma has been reported. To study the possible role of PTEN
in MCC oncogenesis, loss of heterozygosity (LOH) analysis
for the 10q23 region was performed on 26 MCC tumor sam-
ples from 23 MCC patients. The PTEN locus was deleted in 9
of 21 (43%) informative MCC tumor samples [7 of 18 (39%)
MCC patients]. Despite this high frequency of LOH at 10q23,
mutation and homozygous deletion screening of the PTEN
gene revealed only one tumor with a nonsense mutation and
a second with a homozygous deletion of exon 9. These data
suggest that either alternative mechanisms lead to inactiva-
tion of the PTEN gene or that other tumor-suppressor genes
at chromosome 10 are implicated in the development of
MCC.
© 2001 Wiley-Liss, Inc.
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Merkel cell carcinoma (MCC) is a rare neuroendocrine skin
tumor with aggressive clinical behavior. Tumors occur mostly in
the head and neck region or on the arms in older, fair-skinned
people, implicating UV exposure in the etiology.1 The tumor
shares common features with small cell lung carcinoma (SCLC),
including morphological and immunophenotypical characteris-
tics.2 Both are small cell tumor types with neuroendocrine features
expressing specific neuropeptides and intermediate filament pro-
teins.3 Similarities in clinical behavior include a high incidence of
recurrences and nodal metastases.4
Little is known about the genetic background of Merkel cell
carcinoma. Although cytogenetic findings have been described in
about 30 MCCs, no recurrent chromosomal abnormalities have
been identified except for loss of distal 1p material due to various
types of chromosomal aberrations. Further support for 1p involve-
ment in MCC was provided by Van Gele et al.,5 who showed that
2 distinct regions on 1p36 are implicated in MCC. In the search for
chromosomal losses indicating possible involvement of tumor-
suppressor genes in MCC, loss of heterozygosity (LOH) studies
for markers on 1p, 3p and 13q have been undertaken.6–9 A ge-
nome-wide analysis of chromosomal losses and gains was per-
formed by comparative genomic hybridization (CGH) of 26 MCC
tumors and 8 MCC cell lines. This study revealed a characteristic
pattern of gains and losses in Merkel cell carcinoma pointing at
regions harboring putative oncogenes and tumor-suppressor
genes.10 Interestingly, the CGH pattern of MCC closely resembles
the pattern of chromosomal gains and losses observed in SCLC.11
One of the more frequently observed losses in MCC involved the
entire chromosome 10 or partial loss of the chromosome 10 long
arm.10 Chromosome band 10q23.3 harbors the PTEN tumor-sup-
pressor gene for which mutations and deletions have been reported
in a variety of human neoplasms including SCLC.12
Germline mutations of PTEN predispose affected individuals to
develop various benign and malignant lesions in a wide spectrum
of tissues. These cancer-predisposing syndromes include Ban-
nayan-Zonana syndrome, Juvenile Polyposis Coli and Cowden
syndrome.13–15 Interestingly, Haibach et al.16 reported a patient
with Cowden syndrome who developed renal cell carcinoma and
Merkel cell carcinoma. Based upon the above observations, we
hypothesised that PTEN might play a role in the development or
progression of highly metastatic Merkel cell carcinomas. To in-
vestigate this, LOH analysis at chromosomal band 10q23 and
mutational analysis of PTEN was performed on 26 MCC tumor
samples representing 23 patients and 8 MCC cell lines. In addition,
all samples were examined for the presence of intragenic homozy-
gous PTEN deletions.
MATERIAL AND METHODS
Tumor specimens and cell lines
Tumor and peripheral blood samples were obtained at the
Queensland Radium Institute Laboratory, Queensland Institute of
Medical Research, Brisbane, Australia, and at the Center for Med-
ical Genetics, Ghent University Hospital, Ghent, Belgium. Clinical
data of all patients are summarized in Table I. LOH and CGH data
for these tumors have been reported previously.10,17 Morphologi-
cal characterization and cytogenetic data of the MCC cell lines
have been published previously18–21 except for MCC26 and T95-
45, which will be published elsewhere (Van Gele et al., in prep-
aration). Genomic DNA was extracted from cell lines and frozen
sections of tumor samples by using standard proteinase-K diges-
tion, phenol/chloroform extraction and ethanol precipitation pro-
tocols. Constitutional DNA was isolated from peripheral blood
lymphocytes using the Qiagen blood and cell culture DNA Midi
kit (Qiagen, Hilden, Germany). The investigated tumor samples
contained at least 60% tumor cells.
LOH analysis
Four microsatellite markers, known to map to the 10q23 region,
were used for LOH analysis. The order of these markers from
centromere to telomere is D10S1687, D10S215, PTENCA and
D10S541 and was based on the genetic map of chromosome 10q
(http://www-genome.wi.mit.edu). Primer sequences were obtained
from the Genome Database except for PTENCA.22 PCR amplifi-
cation was performed in a 25 l reaction volume using 200 ng of
Grant sponsor: GOA; Grant number: 12051397; Grant sponsor: Queens-
land Cancer Fund; Grant sponsor: Queensland Radium Institute.
*Correspondence to: Center for Medical Genetics, Ghent University
Hospital, De Pintelaan 185, B-9000 Ghent, Belgium.
Fax: 32-9-240-4970. E-mail: franki.speleman@rug.ac.be
Received 4 July 2000; Revised 18 December 2000; Accepted 20 De-
cember 2000
Int. J. Cancer: 92, 409–413 (2001)
© 2001 Wiley-Liss, Inc.
Publication of the International Union Against Cancer
Part 3. Candidate gene analysis 89
genomic DNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM
MgCl2, 2.5 mM each dNTP, 30 mM of each primer and 1 U
Platinum Taq DNA polymerase (Life Technologies, Merelbeke,
Belgium) on an MJ Research PTC200 thermal cycler. Cycling
conditions were 92°C for 3 min, followed by 35 cycles at 92°C for
30 sec, 55°C for 30 sec and 72°C for 1 min, with a final extension
period of 72°C for 7 min. Each forward primer defining a micro-
satellite repeat marker was 5-tagged with the fluorescent dye
labels HEX, TET or 6-FAM (Biosource International, Keystone
Laboratories, CA). PCR products were electrophoresed on 6%
LongRanger (FMC Bioproducts, ME) 6 M urea denaturing gels
using an ABI PRISM 377 automated DNA sequencer (Applied
Biosystems, Lennik, Belgium) and the GeneScan 500 [TAMRA]
internal size standard (Applied Biosystems). Allele size and fluo-
rescent intensity were determined by GeneScan Analysis 2.1 soft-
ware (Applied Biosystems). LOH was analysed by determining the
fluorescent intensity of each allele and calculating the ratio of peak
intensities. A sample was scored as having LOH if an allelic ratio
of 0.5 or 2.0 was obtained.
PTEN mutation analysis
Intronic primers flanking each of the 9 exons of the PTEN gene
were used for amplification of tumor DNA. Primer sequences were
described by Steck et al.,23 except for exon 5 for which new
primers were designed using Primer Express Software version 1.0
(Applied Biosystems): Ex5 forward (5TTTTCTCTGGAATC-
CAGTGTTTCT3) and Ex5 reverse (5AGATCCAGGAAGAG-
GAAAGGAA3). PCR amplification was performed in a 25 l
reaction volume using 100 ng of genomic DNA, 10 mM Tris-HCl
(pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 2.5 mM each dNTP, 30
mM of each primer and 1 U Platinum Taq DNA polymerase
(Gibco BRL) on an MJ Research PTC200 thermal cycler. Cycling
conditions were 92°C for 3 min, followed by 35 cycles at 92°C for
30 sec, 53°C for 30 sec and 72°C for 1 min, with a final extension
period of 72°C for 7 min. A different annealing temperature was
used for exon 5 (60°C). PCR products were purified by using the
Qiaquick PCR purification kit (Qiagen). Subsequently, the PCR
products were cycle sequenced on an ABI PRISM 377 sequencer
according to the manufacturer’s instructions (Applied Biosys-
tems). The same primers (forward and reverse) as those for am-
plification of tumor DNA were used for the sequencing reactions.
Nucleotide changes were confirmed by reamplification and rese-
quencing of tumor DNA and corresponding constitutional DNA.
Screening for homozygous PTEN deletions
A multiplex PCR assay was used to screen for homozygous
deletions in the PTEN gene. Each PTEN exon (same primers as
above) was co-amplified with a 983 bp control fragment encoding
the human GAPDH gene (primers from Clontech, Heidelberg,
Germany). The same PCR cycling conditions were used as for the
PTEN mutation analysis except that multiplex PCR was performed
at 30 cycles for the MCC cell lines and at 25 cycles for all tumor
samples and their corresponding constitutional DNA. PCR prod-
ucts were visualized on a 1.5% agarose gel stained with ethidium
bromide, and signal strengths were compared and interpreted by 2
independent persons.
RESULTS
LOH analysis
A panel of 26 MCC tumor samples from 23 patients and
corresponding constitutional DNAs (except for MCC21 and UHG-
RM) were analysed using 3 microsatellite markers flanking the
PTEN locus (D10S1687, D10S215 and D10S541) and marker
PTENCA, which is located in the PTEN gene. Results of LOH
analyses are summarized in Table II. The frequencies of LOH for
the 4 loci on chromosome 10q23 were 6 of 20 informative tumor
samples (30%) [5 of 19 patients (26%)] at D10S1687, 3 of 9
informative tumor samples (33%) [3 of 9 patients (33%)] at
D10S215, 9 of 21 informative tumor samples (43%) [7 of 18
patients (39%)] at PTENCA and 7 of 17 informative tumor samples
(41%) [6 of 16 patients (37.5%)] at D10S541. LOH at one or more
loci was detected in 10 of the 26 MCC tumor samples examined
(38%), representing 8 of the 23 patients (35%) (MCC2, 8, 11, 12,
14, 18, 26 and UHG-RJ). PTENCA was the most frequently
affected marker in these tumor samples.
TABLE I – CLINICAL DATA FROM 26 SAMPLES
OF 23 PATIENTS WITH MCC
Tumor Sex Age at presentation Specimen1
MCC2 M 66 Node
MCC3 M 68 Node
MCC4 M 76 Node
MCC5 F 72 Rec
MCC7T1/T22 F 63 Rec/Met
MCC8 M 84 Rec
MCC9 M 81 Rec
MCC11 M 71 Rec
MCC12 M 60 Rec
MCC13 F 65 Rec
MCC14T1/T2 M 80 Node/Node
MCC16 M 70 Rec
MCC17 M 74 Rec
MCC18 M 64 Rec
MCC21 M 53 Node
MCC22 M 72 Node
MCC24 M 79 Rec
MCC26T1/T2 F 82 Rec/Node
UHG-VM F 79 Met
UHG-RM F 62 Met
UGH-FA F 69 Prim
RJ M 86 Prim
SA F 66 Prim
1Node, specimen taken from regional lymph node; Rec, recurrence
at site; Met, metastasis; Prim, primary tumor.–2T1, first tumor speci-
men; T2, second tumor specimen.
TABLE II – RESULTS OF LOH ANALYSIS AT THE 10q23 REGION IN 23
PATIENTS WITH MCC
Marker
cen 3 tel D10S1687 D10S215 PTENCA D10S541
MCC2 LOH H LOH LOH
MCC3 ROH H ROH ROH
MCC4 ROH H ROH ROH
MCC5 H H ROH H
MCC7T1 ROH H ROH H
MCC7T2 ROH H ROH H
MCC8 H LOH H LOH
MCC9 ROH ROH ROH ROH
MCC11 LOH LOH LOH LOH
MCC12 H H LOH LOH
MCC13 ROH ROH ROH ROH
MCC14T1 LOH H LOH LOH
MCC14T2 LOH H LOH LOH
MCC16 ROH ROH H ROH
MCC17 ROH H ROH ROH
MCC18 LOH LOH LOH LOH
MCC21 ROH ROH H H
MCC22 ROH H ROH ROH
MCC24 ROH H ROH ROH
MCC26T1 H NA LOH H
MCC26T2 H NA LOH H
UHG-VM ROH ROH ROH H
UHG-SA ROH H ROH H
UHG-RM H H H ROH
UHG-FA ROH ROH H ROH
UHG-RJ LOH H LOH H
ROH, retention of heterozygosity; H, homozygosity (not informa-
tive); LOH, loss of heterozygosity; NA, not available due to no
interpretable results; T1, T2, tumor specimens from same tumor but
obtained from different sites.
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Screening for PTEN mutations and homozygous deletions in
MCC tumors and cell lines
All 26 MCC tumor samples and 8 additional MCC cell lines
were analysed for mutations of the PTEN gene by direct sequenc-
ing of all 9 PTEN exons. Two polymorphisms at position IVS8
32 (G/T) and IVS2 –96 (G/A) were found in most of the
examined samples (58.8% and 82.3%, respectively). A nonsense
mutation was detected at exon 5 in 1 MCC tumor (MCC2), leading
to an AAG to TAG change at codon 147, which was not seen in the
constitutional DNA (Fig. 1a,b). This mutation would probably
result in a premature termination of the PTEN protein at the same
codon leading to a complete loss of PTEN protein activity. To our
knowledge, this PTEN mutation has not been reported before. The
same tumor also showed loss for all informative loci including the
PTENCA marker (Fig. 2). Despite loss of 1 PTEN allele, the
sequencing profile of the mutation shows a heterozygous mutation
(Fig. 1a). This observation could be the result of genetic hetero-
geneity within the tumor biopsy as evidenced by presence of
mitoses with and without monosomy for chromosome 10.17 CGH
clearly demonstrated loss of the 10q region in this tumor.10
In addition, all samples were screened for homozygous PTEN
deletions by multiplex PCR. Due to the presence of specific PCR
products for all 9 PTEN exons in all MCC cell lines, we assumed
them not to carry homozygous PTEN deletions. In 1 MCC tumor
(MCC5), the PCR assay showed a reduced PCR product for exon
9 when compared with the corresponding constitutional DNA, in
contrast to the equal signals for GAPDH, strongly suggesting the
presence of a homozygous deletion for this particular exon (Fig.
3). In the tumor DNA, a faint band is still present, probably due to
stromal contamination within the tumor specimen.
DISCUSSION
The PTEN gene (also called MMAC1 or TEP1) encodes for a
dual-specificity protein phosphatase that can dephosphorylate ty-
rosine, serine and threonine residues. PTEN also shows extensive
homology with the cytoskeletal proteins tensin and auxilin which
are involved in focal cell adhesion.23–25 Recent studies with PTEN
knockout mice showed that PTEN is essential for embryonic
development and tumor suppression through its ability to control
cellular differentiation and anchorage-dependent growth.26 More-
over, PTEN seems to be involved in cell proliferation and regula-
tion of apoptosis through negative regulation of the PI3K/PKB/
Akt cell survival signaling pathway.27 A high frequency of reported
PTEN mutations resides within the highly conserved protein ty-
rosine phosphatase (PTPase) core motif located in exon 5 at
residues 122–132 (IHCKAGKGRTG).14 This points to the impor-
tance of the phosphatase activity in the tumor-suppression function
of PTEN. Genetic changes of PTEN occur in multiple cancer types,
suggesting that PTEN may play a more general role in the patho-
genesis of a variety of human malignancies. The following obser-
vations prompted us to perform LOH analysis of the 10q23 region
and to search for inactivating PTEN mutations and homozygous
deletions in MCC: 1. reported CGH data showing loss of chromo-
some 10 or the long arm of chromosome 10 in 33% of examined
cases;10 2. clinical and histopathological resemblance between
MCC and SCLC and reported deletions and mutations of the PTEN
gene in SCLC;2–4,28,29 3. the finding of an MCC in a patient with
Cowden disease, a syndrome for which germline PTEN mutations
have been reported.16 LOH of 1 or more loci at the 10q23 region
was detected in 38% (10 of 26) of the examined MCC tumor
samples [8 of 23 (35%) MCC patients]. The PTEN locus was
deleted in 9 of 21 (43%) informative samples [7 of 18 (39%) MCC
patients]. Despite the high incidence of LOH at the PTEN locus,
PTEN mutations were detected in only 1 tumor of 34 examined
MCCs. The detected somatic point mutation, resulting in a change
from lysine to a stop codon, was located in the phosphatase domain
of PTEN, 15 codons downstream of the PTPase core motif. This
nonsense mutation might lead to a truncated protein missing a part
of exon 5 and all the following exons (6, 7, 8 and 9), resulting in
complete loss of PTEN protein activity or a truncated protein with
reduced phosphatase activity leading to a decrease or inactivation
of the tumor-suppressor function of PTEN. Alternatively, loss of
the C-terminal region of PTEN could lead to loss of a particularly
important but as yet undefined function, as the role of the C-
terminus remains unclear. In addition, exon 9 of PTEN was found
to be homozygously deleted in 1 MCC tumor. Unfortunately, no
RNA or cell lysates of these tumors were available to examine the
above mentioned alterations in further detail.
FIGURE 1 – A detail of the reverse sequencing profile of exon 5 of
PTEN showing the point mutation in tumor MCC2 at codon 147 (a).
Same sequencing profile but in the constitutional DNA of patient
MCC2 (b).
FIGURE 2 – Loss of heterozygosity analysis in tumor MCC2 for the
polymorphic marker PTENCA. The alleles present in the constitutional
DNA (a) and in the tumor DNA (b) of patient MCC2 are indicated by
arrows. LOH, loss of heterozygosity.
FIGURE 3 – Detail of multiplex PCR with GAPDH and exon 9 of the
PTEN gene showing a homozygous deletion in tumor MCC5. PCR
products were visualised on a 1.5% agarose gel. Sizes in base pairs are
shown on the right. T, tumor DNA; N, constitutional DNA of patient
MCC5.
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Overall, our data suggest that inactivation of PTEN by loss of 1
allele and disruption of the second allele by mutation or homozy-
gous deletion is a relatively rare event in the pathogenesis of MCC.
Other mechanisms leading to deregulation or inactivation of PTEN
may be involved. For example, down-regulation at the mRNA or
protein level of PTEN has been reported for prostate cancer in at
least 50% of advanced human prostate cancers.30 A report by Zhou
et al.31 suggested an epigenetic mechanism of bi-allelic functional
inactivation of PTEN in malignant melanomas without PTEN
mutations or deletions. Mutations located in the promoter region or
in intronic sequences may result in PTEN inactivation. Alterna-
tively, 1 or more unidentified tumor-suppressor genes within the
10q23 deleted region could also be involved in the oncogenesis of
Merkel cell carcinoma.
Since CGH indicated loss of an entire copy of chromosome 10
in one-quarter of the examined MCC patients,10 we cannot exclude
that 1 or more other tumor-suppressor genes located either on 10p
or 10q might be involved in the etiology of MCC. Several putative
tumor-suppressor genes have been mapped to 10q. In the DMBT1
gene, intragenic homozygous deletions were detected in medullo-
blastomas and glioblastoma multiforme.32 A study by Wu et al.33
showed that in contrast to high expression of DMBT1 in normal
adult lung tissue, DMBT1 expression was absent in 100% of
SCLC cell lines and 43% of NSCLC cell lines due to gene deletion
and to other yet unidentified mechanisms. MXI1 is mutated in a
small fraction of prostate carcinomas.34 The LGI1 gene, predom-
inantly expressed in neural tissue, showed reduced expression in
low-grade brain tumors and significantly reduced or absent expres-
sion in malignant gliomas.35 The h-neu gene was expressed at very
low level in human malignant astrocytoma tissues and the majority
of examined glioma cell lines, while normal brain expressed higher
levels of h-neu transcripts. One of the glioma cell lines had a single
nucleotide substitution. It is hypothesized that the h-neu gene plays
a role in determination of cell fate in the human central nervous
system, and it is conceivable that a loss of function of the h-neu
gene may lead to the development of neuroectodermal tumors.36
Previous studies of human gliomas and primary glioblastomas
showed, beside loss of 10q in these tumors, patterns of deletions on
10p14–15 possibly harbouring not yet identified putative tumor-
suppressor gene(s).37–41 Analysis of additional Merkel cell carci-
nomas and detection of small deletions on 10p and/or 10q may
allow further refined delineation and molecular analysis of the
most likely candidate tumor-suppressor genes within these regions.
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4.1 Differential gene expression analysis in Merkel cell and small cell
          lung carcinoma
4.1.1 Analysis of gene expression profiles in Merkel cell and small cell lung
carcinoma: improved differential diagnosis and classification of different Merkel cell
phenotypes Van Gele Mireille et al. (in preparation)
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4.1.1 Analysis of gene expression profiles in Merkel cell and small cell lung
carcinoma: improved differential diagnosis and classification of different Merkel cell
phenotypes
At present few insights into the genetic defects and molecular pathways involved in MCC
pathogenesis are available. The genome wide screening approach described in Paper 2.1.2
identified new regions of recurrent gains and losses involved in MCC and revealed a
number of common genetic changes for MCC and SCLC (overviewed in Figure 4-1)
indicating that certain biological pathways or genes are implicated in the etiology of both
tumors. Evidence for frequent inactivation of tumor suppressor genes such as FHIT, RB1,
and TP53 was obtained in SCLC whereas PTEN, TP73 and P16INK4a seemed rarely
involved in this tumor type (Minna et al., 2002). Molecular studies described in this thesis
(see Part 3) and reported by other groups (Sozzi et al., 1996a; Leonard and Hayward, 1997;
Cook et al., 2001) revealed that the same genes were also involved in MCC.
Figure 4-1: Overview of common recurrent gains and losses between Merkel cell (MCC, green bars)
and small cell lung carcinoma (SCLC, blue bars). Lines on the right side of the ideograms show
overrepresentations, lines on the left side show underrepresentations. Tumor suppressor genes
investigated in both SCLC and MCC are indicated next to the ideograms   (*only examined in SCLC).
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Besides these similarities in occurrence of genetic alterations in MCC and SCLC, both
tumors also share other features such as (a) small round blue cell histology; (b) presence of
neurosecretory granules; (c) neuroendocrine origin; (d) expression of identical
histochemical markers; (e) clinical aggressive behavior and (f) variable response to
therapy. These similarities may hamper the differential diagnosis for these tumors,
especially when no obvious primary lesion can be detected. Identification of additional
molecular markers could thus improve the differential diagnosis between both tumors. Cell
lines derived from both tumors also showed identical morphological and growth
characteristics. Analogous to SCLC, MCC cell lines were classified into two
phenotypically different subgroups, i.e. Classic and Variant types (Carney et al., 1985;
Gazdar et al., 1985; Leonard and Bell, 1997). Previous studies showed that SCLC tumors
from whom Variant SCLC cell lines were established behaved aggressively, patients
responded poorly to therapy and showed a worse prognosis compared to those tumors from
whom Classic SCLC cell lines were derived, indicating biological and clinical differences
between both groups (Gazdar et al., 1985). A number of histochemical markers (Broers et
al., 1985; Broers et al., 1986) and recently also genes differentially expressed between
Classic and Variant SCLC cell lines (Zhang et al., 2000), have been identified thus
offering insight into the molecular basis of their different malignant behavior. In contrast to
SCLC, no differential gene expression studies have been performed for MCC. Only one
recent molecular study indicated that lack of the Brn-3c transcription factor and/or basic
helix-loop-helix transcription factor HATH1 was correlated with loss of the neuroendocrine
phenotype in Variant MCC cell lines and could serve as useful prognostic markers
(Leonard et al., in press). Although this study yielded valuable information, it is obvious
that additional studies are warranted to gain more insight into the biology of MCC.
In order to learn more about the molecular pathogenesis of MCC and identify molecular
markers which could improve the differential diagnosis between MCC and SCLC, we
determined the gene expression profiles of 10 MCC and 4 SCLC cell lines using Atlas
cDNA filter expression arrays containing 1891 unique genes involved in many cellular
processes. Supervised analysis of the data allowed us to identify a set of 23 classifier genes
which could improve differential diagnosis between MCC and SCLC. Some of these
molecular markers or disrupted pathways could be potential targets for new therapeutic
treatments and improve patient survival in MCC and/or SCLC. In addition, we identified
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89 significant differentially expressed genes which allowed classification of the MCC cell
lines into their Variant and Classic subgroups. We assume that the differential expression
levels of some of these genes reflect, analogous to SCLC, the different biological and
clinical properties of MCC phenotypes. This would implicate a more aggressive treatment
for tumors with a Variant morphology and a closer follow-up for this patient group.
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Analysis of gene expression profiles in Merkel cell and small cell lung
carcinoma: improved differential diagnosis and classification of different
Merkel cell phenotypes
Van Gele Mireille, et al. (in preparation)
Introduction
Merkel cell carcinoma (MCC) is a rare aggressive neuroendocrine skin tumor, mostly
affecting elderly people. The disease occurs predominantly on the sun-exposed areas of the
skin suggesting UV-exposure in its etiology (reviewed in1). The number of MCC tumors
and cell lines which have been cytogenetically investigated is relatively small2. Although
no recurrent translocations have been reported, cytogenetic analysis showed near-diploid
karyotypes with complex structural changes in most cases, often presenting as multi-way
translocations. The distal part of the short arm of chromosome 1 is frequently affected and
has been reported as the sole structural chromosome change in 3 MCC tumors3, 4 (Van
Gele et al., unpublished results). In contrast to the rather inhomogeneous pattern of
chromosomal changes described in cytogenetic studies, CGH analysis revealed a number
of typical chromosomal imbalances including loss of chromosomal regions 3p, 5q, 8p, 10,
11q, 13q and 17p and gain of chromosomal regions 1, 3q, 5p and 8q5. Interestingly, the
pattern of gains and losses resembled the pattern observed in previous CGH reports of
small cell lung carcinoma (SCLC)6-8.
MCC and SCLC are both derived from neuroendocrine cells (Merkel and
Kulchitsky cells, respectively) expressing peptide hormones such as neuron-specific
enolase and bombesin. Histologically, both tumors are composed of small round blue cells
and contain often neurosecretory granules visible by electron microscopy. Clinically, they
are aggressive tumors responding initially to chemotherapy, but response is typically short-
lived. They show a high degree of local recurrence and have a tendency to metastazise
early9. Differential diagnosis between MCC and SCLC is often difficult in SCLC patients
presenting with metastasis to the skin especially when the primary lesion is not detected.
Identification of additional molecular markers could thus improve/facilitate the differential
diagnosis between both tumor types. Moreover, further insights into the genes and
signaling pathways involved in these tumors is a prerequisite for development of the new
rational therapeutic interventions which could lead to an improved patient survival or even
complete remission.
In addition to the above mentioned clinical and histological resemblance between
MCC and SCLC, similarities in morphology and growth characteristics were observed in
cell lines derived from both tumors. Comparable to SCLC cell lines, MCC cell lines can
also be grouped into four different morphological classes (Type I to IV). In addition,
different expression patterns of cytokeratins and neuroendocrine markers, such as
chromogranin A and neuron-specific enolase, allowed further classification of these cell
lines into “Classic” and “Variant” groups10, 11. Recent studies on the POU-IV family
member Brn-3c and basic helix-loop-helix transcription factor HATH1 showed that lack of
their expression was linked to loss of the neuroendocrine phenotype of Variant MCC cell
lines12.
In contrast to MCC, numerous molecular genetic studies have been performed on
SCLC which contributed to the understanding of SCLC pathogenesis (reviewed in13, 14). In
addition, histochemical markers and differentially expressed genes distinguishing Classic
from Variant SCLC cell lines have been identified and led to an improved understanding of
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the underlying genetic basis responsible for the biological and clinical heterogeneity
among small cell lung cancers15, 16.
In order to obtain further insights into the molecular pathogenesis of MCC, the
factors influencing cell line morphology, aggressiveness and neuroendocrine phenotype
and the relationship of MCC versus SCLC, we decided to determine the gene expression
profiles of 10 MCC cell lines and four SCLC cell lines using Atlas cDNA expression
arrays containing 1891 unique genes involved in many cellular functions.
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Material and Methods
Cell lines
Merkel cell carcinoma cell lines MCC5, MCC6, MCC13, MCC14/1, MCC14/2 and
MCC26 were established at the Queensland Radium Institute Laboratory, Queensland,
Australia and have been described in detail previously by Leonard et al.17, 18. MCC cell line
UISO was described by Ronan et al.19, MKL-1 by Rosen et al.20. MKL-2 was established
at the Robert H. Lurie Comprehensive Cancer Center, Illinois, USA and reported by Van
Gele et al.2. T95-45 was established at the Center for Medical Genetics, Ghent, Belgium.
Most cell lines were previously analyzed by CGH and/or M-FISH2, 5. Small cell lung
carcinoma cell lines NCI-H69 and NCI-146 were obtained from the American Type
Culture Collection, CorL88 was a gift from Dr. P. Twentyman, Cambridge, UK and GLC4
was a gift from Dr. Marc Maliepaard, Amsterdam, The Netherlands. Neuroblastoma cell
lines IMR3221, SK-N-SH22, SK-N-AS23, NGP24 and N20625 were included for analysis. All
cell lines were grown to subconfluency in RPMI 1640 (Invitrogen) supplemented with
antibiotics, 15% fetal calf serum and 1% L-glutamine. Cells from 10 tissue culture flasks
(75 cm2) were pelleted, quick frozen in liquid N2 and stored at –80°C. Melanocytes and
neonatal foreskin fibroblasts (NFF) were isolated at the Queensland Radium Institute
Laboratory, Queensland, Australia and used as a normal control RNAs.
cDNA array hybridization
Total RNA from cell lines, melanocytes and fibroblasts was extracted using the Atlas Pure
Total RNA Labeling System (Clontech) and DNase I (Roche) treated. The quality and
integrity of the DNase treated RNA were checked by ethidium bromide agarose gel
electrophoresis. Expression analysis was performed using the Atlas Human 1.2 (7850-1)
and Atlas Human Cancer 1.2 (7851-1) nylon arrays (Clontech). Both filters contained 1176
genes (http://atlasinfo.clontech.com/atlasifo/array-list-action.do) of which 461 were
present on both arrays. For each sample, 12.5 µg of total RNA was used in the cDNA
probe synthesis with [α-32P]dATP (NEN Life Science Products) and performed according
to the Clontech Atlas cDNA Expression Arrays User Manual. Purification of the probe,
hybridization and washes were done following the manufacturer’s instructions (Clontech).
Each cell line was simultaneously hybridized to both filters. After the washes, membranes
were exposed for 1 to 3 nights to phosphoimager plates and scanned with a Storm
Phosphoimaging System (Molecular Dynamics).
Analysis of cDNA arrays
The scanned gel images were converted to 16bit TIFF-file format. Signal intensities were
quantified using the VisualGrid software version 2.1 (http://www.GPC-Biotech.com). The
ArrayAn2 software (Boonefaes et al., manuscript in preparation) was used for further
primary data analysis. In short, the spot intensities were corrected for the local background
signal intensity, followed by a spot quality control step to exclude spots influenced by
overshining  effects of adjacent spots. Constitutive genes were selected (the 50% of spots
showing the lowest coefficient of variation over all arrays) and used for normalization.
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Expression data analysis
Genes with an expression value above background level in at least 9 of the analyzed
samples were selected for further analysis. This resulted in a total of 1060 genes of which
410 were common genes. Cluster and Treeview software were used for unsupervised
hierarchical clustering and visualization of the data26. Prior to clustering, genes were
median centered and the expression data matrix was log transformed (base 2).
Subsequently, complete linkage clustering using Pearson correlation coefficient as
similarity metric was performed to the samples and genes. The complete expression data
matrix is available as tab delimited file from the authors on request.
Unsupervised clustering of array data allows to find coherent patterns of gene expression
but provides little information about the statistical significance. Therefore, we used the
SAM algorithm (Significance Analysis of Microarrays, http://www-stat-
class.stanford.edu/SAM/SAMServlet) which allows supervised identification of
significantly expressed genes between predefined sample groups. In order to include less
representative genes for the SAM analysis the filter threshold was lowered by including
genes expressed above background in at least 4 of the analyzed samples (1513 genes).
Real-time quantitative RT-PCR
Sixteen SAM identified genes were selected and quantified by real-time quantitative RT-
PCR on the same 21 RNA samples as for array hybridizations. Primer sequences for all 16
genes were designed with Primer Express 1.0 software (Applied Biosystems) using the
default TaqMan parameters, with modified minimum amplicon length requirements (75
bp). The primer sequences are available from the authors on request and will be deposited
in a public database for real-time PCR primers, which is under construction
(www.realtimepcr.ht.st). Relative gene expression levels were determined using an
optimized two-step SYBR green I RT-PCR assay as described by Vandesompele et al.27.
The standard curve method (serial dilutions of a cDNA mixture containing 2 SCLC and 2
MCC samples) or the comparative Ct method was used for quantification. PCR reagents
were obtained from Applied Biosystems as SYBR Green I mastermixes and used
according to the manifacturer’s instructions. PCR reactions were run on an ABI Prism
5700 Sequence Detection System (Applied Biosystems). To correct for differences in RNA
quantities and cDNA synthesis efficiency relative gene expression levels were normalized
using the geometric mean of 5 housekeeping genes (UBC, HPRT1, GAPD, TBP and
PBGD)  according to Vandesompele et al.28.
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Results
Validation of Atlas cDNA array expression data
Several points of evidence indicate good reliability of the array gene expression data:
1) Of the 1060 genes used for hierarchical clustering, 205 were present on both arrays
(Human and Human Cancer 1.2 array, respectively).  Hierarchical cluster analysis showed
that 60 % of these common genes clustered next to each other  (see Fig. 1D) indicating a
minimal variation between the two filters after normalization. In order to assess more
accurately the variation of two different filter experiments the Spearman correlation
coefficient was calculated between the common genes on the 2 different filters for each
sample. The mean correlation coefficient was 82.4 % which indicates a good correlation
and demonstrates the reproducibility and the reliability of our results.
2) Sixteen SAM identified genes were randomly selected and quantified by real-time
quantitative RT-PCR. The mean Spearman correlation coefficient between the array gene
expression levels and real-time RT-PCR expression levels for these genes was 79.5 %
indicating the reliability of the array gene expression (data not shown). Real-time RT-PCR
analysis will be extended to additional cell lines and biopsies of MCC and SCLC in the
near future in order to confirm the classification potential of these genes.
3) Two cell lines MCC14/1 and MCC14/2, derived from the same tumor, were found to
cluster next to each other illustrating a highest degree of similarity as should be expected
(see Fig. 1B).
4) Our gene expression analysis confirms the differential gene expression of ASH1 in
SCLC versus MCC already reported in the literature (see discussion).
Gene expression patterns of MCC, SCLC and NB cell lines
Hierarchical clustering was used to interpret the patterns of expression. Clustering
of the 21 samples was based on the gene expression levels of 1060 pre-selected genes. Fig.
1A shows the complete cluster diagram. The dendogram (Fig. 1B) summarizes the degree
of similarity in gene expression among the 21 analyzed samples. Three main groups were
observed. Group 1 contained the two normal control samples (NFF and melanocytes) and
four MCC cell lines (MCC13, MCC14/1, MCC14/2 and MCC26), indicating that these
samples share a common gene expression pattern. We noticed that the MCC cell lines were
all Type IV, adherent growing cell lines characterized by loss of expression of some
neuroendocrine markers (i.e. Variant cell lines) (see Table 1). The observation of a number
of overlapping gene expression patterns between the two normal samples and these four
Variant, adherent growing MCC cell lines can possibly be explained by the fact that
fibroblasts (NFF) and melanocytes also grow as attached monolayers and divide rapidly
which is also the case for the Variant MCC cell lines. This in contrast with the Classic
MCC cell lines included in this study, which all grow in suspension. The growth behavior
of NFF, melanocytes and adherent growing MCC cell lines can partially result in a number
of similar expression levels of genes typically involved in attachment such as integrins and
adhesion molecules and of genes involved in cell division such as cyclins. This could
explain the observed sample clustering in Group 1. Group 2 included two SCLC cell lines
(GLC4 and NCI-H146), one MCC cell line (UISO) and all NB cell lines of which SK-N-
SH formed a subcluster with UISO. Although UISO is a Type IV Variant MCC cell line
some neuroendocrine dense-cored granules were observed19, normally absent in Type IV
cell lines. Expression of some neuroendocrine markers by these granules could possibly
explain the clustering of UISO with other neuroendocrine tumors such as neuroblastoma.
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Group 3 consisted of 5 MCC cell lines T95-45, MKL-2, MKL-1, MCC5 and MCC6 all
classified previously as Classic MCC cell lines and the two SCLC cell lines CorL88 and
NCI-H69.
The classification of MCC into two subgroups apparently coincided with the
phenotypes, either Variant or Classic, of the cell lines. A subset of genes which is
differentially expressed in Classic MCC cell lines as compared to all other samples is
shown in Fig. 1C. Some of these genes are involved in neuronal development while others
encode for ligand or voltage-gated ion channels. Similar, a selection of genes differentially
expressed in the Variant MCC cell lines is shown in Fig. 1D. This cluster contains many
oncogenes, transcription factors, cell cycle regulating kinases, and apoptosis-associated
genes.
Identification of differentially expressed genes in SCLC versus MCC
From the above data we could conclude that gene expression differences between
SCLC and MCC were not evidently by hierarchical cluster analysis. In order to identify a
set of markers whose expression pattern could distinguish SCLC from MCC, we adopted a
supervised strategy. Briefly, two sample groups namely SCLC (n=4) and MCC (n=10)
were predefined. Subsequently, a two-class SAM-analysis on the log transformed data
matrix containing 1513 genes (see Material and Methods) was performed. SAM identified
genes were further selected as highly significant differentially expressed genes in SCLC
versus MCC when a differential expression pattern was present in at least three of the four
SCLCs as compared to MCC or in at least half of the MCC cell lines as compared to
SCLC. Eight genes were higher expressed and 15 genes were lower expressed in SCLC as
compared to MCC. Re-clustering of these genes confirmed the classification of the SCLC
and MCC cell lines (Fig. 2A). In three of the four SCLC cell lines high-level expression of
the neuronal differentiation marker ASH1 (achaete-scute homolog 1), the basic helix-loop-
helix transcription factor ID2 (inhibitor of DNA binding protein 2) (Fig. 2B) and GPRP
(glutathione peroxidase-related protein) was observed as compared to the MCC cell lines.
The lower expression level of ASH1 in cell line GLC4 corresponded with the fact that this
was a Variant SCLC cell line while all others were Classic ones with neuroendocrine
phenotype (see Table 1). Other highly expressed markers in all SCLCs included the
transcription factors AP4 and EGR1, histone H4, insulin-like growth factor binding protein
2 and fms-related tyrosine kinase also known as vascular endothelial growth factor
receptor 1. Genes lower expressed in all SCLCs or higher expressed in most MCC cell
lines included several intracellular kinase network members such as PKCA (Fig. 2C),
MAPKK3, YSK1 and cell cycle regulating kinases such as cyclin G-associated kinase
(GAK) and aurora-related kinase 1 (ARK1).
Identification of differentially expressed genes in Variant versus Classic MCC cell
lines
The same strategy as outlined above was applied to identify genes differentially
expressed in Variant versus Classic MCC cell lines. Thirty-three genes with an increased
expression level in the Variant MCC cell lines and 56 genes with an elevated expression
level in the Classic ones were identified. Hierarchical cluster analysis of these 89 genes
clearly confirmed the classification  of the MCC cell lines in their respectively groups (Fig.
3). The genes with a higher expression in the Variant cell lines were particularly involved
in cell cycle control and proliferation. Genes with kinase activities but also genes encoding
for ligand and voltage-gated ion channels, neuromediators, GDP/GTP exchangers and
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signal transduction receptors showed an increased expression level in the Classic MCC cell
lines (Fig. 3).
Discussion
In an attempt to identify (1) new molecular markers whose gene expression patterns could
improve differential diagnosis between MCC and SCLC and (2) typically gene expression
signatures associated with Variant and Classic MCC cell lines we adopted a supervised
data mining strategy.
This led to the identification of 23 genes that were shown to have a significantly
altered gene expression between MCC and SCLC. Eight were found to be higher expressed
in SCLC as compared to MCC. Our data confirmed the increased expression of the
neuroendocrine differentiation marker ASH1 in SCLC29, 30 and absence of ASH1 expression
in MCC cell lines12. The ID2 basic helix-loop-helix transcription factor was increased
expressed in Classic SCLCs compared to MCCs. ID2 plays a role in cell proliferation and
differentiation and is able to disrupt the antiproliferative effects of retinoblastoma family
members31. Disruption of the RB1 pathway through increased expression of ID2 could be
an important mechanism in neuroendocrine SCLCs but not in MCC. The higher expression
level of glutathione peroxidase (GPRP) in SCLC compared to MCC could reflect a
mechanism of resistance of these SCLC cell lines to chemotherapeutic agents such as
cisplatin. A similar observation was already described for another glutatione-related
enzyme, glutathione S-transferase of which an increased expression in SCLC cell lines was
seen after treatment with cisplatin32, 33. These findings warrants further investigation in
SCLC and MCC cell lines and could suggest that alterations in glutathione metabolism do
not play a role in MCCs in acquiring resistance to cisplatin. For the five remaining genes
(EGR1, FLT1, IGFBP2, histone H4 and AP4) higher expressed in all SCLC cell lines as
compared to MCC no previous involvement in SCLC has been described. Early growth
response 1 (EGR1) was frequently overexpressed in prostate carcinoma and played an
important role in tumor initiation and progression. High level expression of EGR1 in
prostate carcinoma was the result of loss of a novel corepressor molecule NAB2 that
modulates EGR1 activity34. A similar mechanism could be involved in SCLC
tumorigenesis. FLT1 or vascular endothelial growth factor receptor 1 binds the vascular
endothelial growth factor (VEGF), an important angiogenesis inducer. Frequent expression
of FLT1 was previously observed in squamous cell lung carcinoma, pointing at a possible
autocrine role of VEGF35. Clinical trails with inhibitors against VEGF and VEGF receptors
are ongoing in lung cancer13. The low expression of FLT1 in MCC suggests the
involvement of other angiogenesis inducers in MCC. The observed high level expression
of IGFBP2 in SCLC has also been reported in glioblastoma multiforme and might
implicate involvement of the insulin growth factor (IGF) pathway in SCLC36. Further
investigation of the transcription factor AP4,  and histone H4, involved in cellular tracking
and chromatin remodeling respectively37, 38, should elucidate their role in SCLC or MCC
biology.
Fifteen genes with increased expression in MCC were detected as compared to
SCLC. None of these genes was previously shown to be implicated in SCLC and MCC
biology. One striking finding was the differential expression of PKCα in MCC compared
to SCLC cell lines. The protein kinase C is a key protein involved in regulation of cell
growth and activation of the MAP kinase pathway39, and the finding of increased
expression is in keeping with the observed increased expression for MAPKK3. Both
overexpression and downregulation of PKCα have been observed in tumor cells and
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correlated with malignant transformation and proliferative activity of PKCα. PKCα could
thus be involved in SCLC and MCC, albeit through a different mechanism in each of these
tumor types. The CDC25B phosphatase gene activates cylin-dependent kinases at different
points of the cell cycle. High expression of CDC25B has been reported in non-small cell
lung carcinomas and was associated with unfavorable prognosis40. This could also be true
for MCC in whom CDC25B is highly expressed compared to SCLC. The integrin linked
kinase (ILK) is yet another interesting gene in relation to cancer biology. ILK is involved in
adhesion of cells to the extracellular matrix and is integrated into the PI3K pathway as an
activator of AKT. Recent studies showed that activation of AKT was one of the key
elements during the different steps of mouse skin oncogenesis41. Enhanced expression of
ILK in MCC followed by activation of AKT could thus play an important role in MCC
development. Since the PTEN gene is rarely mutated in MCC42, increased expression of
ILK could therefore be a possible alternative mechanism for disruption of the PI3K/AKT
kinase pathway in MCC. Further investigation of these genes and other SCLC and MCC
classifier genes such as RAC1, ITGA3, ARK1, p68 kinase, BDNF, CDH2, NRGN, GAK,
GPRK6, and YSK1 should elucidate their role in SCLC and/or MCC biology. Finally, some
of these genes or disrupted pathways could serve as potential targets for new rational
therapeutic interventions in SCLC and/or MCC.
The present analysis revealed for the first time particular gene expression profiles
for Variant and Classic MCC cell lines, respectively. We identified 89 highly significant
differentially expressed genes of which 33 were higher expressed in the Variant MCC cell
lines and 56 higher expressed in the Classic types. Upregulated genes in the Variant cell
lines were involved in cell cycle control (CCND1, CCNB1 and G1 to S phase transition
protein 1 homolog) and cell proliferation (HSP60, CSK2, MMP11, DBPA, MAPK9, FRA1
and MAP kinase 38). Some of these upregulated genes are possibly correlated with the
shorter doubling time and aggressive nature of the Variant MCC cell lines as illustrated by
the high cloning efficiency in vitro of these cell lines and poorly response to radiation11. In
addition, we observed high expression of vimentin, a mesenchymal marker, together with
FRA1 (FOS-related antigen 1). A tight correlation of vimentin and FRA1 expression was
also recently found in highly invasive breast cancer cell lines pointing at a possible role in
tumor progression and enhanced cell migration of these cancer cells43. These two genes
could be significant prognostic markers for the more aggressive MCC Variant types.
Increased expression of vimentin has also been previously observed by immunochemical
studies in Variant SCLC cell lines15, 44 and as a result of a suppression subtractive
hybridization experiment comparing a Variant to a Classic SCLC cell line16.  These
observations could point at a similar mechanism of tumor progression or metastatic
properties between MCC and SCLC Variant phenotypes. High level expression of CCND1,
CCNB1, the Axl receptor tyrosine kinase and MAP kinase p38, genes involved in
promoting cell growth and cell proliferation, was observed in Variant cell lines and could
represent an important biological subset of markers for this aggressive group of MCCs.
A subset of genes with an increased expression level in the Classic cell lines are
involved in signal transduction pathways leading to uncontrolled cell growth when
overexpressed. This is exemplified by genes such as MAPK3, MAPK7 and MAPKK7
involved in the mitogen-activated protein (MAP) kinase pathway and genes such as PI3-K
p85 beta and PI4K-alpha in the phosphatidylinositol 3-kinase (PIK3) pathway. In addition,
Classic cell lines showed increased expression of genes encoding for neuromediators (7B2)
and neurotransmitters (NEC2) and proteins involved in neuronal development such as
lissencephalin and MARCKS-related protein (MLP). This reflects the neuroendocrine and
differentiated character of the Classic types. Ligand- and voltage gated ion channels and
receptors essential for neurotransmission were also upregulated. Some of these ion
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channels are known to play a role during mechanical stimulation of normal Merkel cell
receptors45, 46. Their specific function in MCC tumor cells has yet to be elucidated.
The differential expression levels of some of these markers reflect the different
biological and clinical properties of Variant and Classic MCC phenotypes. Interestingly,
SCLC tumors derived from morphological Variant cell lines are more aggressive and
patients have a worse prognosis47. Comparable to SCLC, lack or overexpression of Variant
MCC markers could indicate a subset of more aggressive MCCs for which more intensive
treatment and closer follow-up are warranted. Future investigations of overexpressed
markers or deregulated pathways involved in Variant and Classic MCC cell lines could
lead to potential targets for development of new therapeutic strategies specific for each
subgroup.
In conclusion, we demonstrated the potential power of gene expression profiling for
improved differential diagnosis between Merkel cell and small cell lung carcinoma. In
addition, we generated a gene expression-based classification of two biological and clinical
distinct subgroups of MCC. This could result in a more selective therapeutic treatment and
improvement of MCC patient outcome. Our study serves also as a first step to study
differentially expressed genes involved in cell proliferation, signal transduction and
neurotransmission in further detail, finally leading to more insight into the complex and
heterogeneous biology of MCC.
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Table 1. Characteristics of the MCC and SCLC cell lines used for gene expression
               profiling
Cell line Morphological Colony    Colony        Classification*
                            Type               shape    aggregation
MCC cell lines
MCC5 I  3-d Tight              Classic
MCC6 I  3-d Tight  Classic
MCC13 IV  Flat NA°  Variant
MCC14/1 IV  Flat NA  Variant
MCC14/2 IV  Flat NA  Variant
MCC26 IV  Flat NA  Variant
UISO IV  Flat NA  Variant
MKL-1 III  2-d Loose  Classic
MKL-2 III            2-d Loose  Classic
T95-45 II                      3-d Loose  Classic
SCLC cell lines
NCI-H69 II  3-d Loose   Classic
NCI-H146 II  3-d Loose   Classic
CorL88 III  2-d Loose   Classic
GLC4 III  3-d Loose   Variant
° Not applicable, adherent growing cell lines
*Classic MCC cell lines have elevated expression levels of neuroendocrine markers including
neurone-specific enolase and Chromogranin A and contain neurosecretory granules. Variant
MCC cell lines have a selective loss of neuroendocrine markers including Chromogranin A
and do not contain neurosecretory granules as evidenced by electron microscopy (Leonard et
al., 1997). Classic SCLC cell lines express elevated levels of L-dopa decarboxylase and
bombesin while variant ones have undetecable levels of L-dopa decarboxylase and bombesin
(Carney et al., 1985).
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Legends to the figures
Figure 1.
Hierarchical clustering sorted 1060 selected genes and 10 Merkel cell carcinoma (MCC)
cell lines, 4 small cell lung carcinoma (SCLC) cell lines, 5 neuroblastoma (NB) cell lines,
melanocytes and neonatal foreskin fibroblasts (NFF) based on similarity in gene
expression. Gene clusters relevant to Classic and Variant MCC subtypes were extracted
from the large gene cluster of 1060 genes in the regions indicated by the colored bars and
expanded on the right to include gene names. A row in the cluster indicates expression of a
specific gene across all 21 samples. A column indicates the sample in which the gene is
expressed. Red, green, and black squares indicate that expression of the gene is greater,
less than, or equal to the median level of expression across all 21 samples, respectively.
Gray represents missing data. (A) Scaled-down representation of the 1060-gene cluster
diagram; colored bars to the right identify the location of the inserts displayed in C and D.
(B) Dendogram representing similarities in the expression patterns between experimental
samples. The colored horizontal lines reflect the different (sub)groups of tumor cell lines
(dark blue, Variant MCC; light blue, Classic MCC; red, SCLC; green, NB). (C) Detail of gene cluster
relevant to Classic MCC cell lines (light blue bar). (D) Detail of gene cluster relevant to
Variant MCC cell lines (dark blue bar).
Figure 2.
Hierarchical cluster analysis was performed on 23 genes identified by SAM as MCC and
SCLC classifiers. (A) Cluster diagram showing the classification of SCLC and MCC cell
lines and their differentially expressed genes (red vertical bar, SCLC cell lines; blue vertical bars,
MCC cell lines) (B) Histogram representing the normalized and log transformed (base 2)
array gene expression level of ID2 (Inhibitor of DNA binding protein 2) and (C) of PKCA
(Protein kinase C alpha polypeptide) in MCC and SCLC cell lines.
Figure 3.
Hierarchical cluster analysis of 89 genes identified by SAM to classify the two distinct
MCC subtypes. (light blue vertical bar, Classic MCC cell lines; dark blue vertical bar; Variant MCC cell
lines).
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integrin-linked kinase (ILK)
protein kinase C alpha polypeptide (PKCA)
interferon-inducible RNA-dependent protein kinase (p68 kinase)
brain-derived neurotrophic factor (BDNF)
cadherin 2 (CDH2)
cyclin G-associated kinase (GAK)
neurogranin (NRGN)
cell division cycle 25 homolog B (CDC25B)
YSK1
G protein-coupled receptor kinase 6 (GPRK6)
heat shock-related 70-kDa protein 2
mitogen-activated protein kinase kinase 3 (MAPKK3)
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Figure 3
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5. General discussion and perspectives
As explained in the Introduction section, the data on genetic aberrations occurring in
Merkel cell carcinoma (MCC) at the start of this investigation were sparse and few if any
insights into the molecular pathology of this aggressive rare skin tumor were available at
that time. In order to learn more about the underlying genetic basis and biology of MCC
three major strategies were followed in this study.
1) Whole genome screening methods i.e. karyotyping, multiplex FISH (M-FISH) and
comparative genomic hybridization (CGH), were used in order to identify recurrent
patterns of chromosomal changes and specific involvement of particular genomic
regions.
2) Functional candidate genes located in some of these putative critical regions were
investigated in order to determine their possible role in MCC.
3) Gene expression profiles of 1891 unique genes known to be involved in cell cycle
control, cell-cell interactions, apoptosis, and signal transduction pathways were
analyzed in MCC and SCLC in order to identify genes and pathways involved in MCC
and to search for molecular markers which could improve differential diagnosis
between MCC and SCLC.
5.1 Chromosome region 1p
5.1.1 Mapping of critical regions on 1p
Although several MCCs were described with 1p deletions, including an MCC tumor with a
deletion of the distal part of 1p (1p36.1→pter) as the sole chromosomal abnormality
(Gibas et al., 1994), the size and position of these deletions was only determined by G-
banding. The only exception was the study of three other MCC tumors which were
examined for loss of 1p by Southern blot analysis with six polymorphic probes (Harnett et
al., 1991). All cases were found to have LOH for at least one locus but due to insufficient
density of the polymorphic probes no common region of deletion could be defined. In
contrast to MCC, other more common tumors (e.g. neuroblastoma, melanoma, breast
carcinoma, colon carcinoma and hepatocellular carcinoma) with 1p loss were extensively
studied by FISH and high-polymorphic LOH markers. This led to the delineation of
shortest regions of overlap (SRO) for the recurrent deletions on 1p in each tumor type and
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allowed the determination of overlapping SROs for the different tumor types (Schwab et
al., 1996). These SROs provided critical evidence for the localization of putative tumor
suppressor genes which could have been targeted by these common deletions.
In this study, we investigated two particular chromosome 1p36 rearrangements in an MCC
tumor and cell line, respectively. In the tumor UHG-VM, karyotyped at the Center for
Medical Genetics, an unbalanced translocation between two chromosomes 1 was observed
with evidence for loss of the most distal 1p36 region only. This further supported the
finding of Gibas et al. (1994) that this region was specifically implicated in MCC.
Moreover, the fact that this chromosome 1 rearrangement was the only structural change in
the karyotype of patient UHG-VM further stressed the importance of distal 1p loss in the
development of MCC. Detailed FISH analysis with region specific probes and high-
polymorphic microsatellite markers allowed the assignment of a deletion breakpoint distal
to the enolase 1 (ENO1) gene located within chromosome subband 1p36.31 (see Paper
2.1.1), thus indicating that the 1p36.1→pter segment was lost in this tumor. This finding
allowed us to delineate a minimal region of loss in MCC which could harbour a putative
tumor suppressor locus. Recently, a new MCC patient was investigated in our laboratory.
The karyotype of the MCC tumor of this patient showed an apparently identical
der(1)t(1;1) (p36;q21) resulting in loss of distal 1p and gain of the entire chromosome 1
long arm. This observation provides further support for the involvement of loss of distal
1p36 in MCC. Refined mapping of the breakpoint is ongoing. Interestingly, this type of
chromosomal rearrangements involving band regions 1p36, 1p11-12 and 1q21 were also
frequently observed in melanoma (Zhang et al., 1999). These regions contain homologous
sequences associated with chromosomal instability. A mechanism of preferentially
homologous recombination between these regions could directly play a role in the
generation of these types of chromosomal rearrangements and could also be implicated in
MCC.
The MCC cell line, UISO, was initially believed to carry an unbalanced 1;17 translocation
(Ronan et al., 1993). FISH analysis, however, showed that the abnormal chromosome 1
resulted from insertion of repetitive DNA sequences into the 1p36 region (see Paper 2.1.3).
Additional FISH analysis mapped the breakpoint to 1p36.2 between markers RIZ and
A12M2 within a cluster of repetitive genes and pseudogenes (van der Drift et al., 1994).
Interestingly, this insertion breakpoint coincides with the 1p36 breakpoint of the
constitutional 1;17 translocation previously observed in a patient with neuroblastoma in
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our laboratory (Laureys et al., 1995; van der Drift et al., 1995; Van Roy et al., in press).
Cloning of the 1;17 translocation breakpoints in this neuroblastoma patient revealed that
the 1p36.2 breakpoint disrupted a gene belonging to a new gene family. Further
characterization of this gene and studies to unravel its possible role in tumor development
are currently ongoing. Future research should resolve whether the same gene is affected by
both rearrangements and whether this gene plays a role in the development of both tumor
types and possibly also in other tumors showing 1p loss. Consequently, the molecular
analysis of these two MCC cases already indicated that two distinct regions on 1p36, each
harbouring a putative tumor suppressor locus, could be involved in MCC. This picture was
further complicated by a second more extensive LOH study performed with 1p markers, in
which our group contributed. This study revealed a complex pattern of LOH with several
regions of loss occurring within a given tumor and the observation of a total of three SROs
(Leonard et al., 2000). The frequent finding of loss of distal 1p36 in MCC led us to assume
that a putative tumor suppressor gene located in this particular region could play a role in
MCC development. Interestingly, this distal region was also frequently deleted in
neuroblastoma and was thought to harbour an imprinted tumor suppressor gene (Caron et
al., 1995). A recently identified (imprinted) candidate tumor suppressor gene for this
region was TP73 (Kaghad et al., 1997) and is discussed below. In addition to the TP73
gene, mutation analysis and expression analysis by real-time quantitative PCR was
performed for the RIZ1 (retinoblastoma protein-interacting zinc finger) (1p36.2) candidate
tumor suppressor gene. No mutations were found in MCC, but one mutation was detected
in a neuroblastoma cell line. This finding together with the observation of other RIZ1
mutations in ten diffuse large B-cell lymphomas, one osteosarcoma cell line and the
development of a broad range of tumors in RIZ1-/- mice provided evidence for a tumor
suppressor function of RIZ1 in human cancers (Greenwood, 2001; Steele-Perkins et al.,
2001).
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5.1.2 Candidate gene analysis: TP73
In view of the structural and functional homology of TP73 with TP53, the location of TP73
in SROs for 1p deletions occurring in various cancers and the initially described
monoallelic expression of the gene, TP73 was regarded as a strong candidate tumor
suppressor gene. In order to test this hypothesis, mutation analysis studies for TP73 were
performed. Thus far, mutations were found in the carboxy-terminal region of TP73 in two
neuroblastoma tumors, one breast carcinoma and three lung cancer cell lines (Han et al.,
1999; Ichimiya et al., 1999; Yoshikawa et al., 1999). Functional analysis showed that at
least one of these mutations (P425L) reduced the transactivation and growth-suppressive
activity of TP73 in TP53-deficient SAOS-2 cells (Naka et al., 2001). As TP73 also mapped
within the small distal 1p36 deletions observed in MCC, we decided to screen the gene for
inactivating mutations in five MCC cell lines and ten MCC tumors. In view of the possible
complementary functions of TP73 and TP53, the mutation status of TP53 was also
examined (see Paper 3.1.1). Mutation analysis of TP73 revealed a TP73 missense mutation
located in the NH2-terminal transactivation domain of the gene in one MCC tumor. The
transcriptional transactivation function of the amino-terminal regions of TP73 and TP53
were shown to have an equally strong activity (Takada et al., 1999). We hypothesized that
the observed TP73 missense mutation in MCC could lead to a reduction or complete loss
of the transactivation function of the amino-terminal region in TP73 which could lead to
the disruption of certain specific growth-inhibitory functions of TP73. The MCC tumor
mutated for TP73 still expressed the remaining wild-type allele. Therefore analogous to
TP53, this missense mutation could exert a dominant negative effect by an increased
stability of the mutant protein compared to that of the wild-type protein. The MCC tumor
harbouring the mutated TP73 contained also a TP53 non-sense mutation. Mutation of both
genes was also observed in a patient with breast cancer and two lung cancer cell lines
(Han et al., 1999; Yoshikawa et al., 1999). These findings suggest that TP73 and TP53 are
not involved in the same tumor suppressor pathway or that TP73 plays only a minor role in
tumorigenesis. Four other TP53 mutations were also identified in two MCC cell lines. Our
results showed for the first time the occurrence of inactivating TP53 mutations in MCC,
suggesting that TP53 may play a role in the pathogenesis or progression of a subset of
MCCs. The finding of typical UVB induced mutations in one MCC cell line provided
further evidence for sun-exposure in the etiology of this skin tumor. Recently, additional
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UVB type mutations in the TP53 gene have been identified in two other MCC cell lines by
Popp et al. (2002). This further supports a role of UVB radiation in MCC development.
The fortuitous discovery of a first TP53 family member, TP73, and its location in a region
frequently deleted in many tumor types triggered a lot of attention in the cancer field.
However, the present data are not convincing that loss of expression of TP73, like TP53,
plays a crucial role in cancer development. Mutations are infrequently found in tumors
with 1p loss and a recent report demonstrated that TP73 deficient mice showed no
increased tendency to develop spontaneous tumors, but exhibited neurological and
inflammatory defects indicating involvement of TP73 at specific stages of development
(Yang et al., 2000). Initially, TP73 was assumed to be monoallelic expressed. Several
studies, including ours, showed however biallelic expression of TP73 (reviewed in Levrero
et al., 2000). Consequently, deletion of one allele, at least in these investigated cell types,
would not be sufficient for complete silencing of the TP73 locus. The recent discovery that
certain splice variants of TP73 may exert a dominant negative effect on TP53 activity
points at another mechanism through which TP73 might be involved in tumorigenesis.
(reviewed in Yang et al., 2002). In addition, elevated expression of TP73 was observed in
various tumor tissues compared to the tissue of origin indicating that altered expression of
TP73 rather than loss of function is involved in instability and tumorigenesis (Tannapfel et
al., 1999).
Our data revealed that the TP73 gene itself is infrequently mutated in MCC. However, the
observation of loss of distal 1p material, often reported as sole structural change in MCC,
and in many other cancers suggests that this region is important. At the moment there are
no reports of TP73 protein levels, or of different splice variants in MCC. If such studies
would show no involvement of TP73 in MCC then we must assume that other, as yet
unidentified tumor suppressor gene(s) are involved in MCC carcinogenesis.
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5.2 Search for other chromosomal regions involved in MCC
5.2.1 Comparative genomic hybridization analysis
CGH analysis of 26 tumor samples and eight MCC cell lines led to the identification of a
characteristic pattern of recurrent gains and losses in MCC (see Paper 2.1.3).
The following new information resulted from these CGH patterns:
(1) gene amplification was, in contrast to CGH findings in many other tumors, a
rare event in MCC. This suggests that high level amplification of proto-
oncogenes is not a major step in the oncogenesis of MCC;
(2) significant gains were detected for chromosomes 1 (63%), 19 (63%) and X
(41%) and chromosomal regions  3q (33%), 5p (38%) and 8q (38%) which may
lead to a dosage effect for genes located in these regions;
(3) frequent losses were observed for 3p (46%), 5q (21%), 8p (21%), 10 (33%),
11q (17%), 13q (33%) and 17p (25%) suggesting the presence and involvement
of tumor suppressor genes;
(4) the pattern of gains and losses closely resembled those described in SCLC
(Ried et al., 1994; Levin et al., 1995; Petersen et al., 1997). This suggests that a
number of common genetic changes or genes may play an important role in the
tumorigenesis of both tumors.
Recurrent regions of loss and analysis of candidate tumor suppressor genes located in these
regions are discussed in more detail below. The most frequently observed loss in MCC was
loss of chromosomal region 3p, which is in agreement with previously reported LOH data
by Leonard et al. (1996). A consensus deletion region at 3p11~14 was defined by CGH
thus overlapping the 3p SRO defined in SCLC (Petersen et al., 1997). The FHIT gene is
located within this region and showed exonic loss in 80% of SCLCs (Sozzi et al., 1996b)
and 57% of MCCs (Sozzi et al., 1996a). This suggests an important role for this gene in
lung and Merkel cell carcinogenesis. A second more distal region of loss (3p21→pter)
described in SCLC could not be attributed in MCC. However, as loss of the entire
chromosome 3 arm was present in 38% of the MCCs possible involvement of tumor
suppressor genes in this more distal region can not be excluded. In a recent study no
mutations nor promotor hypermethylation of the von Hippel-Lindau (3p25-26) tumor
Part 5. General Discussion and Perspectives 125
suppressor gene were detected in MCC (Hoebeeck et al., unpublished results). Inactivation
by allele loss and promoter region methylation of RASSF1A (Dammann et al., 2000;
Burbee et al., 2001) and SEMA3B (Tomizawa et al., 2001), both located at 3p21, has been
demonstrated in SCLC and will be investigated in future studies in MCC.
Chromosomal region 13q was the second most frequently lost region in MCC. The shortest
region of overlap was 13q14~21, a region containing the RB1 locus in agreement with
LOH data reported by Leonard and Hayward (1997). These authors also showed by
Western blot analysis absence of RB1 expression in all tested MCC cell lines. Inactivation
of RB1 was also observed in 90% of SCLCs, resulting in deregulation of the
RB1/p16INK4a/cyclinD1 cell cycle control pathway (see Figure 1-2, Part 1) (Fong et al.,
1999). Co-inactivation of RB1 and p16INK4a is rarely observed in both SCLC and MCC but,
unlike SCLC, p14ARF expression was not lost in MCC (Shapiro et al., 1995; Gazzeri et al.,
1998; Cook et al., 2001). In addition, LOH analysis of the 9p region implicated the
existence of tumor suppressor genes mapping both proximal and distal to the CDKN2A
locus in MCC (Cook et al., 2001).
Loss of chromosomal region 17p, harbouring TP53, was observed in one quarter of the
examined cases. Mutation analysis of the TP53 gene was performed by us in this study (see
Paper 3.1.1) and revealed mutations in 19% of the examined MCC cases. These results
suggested that TP53 may play a role in the pathogenesis of a subset of MCCs.
A new, previously unexplored region of frequent chromosomal loss detected in MCC
involved chromosome 10. Deletions of the long arm of chromosome 10 have been
observed in many tumor types including SCLC, melanoma and prostate carcinoma. The
recently discovered tumor suppressor gene PTEN, located at 10q23, was shown to be
mutated in various tumors (reviewed in Ali et al., 1999). We proposed that this gene could
also be affected in MCC and investigated therefore its possible role in MCC.
5.2.2 Candidate gene analysis: PTEN
LOH analysis of the 10q23 region was performed in 23 MCC patients. These tumors and
eight additional cell lines were subsequently screened for PTEN mutations and intragenic
homozygous deletions. A high frequency of LOH at the PTEN locus (43% of informative
samples) was detected. Despite this high incidence of LOH, we found only one PTEN
mutation located at exon 5 and one homozygous deletion for exon 9 in two different MCC
tumors. The second PTEN allele was deleted in the patient harbouring the mutated PTEN
Part 5. General Discussion and Perspectives 126
gene. The detected PTEN mutation was located in the phosphatase domain, 15 codons
downstream of the protein tyrosine phosphatase (PTPase) core motif of PTEN and resulted
in a stopcodon. This non-sense mutation could lead to a truncated protein missing a part of
exon 5 and the following exons, resulting in complete loss of PTEN protein activity or a
truncated protein with reduced phosphatase activity leading to a decrease or inactivation of
the tumor suppressor function of PTEN. Alternatively, loss of the C-terminal region
harbouring the C2 domain and PDZ motifs of PTEN could lead to PTEN instability and
loss of phosphatase activity (Georgescu et al., 1999).
Our results indicate that inactivation of PTEN by loss of one allele and by mutation or
homozygous deletion of the remaining allele is a relatively rare event in MCC. However,
we can not exclude that deregulation or inactivation of PTEN in MCC may involve other
mechanisms such as a) mutations located in the promotor or intronic regions of PTEN; b)
PTEN promotor methylation as recently reported in metastatic endometrial carcinomas
(Salvesen et al., 2001) or c) bi-allelic inactivation of PTEN through other epigenetic
mechanisms as suggested in malignant melanomas without PTEN mutations or deletions
(Zhou et al., 2000). Presently, the above mentioned mechanisms have not been confirmed
by many other research groups. Interestingly, haploinsufficiency of the PTEN gene as
recently demonstrated for prostate cancer and other tumor types (Kwabi-Addo et al., 2001)
can also lead to tumor formation or progression. The latter possibility could explain the
higher rates of LOH at 10q23.3 and the much lower rates of inactivation of the retained
PTEN allele by mutations or homozygous deletions in a subset of MCCs with loss of
chromosome 10. The relatively low expression levels for PTEN measured by cDNA
expression arrays and real-time quantitative RT-PCR could be in keeping with the
observed inactivation of one or both PTEN alleles in MCC. However, in the absence of
data concerning PTEN expression levels in normal Merkel cells (both at the expression and
protein level) no definitive conclusion can be drawn from the above expression results.
Further studies are needed, including assessment of PTEN protein levels, to clarify the role
of PTEN in MCC. Alternatively, one or more tumor suppressor genes located either
proximal or distal to PTEN might be involved in the etiology of MCC since CGH and M-
FISH (see Paper 2.1.3) revealed that loss of an entire copy of chromosome 10 was a
frequent finding in MCC. The recent observation of a new MCC patient with a 1p loss and
monosomy 10 as the only numerical change supports the fact that loss of chromosome 10
is an important event in MCC (Van Gele et al., unpublished results). The observation of
two MCC cases with unbalanced translocations resulting in loss of the 10q23→qter region
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(see Paper 2.1.3) indicated that a tumor suppressor gene located distal to PTEN could be
more likely involved in MCC. Putative candidate tumor suppressor genes located distal to
PTEN include DMBT1 (10q25.3-26.1) (Mollenhauer et al., 1997), MXI1 (10q24-25) (Eagle
et al., 1995), LGI1 (10q24) (Chernova et al., 1998) and h-neu (10q25.1) (Nakamura et al.,
1998) and could be targets for future investigations.
5.2.3 Multiplex FISH (M-FISH) analysis
To obtain a more detailed picture of the genetic changes that lead to MCC development,
we combined karyotyping, CGH, M-FISH and FISH with region specific probes and
analyzed six MCC cell lines and one MCC tumor  (see Paper 2.1.3). The patterns of
chromosomal changes in MCC were heterogeneous: simple karyotypic changes, multi-way
translocations and karyotypes with various numerical and structural changes. The major
chromosomal changes observed in this study were: chromosomal rearrangements involving
the short arm of chromosome 1, leading in one case to loss of 1p36.3 material and the long
arm of chromosome 3, gain of 5p material and loss of chromosome 10. The occurrence of
isochromosomes of the short arm of chromosome 5 and gain of 3q23-26 material could
correlate to a low level copy number gain of genes which might induce a growth advantage
important for tumor initiation or progression. No high level gene amplifications however
were detected. All these observations were in agreement with previously reported
cytogenetic studies and/or CGH results described in Paper 2.1.2. In addition, M-FISH
combined with karyotyping and CGH provided a detailed and accurate description of
previously unidentified (complex) rearrangements and contributed to the limited
cytogenetic data of MCC. This study should invite other investigators to characterize
chromosomal rearrangements occurring in newly established MCC cell lines and tumors in
a similar way if possible which would contribute to a better insight into the chromosomal
events and mechanisms affecting and regulating MCC.
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5.3 Differential gene expression analysis
Atlas cDNA filter expression arrays were successfully applied to determine the gene
expression profiles of MCC and SCLC cell lines. Data mining analysis tools were used to
identify significant differentially expressed genes between MCC and SCLC and to find
typical gene expression signatures associated with the phenotypically different subgroups
(i.e. Classic versus Variant) of MCC.
We identified a set of 23 powerful predictor genes, which could improve differential
diagnosis between MCC and SCLC. For the majority of these genes no previous
involvement was shown in MCC and SCLC biology although they have well known roles
in angiogenesis and tumor progression. These genes are integrated into the insulin growth
factor, MAP kinase or PI3K kinase pathways. Further investigation of these 23 classifier
genes and pathways may provide insight into the altered cellular functions which lead to
MCC or SCLC tumorigenesis. Some molecular markers or disrupted pathways could be
potential targets for new therapeutic treatments and improve patient survival in MCC
and/or SCLC. Of particular interest was the finding of an increased expression level of the
integrin linked kinase (ILK) in MCC as compared to SCLC. ILK is integrated into the PI3K
pathway as an activator of AKT. Enhanced expression of ILK in MCC followed by
activation of AKT could thus play an important role in MCC development. Since our
molecular analysis study of the PTEN gene showed that PTEN itself is infrequently
mutated in MCC, increased expression of ILK could therefore be a possible alternative
mechanism for disruption of the PI3K/AKT kinase pathway in MCC. cDNA expression
profiling provided thus additional useful information.
Typical gene expression profiles were found to be associated with the Variant and Classic
MCC cell lines, respectively. We identified a set of 89 highly significant differentially
expressed genes, which allowed classification of the MCC cell lines into Variant and
Classic subgroups. Genes mainly involved in cell cycle progression and cell proliferation
showed higher expression levels in Variant MCC cell lines, mainly reflecting their more
aggressive behavior. Genes involved in signal transduction, neurotransmission and
neuronal development showed a higher expression level in Classic MCC types associated
with their neuroendocrine and differentiated character. We assume that the differential
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expression levels of some of these genes reflect, analogous to SCLC, the different
biological and clinical properties of Variant and Classic MCC phenotypes. This would
implicate a more aggressive treatment for tumors with a Variant morphology and a closer
follow-up for this patient group. Further investigation on clinical samples should reveal
which genes could serve as useful prognostic markers and potential targets for the
development of new therapeutic interventions specific for each MCC subgroup. A further
detailed molecular study of differential genes and pathways involved in Variant and
Classic subtypes respectively, could contribute to a better insight into the molecular basis
of their different malignant behavior.
Furthermore, a targeted search to identify similar upregulated genes or disrupted pathways
involved in Variant and Classic MCC and SCLC cell lines would also be of interest to
develop novel therapeutic interventions applicable for both tumors. The usefulness of such
an approach was recently exemplified by studies of the tyrosine kinase inhibitor STI-571.
This drug was originally developed as a tyrosine kinase inhibitor against the Abl tyrosine
kinase activity and shown to be highly effective in treating patients with CML (Druker et
al., 1996). Interestingly, STI-571 also inhibited the tyrosine kinase activities of the PDGF
and c-kit receptor. This led to the investigation of STI-571 in selected SCLC cell lines
known to express the c-kit receptor. Experimental studies showed that STI-571 inhibited
cell growth of these SCLC cell lines through a mechanism that involved inactivation of the
tyrosine kinase c-kit and may be useful in a clinical trial for patients with SCLC (Wang et
al., 2000). The therapeutic effects of this new drug on other solid tumors expressing
activated or mutated c-kit are currently ongoing. Parallel to this example, identification of
common activated genes, receptors or pathways in SCLC and MCC could thus result in
development of a common therapeutic drug benefiting both patient groups.
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To conclude, a major finding of the research conducted in this thesis was the fact that
MCC and SCLC shared many similarities both on the genomic and expression level. Both
tumors are neuroendocrine tumors expressing a number of common immunohistochemical
markers and belong to a family of “small round blue cell” tumors. The overlapping CGH
results of MCC and SCLC, the involvement of common disrupted pathways and the
identical heterogeneity of MCC and SCLC cell lines suggest that both tumor entities are
genetically related. This proposed model could indicate that MCC and SCLC are possibly
derived from a similar precursor cell. Interestingly, a number of common typical genetic
changes between MCC and SCLC including loss of 3p, 10q, 17p and gain of 3q, 5p and 8q,
are also often found in other tumor types. The significance of these observations remains to
be determined.
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5.4 Perspectives
Refined delineation of critical regions
Our molecular cytogenetic analysis contributed to the identification of new chromosomal
candidate regions involved in MCC. This analysis will in the future be extended by the use
of genomic arrays (array CGH). This approach could lead to a further refined delineation
of known critical regions, the identification of new candidate regions or even homozygous
deletions. Putative candidate genes located in new identified regions will be targets for
future investigations.
Candidate gene analysis
Known chromosomal regions involved in MCC will be further analyzed and candidate
genes residing in these regions will be examined.
Specifically, the 10q region distal to PTEN will be subjected to further LOH analysis.
Depending on these results, candidate tumor suppressor gene such as DMBT1 (10q25.3-
26.1), MXI1 (10q24-25 ), LGI1 (10q24) and h-neu (10q25.1) could be further examined by
mutation analysis and/or methylation-specific PCR.
Loss of chromosomal region 3p is a recurrent finding in MCC. Therefore, the possible role
of candidate tumor suppressor genes such as RASSF1A, SEMA3B and BLU, all located at
3p21.3 (Lerman and Minna, 2000), will be examined in MCC by mutation analysis,
methylation-specific PCR and homozygous deletion screening.
Validation of differentially expressed genes in MCC and SCLC by real-time quantitative
RT-PCR
Presently,  real-time RT-PCR is ongoing in our laboratory to quantify the expression levels
of differentially expressed genes in the analyzed cell lines. This analysis will be extended
to additional tumor cell lines and tumor biopsies of SCLC and MCC in order to assess the
diagnostic value of these biological markers in clinical samples. Ultimately, a diagnostic
custom cDNA microarray will be developed at our laboratory leading to an improved
diagnosis of MCC and SCLC and patient outcome prediction.
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Evaluation of clinicopathological significance of biological markers in MCC and SCLC
In addition, biological markers for which antibodies are available will be further
investigated on the protein level by Western blots or immunohistochemistry. In
collaboration with the Department of Pathology (Ghent) paraffin-embedded tumor material
of MCC, SCLC and other neuroendocrine tumors will be collected. These archival tissue
specimens will be used to develop a tissue microarray (TMA). TMA technology allows a
rapid visualization of molecular markers in hundreds to thousands of tumor specimens at a
time (Nocito et al., 2001; Torhorst et al., 2001). Immunohistochemical analysis of our
newly identified biological markers will be performed on the TMA slides in order to study
their clinicopathological significance. In addition, TMA slides can also be used for
fluorescence in situ hybridization and RNA in situ hybrididzation.
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SUMMARY
Merkel cell carcinoma (MCC) is a rare aggressive neuroendocrine skin tumor mostly
affecting elderly people. The disease occurs predominantly on the sun-exposed areas of the
skin, suggesting UV exposure in its etiology. MCC is thought to be derived from Merkel
cells which act as mechanoreceptors in the skin. At the start of this doctoral study, the
molecular events leading to MCC were poorly understood as only limited cytogenetic
studies were available. These studies revealed recurrent involvement of 1p abnormalities,
often leading to loss of chromosomal region 1p36, in MCC but little or no information on
involvement of other chromosomal regions could be obtained from these data. One of the
initial aims of this study was to gain new information concerning genetic aberrations
occurring in MCC. Therefore, various (cyto)genetic and molecular techniques were used to
study MCC. In addition, it was reported that MCC shared clinical and
immunohistochemical features with small cell lung carcinoma (SCLC), another
neuroendocrine tumor and both tumors were often difficult to differentially diagnose. To
understand more about the molecular biology of both tumors, gene expression profiles of
MCC and SCLC were determined and further analyzed in detail.
In view of the evidence for recurrent involvement of 1p in MCC this region was first
targeted in our study. This resulted in the finding that two distinct regions at 1p36 were
implicated. In one MCC tumor, loss of the most distal part of 1p36 (1p36.31→pter) was
observed as the result of an unbalanced structural rearrangement. This region was
previously shown to be deleted in many other tumor types and was thought to harbour an
(imprinted) tumor suppressor gene. The identification of a 1p36.2 insertion breakpoint in
the MCC cell line UISO indicated a second, more proximal region involved in MCC. This
breakpoint was mapped within a cluster of repetitive genes and coincided with the 1p
breakpoint of a constitutional 1;17 translocation found in a patient with neuroblastoma,
previously described by our group. The delineation of these two critical regions provided
further evidence for a role of at least two tumor suppressor genes on 1p involved in MCC
development. TP73, a TP53 family member and located at 1p36.33 was investigated as a
functional and positional candidate tumor suppressor in MCC. A missense mutation which
could possibly reduce the transcriptional transactivation function of the amino-terminal
region of TP73 was detected in one MCC tumor. Our results showed that TP73, analogous
to other cancers, is infrequently mutated in MCC. However, we can not exclude the
possibility that other mechanisms could lead to inactivation of TP73 or the fact that
dominant negative splice variants can exert a role in MCC tumorigenesis. Future research
should clarify these hypotheses. TP53 mutation analysis, which was conducted in parallel,
showed for the first time inactivating mutations in 19% of the investigated MCCs,
indicating implication of TP53 in the pathogenesis or progression of a subset of MCCs as
observed for many other tumor types. The finding of typical UVB induced mutations in
one MCC cell line provided further evidence for sun-exposure in the etiology of this skin
tumor.
Whole genome screening methods including karyotyping, CGH and multiplex FISH were
applied to search for previously unnoticed chromosomal imbalances in MCC. CGH led us
to successfully identify a characteristic pattern of recurrent gains  (1, 3q, 5p, 8q, 19 and X)
and losses (3p, 5q, 8p, 10, 11q, 13q and 17p) pointing at chromosomal positions of
candidate tumor suppressor genes or proto-oncogenes involved in MCC. Interestingly, the
pattern of gains and losses resembled the CGH patterns previously reported for SCLC.
These genetic similarities could point to common pathways or genes involved in the
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development or progression of both MCC and SCLC. The new finding of recurrent loss of
chromosome 10 in MCC was further explored by molecular analysis of the tumor
suppressor gene, PTEN, located at 10q23. Despite the high frequency of LOH at the PTEN
locus, only one homozygous deletion and one mutation, respectively were detected. The
latter mutation was a nonsense mutation located in the phosphatase domain of PTEN and
could result in a reduced or complete loss of the tumor suppressor function of PTEN. Our
results suggested that loss of one PTEN allele and disruption of the second allele by
mutation or homozygous deletion is a relatively rare event in MCC. We propose that other
mechanisms such as PTEN haploinsufficieny or alternatively other tumor suppressor genes
on chromosome 10 may be involved in MCC tumorigenesis.
The gene expression profiles of MCC and SCLC cell lines were determined by the use of
Atlas cDNA expression arrays. We identified a set of 23 biological markers which allow
improved differential diagnosis of MCC and SCLC. In addition, typical gene expression
signatures associated with Variant and Classic MCC subtypes were identified for the first
time. Further investigation of the gene defects and disrupted pathways involved in MCC
and SCLC will lead to identification of molecular targets for new therapeutic interventions
and reveal insight into the molecular basis of the heterogeneous biology of both aggressive
tumors.
In conclusion, our work has provided new insights into the genetic mechanisms leading to
MCC development and could direct future research hopefully leading to an improved
survival of patients with MCC.
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SAMENVATTING
Merkel cel carcinoom (MCC) is een zeldzame agressieve huidtumor van neuroendocriene
oorsprong en wordt vooral gediagnosticeerd bij oudere personen. Deze aandoening komt
hoofdzakelijk voor op die lichaamsdelen die aan zonlicht zijn blootgesteld. Dit suggereert
dat UV stralen een rol zouden kunnen spelen in de ontwikkeling van MCC. Merkel cellen,
de mechanoreceptoren van de huid, worden geassocieerd met het ontstaan van MCC. Bij
de aanvang van deze thesis was slechts zeer weinig informatie beschikbaar omtrent de
moleculaire mechanismen die zouden aanleiding kunnen geven tot MCC, en de reeds
uitgevoerde cytogenetische studies waren zeer beperkt. Deze studies rapporteerden
hoofdzakelijk 1p abnormaliteiten, vaak leidend tot verlies van 1p36, doch leverden zeer
weinig of geen informatie omtrent de betrokkenheid van andere chromosomale regio’s in
MCC. Eén van onze initiële doelstellingen was dan ook het genereren van nieuwe
informatie over genetische afwijkingen in MCC. Daartoe werden verschillende
cytogenetische en moleculaire technieken aangewend. Daarnaast is het reeds gekend dat
MCC klinische en immunohistochemische kenmerken deelt met kleincellig longcarcinoom
(SCLC), eveneens een neuroendocriene tumor. Beide tumoren worden ook vaak
differentieel gediagnosticeerd. Om een beter inzicht in de moleculaire biologie van beide
tumoren te verwerven, werd besloten om de genexpressieprofielen van MCC en SCLC te
bepalen en vervolgens de bekomen data in detail verder te bestuderen.
Op basis van het frequent voorkomen van 1p afwijkingen in MCC, besloten wij in eerste
instantie deze regio te bestuderen. Dit resulteerde in de afbakening van twee subregio’s
betrokken in MCC. Als gevolg van een ongebalanceerde structurele herschikking
constateerden wij verlies van het meest distale deel van 1p36 (1p36.31→pter) in een
patiënt met MCC. Ook in diverse andere tumor types wordt een dergelijke deletie vaak
teruggevonden. De distale 1p36 regio zou mogelijks een (geïmprint) tumorsuppressor-gen
kunnen bevatten. Identificatie van een 1p36.2 insertiebreukpunt in de MCC cellijn UISO
wees op de betrokkenheid van een tweede, meer proximaal gelegen regio in MCC.  Dit
breukpunt werd vervolgens gemapt binnen een groep van repetitieve genen en bleek samen
te vallen met het 1p breukpunt van een constitutionele t(1;17) translocatie in een patiënt
met neuroblastoom, welke werd gerapporteerd door onze onderzoeksgroep. De
identificatie van deze twee kritische regio’s levert bijkomend bewijs dat minstens twee
tumorsuppressor-genen gelocaliseerd op 1p, een rol kunnen spelen in de ontwikkeling van
MCC. TP73, een TP53 homoloog, gelocaliseerd op 1p36.33 werd vervolgens als een
functioneel en structureel kandidaat tumorsuppressor-gen onderzocht in MCC. Eén
“missense” mutatie werd gedetecteerd in het amino-terminaal gedeelte van TP73 en zou
mogelijks tot een verstoring van de transcriptionele transactivatie functie van TP73 kunnen
leiden. Uit onze resultaten blijkt dat, analoog aan andere tumor types, mutaties in het TP73
gen slechts zelden voorkomen. Ondanks deze lage TP73 mutatie frequentie in MCC sluiten
we niet uit dat andere mechanismen kunnen leiden tot TP73 inactivatie of dat mogelijkse
dominant negatieve isovormen een rol kunnen spelen in MCC tumorigenese. Verder
onderzoek zou bovengenoemde hypothesen moeten bevestigen. In dezelfde studie werd
ook het TP53 gen onderzocht door middel van mutatie-analyse. Onze resultaten toonden
voor de eerste maal inactiverende TP53 mutaties aan in 19% van de onderzochte MCC’s,
wat ook wijst op een causale rol van het TP53 gen in de pathogenese en progressie van een
aantal MCCs.  Het vinden van een typische UVB gerelateerde mutatie in één MCC cellijn
onderstreept ook het belang van de invloed van zonlicht bij het ontstaan van deze
huidtumor.
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Methodes zoals karyotypering, CGH en M-FISH, waarbij het volledige genoom in één
experiment bestudeerd wordt, werden aangewend om nog niet gekende structurele en
numerieke chromosoomafwijkingen te identificeren in MCC. Vergelijkende
genoomhybridisatie op een grote reeks MCC tumoren resulteerde in een typisch patroon
van chromosomale toenames (1, 3q, 5p, 8q, 19 en X) en verliezen (3p, 5q, 8p, 10, 11q, 13q
en 17p). Het vinden van dergelijke regio’s is van groot belang omdat juist daar mogelijkse
kandidaat tumorsuppressor-genen of proto-oncogenen kunnen liggen die een rol kunnen
spelen in MCC. Het karakteristiek CGH patroon van MCC bleek tevens ook sterke
gelijkenissen te vertonen met dat van reeds eerder beschreven CGH patronen van SCLCs.
Deze genetische overeenkomsten zouden kunnen wijzen op een aantal gemeenschappelijke
genen en signaaltransductiewegen betrokken in de ontwikkeling of progressie van zowel
MCC als SCLC. Het feit dat chromosoom 10 herhaaldelijk gedeleteerd bleek te zijn in
MCC, zette ons er toe aan om een moleculaire analyse van het tumorsuppressor-gen PTEN,
gelocaliseerd op 10q23, aan te vatten. Ondanks de hoge incidentie van LOH ter hoogte van
de PTEN locus, detecteerden we slechts één homozygote deletie en één mutatie. Deze
laatste was een “nonsense” mutatie gelegen in het fosfatase domein van het PTEN gen en
zou de tumorsuppressor functie van PTEN kunnen reduceren of zelfs volledig uitschakelen.
Onze resultaten suggereren dat bij verlies van één PTEN allel zelden een mutatie in het
tweede allel of een homozygote deletie optreedt bij MCC. Daarom stellen wij voorop dat
andere mechanismen zoals PTEN haplo-insufficiëntie of eventueel andere al dan niet
gekende tumorsuppressor-genen gelegen op chromosoom 10 betrokken kunnen zijn in de
oncogenese van MCC.
“Atlas” cDNA expressie roosters werden aangewend om de genexpressieprofielen van
MCC en SCLC cellijnen te bepalen. Via data-analyse werd een set van 23 biologische
merkers bekomen die toelaten om de differentiële diagnose van MCC en SCLC te
verbeteren.  Tevens werden voor de eerste maal typische genexpressiepatronen voor
“variante” en “klassieke” MCC subtypes geïdentificeerd. Verder onderzoek van genetische
defecten en verstoorde moleculaire mechanismen in MCC en SCLC zal leiden tot
identificatie van moleculaire doelwitten om mogelijkse nieuwe therapieën te ontwikkelen
en zal zeker ons inzicht in de moleculaire basis en heterogeniteit van beide agressieve
tumoren verhogen.
Samengevat kunnen we stellen dat ons werk zeker heeft bijgedragen tot het verkrijgen van
nieuwe inzichten in de genetische mechanismen die optreden tijdens het ontstaan van
MCC. Hopelijk zal toekomstig onderzoek leiden tot hogere overlevingskansen bij
patiënten met MCC.
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RÉSUMÉ
Le carcinome à cellules de Merkel (MCC) est une tumeur neuro-endocrine rare et
aggressive qui se manifeste le plus souvent chez des patients agés. Il se déclare surtout sur
des parties de peau exposées au soleil ce qui suggère une influence externe des rayons
ultraviolets. Les carcinomes neuro-endocrines de la peau sont généralement considérés
comme une prolifération maligne des cellules de Merkel. Celles-ci sont des
mécanorécepteurs de la peau. Lorsque nous avons débuté ce travail, les mécanismes
moléculaires à l’origine des MCC restaient inexplorés. Seules quelques données
cytogénétiques étaient connues. En particulier, des anomalies récurrentes du bras court du
chromosome 1 avec perte fréquente de la région 1p36 avaient été décrites. Le premier but
de cette thèse était la recherche de nouvelles aberrations génétiques dans les carcinomes à
cellules de Merkel au moyen de techniques (cyto)génétiques et moléculaires. En outre, des
études faisaient mention de caractéristiques cliniques et immunohistochimiques similaires
entre les MCC et les carcinomes à petites cellules du poumon (SCLC), une autre tumeur
neuro-endocrine. De plus, un diagnostic différentiel entre les deux tumeurs doit souvent
être posé. Afin de mieux comprendre la biologie moléculaire des MCC et des SCLC, nous
avons étudié et comparé les profils d’expression géniques de ces deux tumeurs.
Des anomalies récurrentes de la région 1p36 étant décrites, nous avons dans un premier
temps étudier en détail cette région chromosomique. Deux régions critiques distinctes ont
été mises en évidence en 1p36 : une délétion de la région distale 1p36.31-pter suite à un
réarrangement non balancé a été retrouvée dans une tumeur. Cette même région est
également délétée dans d’autres types de tumeurs et est suppossée contenir un gène
suppresseur de tumeur. Une seconde région critique plus proximale avec point de cassure
en 1p36.2 a également été mise en évidence dans la lignée UISO. Ce point de cassure (situé
dans un cluster de gènes répétitifs) est identique à celui d’un patient avec neuroblastome
décrit précédemment par notre groupe. L’observation de ces deux régions critiques prouve
que deux gènes suppresseurs au moins doivent être impliqués dans les MCC. Le gène
TP73, de la famille des TP53 et localisé en 1p36.33 est un candidat potentiel. Une mutation
faux-sens pouvant reduire la fonction transcriptionelle de la région amino-terminale du
TP73 a été observée dans un MCC. Cependant, comme dans d’autres cancers, nos résultats
ont montré que TP73 est rarement muté dans les MCC. Néanmoins, il n’est pas exclu que
d’autres mécanismes mènant à l’inactivation de TP73 ou à des épissages alternatifs (avec
formation de variants dominants) soient impliqués dans le développement tumoral des
MCC. L’élucidation de ces mécanismes demandent toutefois des recherches
complémentaires. La recherche de mutation du TP53 faite en parallelle, montre pour la
première fois des mutations inactivantes dans 19% des MCC’s étudiés et démontre
l’implication de TP53 dans la pathogénèse ou dans la progression d’un sous groupe de
MCC comme cela a été montré dans plusieurs autres types tumoraux. L’observation de
mutations induites dans une lignée de MCC après exposition aux UVB confirme
l’influence de l’exposition solaire dans ce cancer de la peau.
Différentes méthodes telles que le caryotype, l’hybridation génomique comparative (CGH)
et l’hybridation fluorescente multiplex (M-FISH) ont été utilisées afin de rechercher des
aberrations chromosomiques de structure non balancées dans les MCC’s. La CGH a permis
la caractérisation de gains (1, 3q, 5p, 8q, 19 et X) et de pertes recurrents (3p, 5q, 8p, 10,
11q, 13q et 17p) déterminant ainsi des régions chromosomiques porteuses de gènes
suppresseurs ou de protooncogènes potentiellement impliqués dans les MCC. Il est
intéressant de constater que ce tableau est semblable à celui déterminé dans les SCLC. La
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similitude des anomalies génétiques pourrait ainsi objectiver l’existence de mécanismes ou
de gènes communs impliqués dan l’étiologie de ces 2 entités. La découverte de la perte
fréquente du chromosome 10 dans les MCC nous a conduit à étudier le gène suppresseur
PTEN (localisé en 10q23) par biologie moléculaire. Malgré le taux élevé de LOH dans le
locus PTEN, nous avons seulement retrouvé une déletion homozygote et une mutation.
Cette dernière est une mutation non-sens dans le domaine phosphatase du PTEN, ce qui
pourrait réduire ou supprimer la fonction du gène PTEN. Les résultats démontrent que la
perte d’une allèle PTEN et la perte d’activité par mutation du deuxième allèle ou la
délétion homozygote sont des évenements rares dans les MCC’s. D’autres mécanismes
doivent être envisagés dans la génèse des MCC’s tels que l’haplo-insuffisance ou
l’implication d’autres gènes suppresseurs portés par le chromosome 10.
Les profils d’expression génique de 2 lignées dérivant d’un MCC et d’un SCLC ont été
déterminés en utilissant “l’Atlas cDNA expression arrays”. Ainsi, 23 marquers biologiques
ont été isolés et identifiés qui permettent un diagnostic différentiel entre les MCC et les
SCLC. De plus, des profils d’expression géniques distincts, associés de manière spécifique
aux sous types de MCC “variantes” ou “classiques” ont été identifiés pour la première fois.
Des études complémentaires des gènes défectueux et des mécanismes impliqués dans le
développement des MCC’s et des SCLC’s autoriseront l’élaboration de nouveaux agents
thérapeutiques dirigés spécifiquement contre de nouvelles cibles moléculaires et une
meilleure compréhension de la base moleculaire et de la biologie heterogène de ces deux
tumeurs aggressives.
En conclusion, notre travail a permis l’accumulation de données nouvelles sur les
mécanismes génétiques impliqués dans le développement des MCC. Elles devraient
permettre une meilleure approche thérapeutique et une amélioration de la survie des
patients souffrant de MCC.
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LIST OF ABBREVIATIONS
A12M2 adenovirus integration site
ABL Abelson oncogene
AKT protein-serine/threonine kinase AKT
APC adenomatous polyposis coli
APUD amine precursor uptake and decarboxylation
ATM ataxia-telangiectasia mutated
BCC basal cell carcinoma
BCR breakpoint cluster region
BMM bone marrow metastasis
CCD charge coupled device
CDKN2A cyclin-dependent kinase inhibitor 2A
CDNA complementary deoxyribonucleic acid
CIN chromosomal instability
CGH comparative genomic hybridization
CH A chromogranin A
CK cytokeratin antigen
CK20 cytokeratin 20
CL cell line
CML chronic myelogenous leukemia
DAPI 4’,6-diamidino-2-phenylindole dihydrochloride
DEAC diethylcoumarine
DNA deoxyribonucleic acid
DMBT1 deleted in malignant brain tumor 1
DOP-PCR degenerated oligonucleotide primer polymerase chain reaction
DPC4 deleted in pancreatic carcinoma 4
EMA epithelial membrane antigen
ENO1 enolase 1
FITC fluorescein isothiocyanate
FHIT fragile histidine traid
GFAP glial filament acidic protein
h-neu human homolog of the Drosophila neutralized gene
Gy Gray
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HNPCC hereditary nonpolyposis colorectal cancer
IGH immunoglobulin heavy chain
JPS juvenile polyposis syndrome
LCA leucocyte common antigen
LGI1 leucine-rich, glioma inactivated 1
LNM lymph node metastasis
LOH loss of heterozygosity
M metastatic tumor
MAPK mitogen-activated protein kinase
MCC Merkel cell carcinoma
M-FISH multiplex fluorescence in situ hybridization
MIN microsatellite instability
MLH1 mutL homolog 1
MSH2 mutS homolog 2
MXI1 max interactor 1
MYC avian myelocytomatosis viral (v-myc) oncogene homolog
MYCL avian myelocytomatosis viral (v-myc) oncogene homolog 1
MYCN neuroblastoma derived avian myelocytomatosis viral (v-myc) related oncogene
NB neuroblastoma
NF1 neurofibromatosis type 1
NFF neonatal foreskin fibroblast
NFP neurofilament protein
nm nanometer
NSE neuron-specific enolase
P primary tumor
PI3K phosphatidylinositol 3-kinase
PM pulmonary metastasis
PTEN phosphatase and tensin homolog deleted on chromosome ten
PTPase protein tyrosine phosphatase
RASSF1 ras association domain family 1
RB1 retinoblastoma gene 1
REC recurrence at site
RIZ1 retinoblastoma protein-interacting zinc finger 1
RNA ribonucleic acid
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RT-PCR reverse transcriptase polymerase chain reaction
SAM statistical analysis of microarrays
SCLC small cell lung carcinoma
SCC squamous cell carcinoma
SEMA3B semaphorin 3B
SNP single nucleotide polymorphism
SO spectrumorange
SRO shortest region of overlap
SSC sodium saline citrate
SSCP single strand conformation polymorphism
TMA tissue microarrays
TP53 tumor protein p53 (Li-Fraumeni syndrome)
TP73 tumor protein p73
TR texasred
TTF-1 thyroid transcription factor-1
UV ultraviolet light
VIP vasoactive intestinal peptide
VHL von Hippel-Lindau
WCL whole chromosome loss
WCG whole chromosome gain
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